WO2002087586A1 - Sustained release drug delivery system containing codrugs - Google Patents

Sustained release drug delivery system containing codrugs Download PDF

Info

Publication number
WO2002087586A1
WO2002087586A1 PCT/US2002/013385 US0213385W WO02087586A1 WO 2002087586 A1 WO2002087586 A1 WO 2002087586A1 US 0213385 W US0213385 W US 0213385W WO 02087586 A1 WO02087586 A1 WO 02087586A1
Authority
WO
WIPO (PCT)
Prior art keywords
prodrug
therapeutically active
sustained release
active form
polymer
Prior art date
Application number
PCT/US2002/013385
Other languages
French (fr)
Inventor
Jianbing Chen
Paul Ashton
Thomas J. Smith
Original Assignee
Control Delivery Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL15852702A priority Critical patent/IL158527A0/en
Priority to BR0209198-4A priority patent/BR0209198A/en
Priority to JP2002584931A priority patent/JP2004536799A/en
Priority to KR10-2003-7014032A priority patent/KR20040005936A/en
Priority to EP02729028A priority patent/EP1383504A1/en
Priority to MXPA03009727A priority patent/MXPA03009727A/en
Priority to CA2444894A priority patent/CA2444894C/en
Priority to AU2002259045A priority patent/AU2002259045B2/en
Application filed by Control Delivery Systems, Inc. filed Critical Control Delivery Systems, Inc.
Priority to IN10834DEN2014 priority patent/IN2014DN10834A/en
Priority to NZ528994A priority patent/NZ528994A/en
Publication of WO2002087586A1 publication Critical patent/WO2002087586A1/en
Priority to US10/449,855 priority patent/US20040022853A1/en
Priority to US12/082,520 priority patent/US20090123546A1/en
Priority to US13/228,774 priority patent/US20120045513A1/en
Priority to US13/937,844 priority patent/US20140037746A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Definitions

  • the present invention relates generally to an improved system of delivering drugs.
  • the present invention relates to a polymer-based, sustained-release drug delivery system and methods of delivering drugs using the same.
  • Implantable drug delivery devices offer an attractive alternative to oral, parenteral, suppository, and topical modes of administration. For example, as compared to oral, parenteral and suppository modes of administration, implantable drug delivery permits more localized administration of drug than do other modes of administration. Thus, implantable drug delivery devices are especially desirable where a clinician wishes to elicit a more localized therapeutic pharmaceutical effect.
  • implantable drug delivery devices to deliver the drug directly to the desired site of action permits the clinician to use drugs that are relatively poorly absorbed, or labile in biological fluids, often to great advantage.
  • Implantable drug delivery devices allow achievement of therapeutic doses at the desired site of action, while maintaining low or negligible systemic levels. Thus implantable drug delivery devices are especially attractive in situations where the drugs in question are toxic or have poor clearance characteristics, or both.
  • implantable drug delivery devices As compared to topical modes of administration, implantable drug delivery devices have the advantage that they can be applied subcutaneously. They can be surgically implanted and thereby deliver drug locally and in high concentrations over a protracted period of time. In comparison, topical application of drugs generally is limited to the epidermis, and must be repeated periodically to maintain concentration of the drug in its therapeutically effective range. Delivery by a transdermal route, such as by a transdermal patch, has the disadvantage of delivering drug systemically. Despite the obvious advantages of implantable drug delivery devices, there are several needs left to be satisfied by implantable devices. For instance, there is a need for a simple drug delivery device that releases drug at a constant rate. Prior art attempts to solve this problem have met with limited success because they were difficult to construct and inconvenient to use.
  • Modern surgical methods employ various and numerous devices that are routinely placed within the body and left there for extended periods of time. Such devices include, but are not limited to sutures, stents, surgical screws, prosthetic joints, artificial valves, plates, pacemakers, etc. Such devices have proven useful over time, however some problems associated with implanted surgical devices remain. For instance, stents, artificial valves, and to some extent even sutures may be associated with restenosis after vascular surgery. It is therefore often necessary to use systemic drugs in conjunction with implantation of surgical devices, which increases the risk of post-operative hemorrhage. Occasionally, surgical implants may be subject to immune response or rejection. Consequently, it is sometimes necessary to abandon surgical implant therapy, or to use immune suppressant drugs in conjunction with certain surgical implants. In an effort to avoid systemic treatment the use of drugs in rate controlling bioerodible polymers has been frequently reported. Such systems are designed to release drug as the polymer erodes. This severely limits the selection of drug and polymer.
  • Surgical implantation often leads to other deleterious side effects such as pain and swelling. It is routine to treat surgical implant patients with anti-inflammatory and analgesic drugs, such as steroidal anti-inflammatories, non-steroidal anti-inflammatories (NSAIDs), such as aspirin, cefacoxib, rofecoxib, or indomethacin, other analgesics, such as acetaminophen, and opiates.
  • NSAIDs non-steroidal anti-inflammatories
  • antipyretics such as aspirin, ibuprofen, naproxen, or acetaminophen.
  • NSAIDs act as blood thinners and anticoagulants, which may increase the risk of postoperative hemorrhage.
  • Certain embodiments of the present invention provide a sustained release system comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A-L-B in which: A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient; L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A.
  • the linkage L is hydrolyzed in bodily fluid. In other embodiments, the linkage L is enzymatically cleaved.
  • linkages which can be used include one or more hydrolyzable groups selected from the group consisting of an ester, an amide, a carbamate, a carbonate, a cyclic ketal, a thioester, a thioamide, a thiocarbamate, a thiocarbonate, a xanthate and a phosphate ester.
  • a sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A::B in which A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient; :: represents a ionic bond between A and B that dissociates under physiological conditions to generate said therapeutically active form of A; and B represents a moiety which, when ionically bonded to A, results in the prodrug having a lower solubility than the therapeutically active form of A.
  • the solubility of therapeutically active form of A in water is greater than 1 mg/ml and the solubility of the prodrug in water is less than 1 mg/ml, and even more preferably less than 0.1 mg/ml, 0.01 mg/ml or even less than 0.001 mg/ml.
  • the therapeutically active form of A is at least 10 times more soluble in water relative to said prodrug, and even more preferably at least 100, 1000 or even 10000 times more soluble in water relative to said prodrug.
  • the sustained release formulation when disposed in biological fluid (such as serum, synovial fluid, cerebral spinal fluid, lymph, urine, etc), provides sustained release of the therapeutically active form of A for a period of at least 24 hours, and over that period of release, the concentration of the prodrug in fluid outside the polymer is less than 10% of the concentration of the therapeutically active form of A, and even more preferably less than 5%, 1% or even 0.1% of the concentration of the therapeutically active form of A.
  • the therapeutically active form of A has a logP value at least 1 logP unit less than the logP value of the prodrug, and even more preferably at least 2, 3 or even 4 logP unit less than the logP value of the prodrug.
  • the prodrug in its linked form, has an ED 50 for producing the clinical response at least 10 times greater than the ED 50 of the therapeutically active form of A, and even more preferably at least 100, 1000 or even 10000 times greater than the ED 50 of the therapeutically active form of A. That is, in many embodiments, the prodrug per se is inert with respect to inducing the clinical response.
  • B is a hydrophobic aliphatic moiety.
  • B is drug moiety having a therapeutically active form generated upon cleavage of said linker L or dissociates of said ionic bond, and may be the same drug or a different drug than A.
  • B after cleavage from the prodrug, is a biologically inert moiety.
  • the duration of release from the polymer matrix of a therapeutically effective amount of the therapeutically active form of A is at least 24 hours, and even more preferably may be at least 72 hours, 100, 250, 500 or even 750 hours.
  • the duration of release of the therapeutically active form of A from the polymer matrix is at least one week, more preferably two weeks, or even more preferably at least three weeks.
  • the duration of release of the therapeutically active form of A from the polymer matrix is at least one month, more preferably two months, and even more preferably six months.
  • the pro-drug has an ED 50 at least 10 times greater than the ED 50 of the therapeutically active form of A.
  • the pro-drug has an ED 50 at least 100 times, or more preferably at least 1000 times, greater than the ED 50 of the therapeutically active form of A.
  • the therapeutically active form of A is at least 10 times more soluble in water relative to said pro-drug. In preferred embodiments, the therapeutically active form of A is at least 100 times, or more preferably at least 1000 times, more soluble in water relative to said prodrug.
  • the A (and optionally B) moiety can be selected from amongst such drugs as immune response modifiers, anti-proliferatives, corticosteroids, angiostatic steroids, anti-parasitic drugs, anti-glaucoma drugs, antibiotics, anti-sense compounds, differentiation modulators, antiviral drugs, anticancer drugs, and non-steroidal anti- inflammatory drugs.
  • the polymer matrix is non-bioerodible, while in other embodiments it is bioerodible.
  • exemplary non-bioerodible polymer matrices can be formed from polyurethane, polysilicone, poly(ethylene-co-vinyl acetate), polyvinyl alcohol, and derivatives and copolymers thereof.
  • Exemplary bioerodible polymer matrices can be formed polyanhydride, polylactic acid, polyglycolic acid, polyorthoester, polyalkylcyanoacrylate, and derivatives and copolymers thereof.
  • the polymer matrix is chosen so as reduce interaction between the prodrug in the matrix and proteinaceous components in surrounding bathing fluid, e.g., by forming a matrix have physical (pore size, etc) and/or chemical (ionized groups, hydrophobicity, etc) characteristics which exclude proteins from the inner matrix, e.g., exclude proteins of greater than lOOkD, and even more preferably exclude proteins greater in size than 50kD, 25kD, lOkD or even 5kD.
  • the polymer matrix is essentially non-release rate limiting with respect to the rate of release of the therapeutically active form of A from the matrix.
  • the subject polymer matrices influence the rate of release.
  • the matrices can be derived to have charge or hydrophobicity characteristics which favor sequestration of the prodrug over the released monomers (A and B).
  • the polymer matrix can influence the pH-dependency of the hydrolysis reaction, or create a microenvironment having a pH different than the bathing bodily fluid, such that hydrolysis and/or solubility of the prodrug is different within the matrix than in the surrounding fluids.
  • the polymer can influence the rate of release, and the rate of hydrolysis of the prodrug, by differential electronic, hydrophobic or chemical interactions with the prodrug.
  • at least one of A or B is an antineoplastic agent.
  • Exemplary antineoplastic agent include anthracyclines, vincaalkaloids, purine analogs, pyrimidine analogs, inhibitors of pyrimidine biosynthesis, and or alkylating agents.
  • Exemplary antineoplastic drugs include 5-fluorouracil (5FU), 5'-deoxy-5- fluorouridine 5-fluorouridine, 2'-deoxy-5-fluorouridine, fluorocytosine, 5- trifluoromethyl-2'-deoxyuridine, arabinoxyl cytosine, cyclocytidine, 5-aza-2'- deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine, N-phosphonoacetyl-L- aspartic acid, pyrazofurin, 6-azauridine, azaribine, 3-deazauridine, arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5-azacytosine, 6- azacytidine
  • the antineoplastic drug is a fluorinated pyrimidine, and even more preferably 5-fluorouracil, e.g., A is preferably 5- fluorouracil in certain embodiments.
  • At least one of A or B is an anti-inflammatory agent, such as, to illustrate, an a non-steroidal anti-inflammatory (diclofenac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, ketorolac, nahumstone, naproxen, piroxicam and the like) or an a glucocorticoid (such as aclometasone, beclomethasone, betamethasone, budesonide, clobetasol, clobetasone, cortisone, desonide, desoximetasone, diflorosane, flumethasone, flunisolide, fluocinolone acetonide, fluocinolone, fluocortolone, fluprednidene, flurandrenolide, fluticasone, hydrocortisone, methylprednisolone aceponate,mometasone furdate,
  • A is an antineoplastic fluorinated pyrimidine, such as 5-fluorouracil
  • B is anti-inflammatory, such as fluocinolone acetonide, triamcinolone acetonide, diclofenac, or naproxen.
  • the prodrug is selected from 5FU covalently bonded to fluocinolone acetonide (Hi), 5FU covalently bonded to naproxen (IV), and 5FU covalently bonded to diclofenac (V).
  • exemplary produgs include:
  • the subject invention provides a medical device having a coating adhered to at least one surface, wherein the coating includes the subject polymer matrix and a low solubility prodrug.
  • Such coatings can be applied to surgical implements such as screws, plates, washers, sutures, prosthesis anchors, tacks, staples, electrical leads, valves, membranes.
  • the devices can be catheters, implantable vascular access ports, blood storage bags, blood tubing, central venous catheters, arterial catheters, vascular grafts, intraaortic balloon pumps, heart valves, cardiovascularsutures, artificial hearts, a pacemaker, ventricular assist pumps, extracorporeal devices, blood filters, hemodialysis units, hemoperfasion units, plasmapheresis units, and filters adapted for deployment in a blood vessel.
  • the subject coatings are applied to a vascular stent.
  • the coating is flexible to accommodate compressed and expanded states of the stent.
  • the weight of the coating attributable to the prodrug is in the range of about 0.05 mg to about 50 mg of prodrug per cm 2 of the surface coated with said polymer matrix, and even more preferably 5 to 25 mg/cm .
  • the coating has a thickness is in the range of 5 micrometers to 100 micrometers.
  • the prodrug is present in the coating in an amount between 5% and 70% by weight of the coating, and even more preferably 25 to 50% by weight.
  • Yet another aspect of the invention provides a method for treating an intraluminal tissue of a patient. In general, the method comprising the steps of:
  • a stent having an interior surface and an exterior surface, said stent having a coating on at least a part of the interior surface, the exterior surface, or both; said coating comprising a low-solubility pharmaceutical prodrug dissolved or dispersed in a biologically- tolerated polymer;
  • the composition comprises a polymer matrix and low solubility prodrug as described above.
  • the coating composition can be provided in liquid or suspension form for application to the surface of a medical device by spraying and/or dipping the device in the composition.
  • the coating composition is provided in powdered form and, upon addition of a solvent, can reconstitute a liquid or suspension form for application to the surface of a medical device by spraying and/or dipping the device in the composition.
  • Another aspect of the invention relates to an injectable composition for use in delivering a medicament to a patient.
  • the composition includes a polymer matrix and low solubility prodrug as described above, and is provided in liquid or suspension form adapted for delivery by injection through a needle.
  • FIG. 1 is a time-dependent graph of the release of a prodrug from a polymer- prodrug dispersion according to the present invention.
  • FIG. 2 is a time-dependent graph of the release of a prodrug from a polymer- prodrug dispersion according to the present invention.
  • FIG. 3 is a side plan view of a non-deployed stent according to the present invention.
  • FIG. 4 is a side plan view of a deployed stent according to the present invention.
  • FIG. 5 is a release profile of TC-112 from PVA-coated glass slides into pH 7.4 buffer.
  • FIG. 6 is a release profile of TC-112 from silicone-coated glass plates into pH 7.4 buffer.
  • FIG. 7 is a release profile of 5-Fluroruracil (5FU) and triamcinolone acetonide (TA) from coated inserts.
  • 5FU 5-Fluroruracil
  • TA triamcinolone acetonide
  • FIG. 8 is a release profile of 5-Flurouracil (5FU) and triamcinolone acetonide (TA) from coated inserts.
  • 5FU 5-Flurouracil
  • TA triamcinolone acetonide
  • FIG. 9 illustrate the release pattern in vitro for a High Dose coated stent.
  • FIG. 10 shows the comparative drug release profiles between explanted stents and non-implanted stents.
  • FIGS. 11 A and 11B are graphs showing the effect of gamma irradiation and plasma treatment on drug release.
  • Group B with plasma treatment, with gamma irradiation.
  • Group C no plasma treatment, with gamma irradiation.
  • Group D with plasma treatment, no gamma irradiation.
  • Group F no plasma, no gamma irradiation
  • active means therapeutically or pharmacologically active.
  • ED 5 o means the dose of a drug that produces 50% of its maximum response or effect.
  • IC 50 means the dose of a drug that inhibits a biological activity by 50%.
  • LD50 means the dose of a drug that is lethal in 50% of test subjects.
  • therapeutic index refers to the therapeutic index of a drug defined as LD 50 /ED5 0 .
  • a "patient” or “subject” to be treated by the subject method can mean either a human or non-human animal.
  • Physiological conditions describe the conditions inside an organism, i.e., in vivo. Physiological conditions include the acidic and basic environments of body cavities and organs, enzymatic cleavage, metabolism, and other biological processes, and preferably refer to physiological conditions in a vertebrate, such as a mammal.
  • LogP refers to the logarithm of P (Partition Coefficient). P is a measure of how well a substance partitions between a lipid (oil) and water. P itself is a constant. It is defined as the ratio of concentration of compound in aqueous phase to the concentration of compound in an immiscible solvent, as the neutral molecule.
  • the LogP value will vary according to the conditions under which it is measured and the choice of partitioning solvent.
  • a LogP value of 1 means that the concentration of the compound is ten times greater in the organic phase than in the aqueous phase. The increase in a logP value of 1 indicates a ten fold increase in the concentration of the compound in the organic phase as compared to the aqueous phase.
  • a compound with a logP value of 3 is 10 times more soluble in water than a compound with a logP value of 4 and a compound with a logP value of 3 is 100 times more soluble in water than a compound with a logP value of 5.
  • compounds having logP values between 7-10 are considered low solubility compounds.
  • the present invention provides a drug delivery system that can provide various release profiles, e.g., varying doses and/or varying lengths of time.
  • the present invention thereby addresses the need for an insertable, injectable, inhalable, or implantable drug delivery system that provides controlled time-release kinetics of drug, particularly in the vicinity of a desired locus of drug activity, while avoiding complications associated with prior art devices.
  • the system of the present invention includes a polymer and a prodrug having a low solubility dispersed in the polymer.
  • the polymer is permeable to the prodrug and is essentially non-release rate limiting with respect to the rate of release of the prodrug from the polymer, and provides sustained release of the drug.
  • the system gives a continuous supply of the prodrug to the desired locus of activity without necessarily requiring additional invasive penetrations into these regions. Instead, the system remains in the body and serves as a continuous source of the prodrug to the affected area.
  • the system according to the present invention permits prolonged release of drugs over a specific period of days, weeks, months (e.g., about 3 months to about 6 months) or years (e.g., about 1 year to about 20 years, such as from about 5 years to about 10 years) until the prodrug is used up.
  • the intraluminal medical device comprises the sustained release drug delivery coating.
  • the inventive stent coating may be applied to the stent via a conventional coating process, such as impregnating coating, spray coating and dip coating.
  • an intraluminal medical device comprises an elongate radially expandable tubular stent having an interior luminal surface and an opposite exterior surface extending along a longitudinal stent axis.
  • the stent may include a permanent implantable stent, an implantable grafted stent, or a temporary stent, wherein the temporary stent is defined as a stent that is expandable inside a vessel and is thereafter retractable from the vessel.
  • the stent configuration may comprise a coil stent, a memory coil stent, a Nitinol stent, a mesh stent, a scaffold stent, a sleeve stent, a permeable stent, a stent having a temperature sensor, a porous stent, and the like.
  • the stent may be deployed according to conventional methodology, such as by an inflatable balloon catheter, by a self-deployment mechanism (after release from a catheter), or by other appropriate means.
  • the elongate radially expandable tubular stent may be a grafted stent, wherein the grafted stent is a composite device having a stent inside or outside of a graft.
  • the graft may be a vascular graft, such as an ePTFE graft, a biological graft, or a woven graft.
  • the drug combinations may be incorporated onto or affixed to the stent in a number of ways.
  • the drug combination is directly incorporated into a polymeric matrix and sprayed onto the outer surface of the stent.
  • the drug combination elutes from the polymeric matrix over time and enters the surrounding tissue.
  • the drug combination preferably remains on the stent for at least three days up to approximately six months, and more preferably between seven and thirty days.
  • the prodrugs are slowly dissolved in physiologic fluids, but are relatively quickly dissociated into at least one pharmaceutically active compound upon dissolution in physiologic fluids.
  • the dissolution rate of the prodrug is in the range of about 0.001 ⁇ g/day to about 10 ⁇ g/day.
  • the prodrugs have dissolution rates in the range of about 0.01 to about 1 ⁇ g/day.
  • the prodrugs have dissolution rates of about 0.1 ⁇ g/day.
  • the low-solubility pharmaceutical prodrug is incorporated into a biocompatable (i.e., biologically tolerated) polymer vehicle.
  • the low-solubility pharmaceutical prodrug is present as a plurality of granules dispersed within the polymer vehicle.
  • the low-solubility pharmaceutical prodrug be relatively insoluble in the polymer vehicle, however the low-solubility pharmaceutical prodrug may possess a finite solubility coefficient with respect to the polymer vehicle and still be within the scope of the present invention.
  • the polymer vehicle solubility of the low-solubility pharmaceutical prodrug should be such that the prodrug will disperse throughout the polymer vehicle, while remaining in substantially granular form.
  • the low-solubility pharmaceutical prodrug is dissolved within the polymer vehicle.
  • the polymer vehicle be a relatively non-polar or hydrophobic polymer which acts as a good solvent for the relatively hydrophobic low-solubility pharmaceutical prodrug.
  • the solubility of the low-solubility pharmaceutical prodrug in the polymer vehicle should be such that the prodrug will dissolve thoroughly in the polymer vehicle, being distributed homogeneously throughout the polymer vehicle.
  • the polymer according to the present invention comprises any biologically tolerated polymer that is permeable to the prodrug and while having a permeability such that it is not the principal rate determining factor in the rate of release of the prodrug from the polymer.
  • the polymer is non- bioerodible.
  • non-bioerodible polymers useful in the present invention include poly(ethylene-co-vinyl acetate) (EVA), polyvinylalcohol and polyurethanes, such as polycarbonate-based polyurethanes.
  • EVA poly(ethylene-co-vinyl acetate)
  • polyurethanes such as polycarbonate-based polyurethanes.
  • the polymer is bioerodible.
  • bioerodible polymers useful in the present invention include polyanhydride, polylactic acid, polyglycolic acid, polyorthoester, polyalkylcyanoacrylate or derivatives and copolymers thereof.
  • bioerodibility or non-bioerodibility of the polymer depends upon the final physical form of the system, as described in greater detail below.
  • Other exemplary polymers include polysilicone and polymers derived from hyaluronic acid.
  • the polymer according to the present invention is prepared under conditions suitable to impart permeability such that it is not the principal rate determining factor in the release of the low solubility prodrug from the polymer.
  • suitable polymers include naturally occurring (collagen, hyaluronic acid, etc.) or synthetic materials that are biologically compatible with bodily fluids and mammalian tissues, and essentially insoluble in bodily fluids with which the polymer will come in contact.
  • suitable polymers essentially prevent interaction between the low solubility prodrug dispersed/suspended in the polymer and proteinaceous components in the bodily fluid.
  • the use of rapidly dissolving polymers or polymers highly soluble in bodily fluid or which permit interaction between the low solubility prodrug and proteinaceous components are to be avoided in certain instances since dissolution of the polymer or interaction with proteinaceous components would affect the constancy of drug release.
  • polypropylene polyester, polyethylene vinyl acetate (PVA or EVA), polyethylene oxide (PEO), polypropylene oxide, polycarboxylic acids, polyalkylacrylates, cellulose ethers, silicone, poly(dl-lactide-co glycolide), various Eudragrits (for example, NE30D, RS PO and RL PO), polyalkyl- alkyacrylate copolymers, polyester-polyurethane block copolymers, polyether- polyurethane block copolymers, polydioxanone, poly-( ⁇ -hydroxybutyrate), polylactic acid (PLA), polycaprolactone, polyglycolic acid, and PEO-PLA copolymers.
  • PVA or EVA polyethylene vinyl acetate
  • PEO polyethylene oxide
  • polycarboxylic acids polyalkylacrylates
  • cellulose ethers silicone
  • poly(dl-lactide-co glycolide) various Eudragrits
  • Eudragrits for example,
  • the coating of the present invention may be formed by mixing one or more suitable monomers and a suitable low-solubility pharmaceutical prodrug, then polymerizing the monomer to form the polymer system. In this way, the prodrug is dissolved or dispersed in the polymer.
  • the prodrug is mixed into a liquid polymer or polymer dispersion and then the polymer is further processed to form the inventive coating.
  • Suitable further processing may include crosslinking with suitable crosslinking prodrugs, further polymerization of the liquid polymer or polymer dispersion, copolymerization with a suitable monomer, block copolymerization with suitable polymer blocks, etc. The further processing traps the drug in the polymer so that the drug is suspended or dispersed in the polymer vehicle.
  • non-erodible polymers may be utilized in conjunction with the drug combination.
  • Film-forming polymers that can be used for coatings in this application can be absorbable or non-absorbable and must be biocompatible to minimize irritation to the vessel wall.
  • the polymer may be either biostable or bioabsorbable depending on the desired rate of release or the desired degree of polymer stability, but a bioabsorbable polymer may be preferred since, unlike biostable polymer, it will not be present long after implantation to cause any adverse, chronic local response.
  • bioabsorbable polymers do not present the risk that over extended periods of time there could be an adhesion loss between the stent and coating caused by the stresses of the biological environment that could dislodge the coating and introduce further problems even after the stent is encapsulated in tissue.
  • Suitable film-forming bioabsorbable polymers that could be used include polymers selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amido groups, poly(anhydrides), polyphosphazenes, biomolecules and blends thereof.
  • aliphatic polyesters include homopolymers and copolymers of lactide (which includes lactic acid d-,1- and meso lactide), ⁇ -caprolactone, glycolide (including glycolic acid), hydroxybutyrate, hydroxyvalerate, para-dioxanone, trimethylene carbonate (and its alkyl derivatives), l,4-dioxepan-2-one, l,5-dioxepan-2-one, 6,6-dimethyl-l,4- dioxan-2-one and polymer blends thereof.
  • lactide which includes lactic acid d-,1- and meso lactide
  • ⁇ -caprolactone glycolide (including glycolic acid)
  • glycolide including glycolic acid
  • hydroxybutyrate hydroxyvalerate
  • para-dioxanone trimethylene carbonate (and its alkyl derivatives)
  • l,4-dioxepan-2-one l,5-di
  • Poly(iminocarbonate) for the purpose of this invention include as described by Kemnitzer and Kohn, in the Handbook of Biodegradable Polymers, edited by Domb, Kost and Wisemen, Hardwood Academic Press, 1997, pages 251-272.
  • Copoly(ether-esters) for the purpose of this invention include those copolyester-ethers described in Journal of Biomaterials Research, Vol. 22, pages 993-1009, 1988 by Cohn and Younes and Cohn, Polymer Preprints (ACS Division of Polymer Chemistry) Vol. 30(1), page 498, 1989 (e.g. PEO/PLA).
  • Polyalkylene oxalates for the purpose of this invention include U.S. Pat. Nos.
  • Polyoxaesters polyoxaamides and polyoxaesters containing amines and/or amido groups are described in one or more of the following U.S. Pat. Nos. 5,464,929; 5,595,751; 5,597,579; 5,607,687; 5,618,552; 5,620,698; 5,645,850; 5,648,088; 5,698,213 and 5,700,583; (which are incorporated herein by reference).
  • Polyorthoesters such as those described by Heller in Handbook of Biodegradable Polymers, edited by Domb, Kost and Wisemen, Hardwood Academic Press, 1997, pages 99-118 (hereby incorporated herein by reference).
  • Film-forming polymeric biomolecules for the purpose of this invention include naturally occurring materials that may be enzymatically degraded in the human body or are hydrolytically unstable in the human body such as fibrin, fibrinogen, collagen, elastin, and absorbable biocompatable polysaccharides such as chitosan, starch, fatty acids (and esters thereof), glucoso-glycans and hyaluronic acid.
  • Suitable film-forming biostable polymers with relatively low chronic tissue response such as polyurethanes, silicones, poly(meth)acrylates, polyesters, polyalkyl oxides (polyethylene oxide), polyvinyl alcohols, polyethylene glycols and polyvinyl pyrrolidone, as well as, hydrogels such as those formed from crosslinked polyvinyl pyrrolidinone and polyesters could also be used.
  • Other polymers could also be used if they can be dissolved, cured or polymerized on the stent.
  • polystyrene resins include polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers (including methacrylate) and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics such as polystyrene; polyvinyl esters such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as etheylene-methyl methacrylate copolymers, acrylonitrile- styrene copolymers, ABS resins and ethylene-vinyl acetate copolymers; polyamides,such as Nylon 66 and polycaprolactam
  • Polyamides for the purpose of this application would also include polyamides of the form -NH-(CH 2 ) n -CO- and NH-(CH 2 ) x -NH-CO-(CH 2 ) y -CO, wherein n is preferably an integer in from 6 to 13; x is an integer in the range of form 6 to 12; and y is an integer in the range of from 4 to 16.
  • n is preferably an integer in from 6 to 13
  • x is an integer in the range of form 6 to 12
  • y is an integer in the range of from 4 to 16.
  • the list provided above is illustrative but not limiting.
  • the polymers used for coatings can be film-forming polymers that have molecular weight high enough as to not be waxy or tacky.
  • the polymers also should adhere to the stent and should not be so readily deformable after deposition on the stent as to be able to be displaced by hemodynamic stresses.
  • the polymers molecular weight be high enough to provide sufficient toughness so that the polymers will not to be rubbed off during handling or deployment of the stent and must not crack during expansion of the stent.
  • the polymer has a melting temperature above 40°C, preferably above about 45°C, more preferably above 50°C and most preferably above 55°C.
  • Coating may be formulated by mixing one or more of the therapeutic prodrugs with the coating polymers in a coating mixture.
  • the therapeutic prodrug may be present as a liquid, a finely divided solid, or any other appropriate physical form.
  • the mixture may include one or more additives, e.g., nontoxic auxiliary substances such as diluents, carriers, excipients, stabilizers or the like.
  • additives e.g., nontoxic auxiliary substances such as diluents, carriers, excipients, stabilizers or the like.
  • Other suitable additives may be formulated with the polymer and pharmaceutically active prodrug or compound.
  • hydrophilic polymers selected from the previously described lists of biocompatible film forming polymers maybe added to a biocompatible hydrophobic coating to modify the release profile (or a hydrophobic polymer may be added to a hydrophilic coating to modify the release profile).
  • hydrophilic polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyethylene glycol, carboxylmethyl cellulose, hydroxymethyl cellulose and combination thereof to an aliphatic polyester coating to modify the release profile.
  • Appropriate relative amounts can be determined by monitoring the in vitro and/or in vivo release profiles for the therapeutic prodrugs.
  • the thickness of the coating can determine the rate at which the active drug(s) or prodrug elutes from the matrix.
  • the active drug(s) or prodrug elutes from the matrix by diffusion through the polymer matrix.
  • Polymers are permeable, thereby allowing solids, liquids and gases to escape therefrom.
  • the total thickness of the polymeric matrix is in the range from about one micron to about twenty microns or greater. It is important to note that primer layers and metal surface treatments may be utilized before the polymeric matrix is affixed to the medical device. For example, acid cleaning, alkaline (base) cleaning, salinization and parylene deposition may be used as part of the overall process described.
  • multiple coatings can be used.
  • the various coatings can differ in the concentration of prodrug, the identity of the prodrugs (active ingredients, linkers, etc), the characteristics of the polymer matrix (composition, porosity, etc) and/or the presence of other drugs or release modifiers.
  • a poly(ethylene-co-vinylacetate), polybutylmethacrylate and drug combination solution may be incorporated into or onto the stent in a number of ways.
  • the solution may be sprayed onto the stent or the stent may be dipped into the solution.
  • Other methods include spin coating and RF plasma polymerization.
  • the solution is sprayed onto the stent and then allowed to dry.
  • the solution may be electrically charged to one polarity and the stent electrically changed to the opposite polarity. In this manner, the solution and stent will be attracted to one another. In using this type of spraying process, waste may be reduced and more precise control over the thickness of the coat may be achieved.
  • the drug combination or other therapeutic prodrug may be incorporated into a film-forming polyfluoro copolymer comprising an amount of a first moiety selected from the group consisting of polymerized vinylidenefluoride and polymerized tetrafluoroethylene, and an amount of a second moiety other than the first moiety and which is copolymerized with the first moiety, thereby producing the polyfluoro copolymer, the second moiety being capable of providing toughness or elastomeric properties to the polyfluoro copolymer, wherein the relative amounts of the first moiety and the second moiety are effective to provide the coating and film produced therefrom with properties effective for use in treating implantable medical devices.
  • the exterior surface of the expandable tubular stent of the intraluminal medical device of the present invention comprises a coating according to the present invention.
  • the exterior surface of a stent having a coating is the tissue-contacting surface and is biocompatible.
  • the "sustained release drug delivery system coated surface” is synonymous with “coated surface”, which surface is coated, covered or impregnated with sustained release drug delivery system according to the present invention.
  • the interior luminal surface or entire surface (i.e. both interior and exterior surfaces) of the elongate radially expandable tubular stent of the intraluminal medical device of the present invention has the coated surface.
  • the interior luminal surface having the inventive sustained release drug delivery system coating is also the fluid contacting surface, and is biocompatible and blood compatible.
  • the inventive process for making a surface coated stent includes deposition onto the stent of a coating by, for example, dip coating or spray coating. In the case of coating one side of the stent, only the surface to be coated is exposed to the dip or spray.
  • the treated surface may be all or part of an interior luminal surface, an exterior surface, or both interior and exterior surfaces of the intraluminal medical device.
  • the stent may be made of a porous material to enhance deposition or coating into a plurality of micropores on or in the applicable stent surface, wherein the microporous size is preferably about 100 microns or less.
  • the chosen pharmaceutical prodrug is a moiety of low-solubility and comprises at least two pharmaceutically active compounds.
  • the pharmaceutically active compounds can be the same or different chemical species, and can be formed, as desired, in equi-molar or non-equi-molar concentrations to provide optimal treatment based on the relative activities and other pharmaco-kinetic properties of the compounds.
  • the drug combination may itself be advantageously relatively insoluble in physiologic fluids, such as blood and blood plasma, and has the property of regenerating any or all of the pharmaceutically active compounds when dissolved in physiologic fluids.
  • physiologic fluids such as blood and blood plasma
  • the low-solubility of the pharmaceutical prodrug thus insures persistence of the prodrug in the vicinity of an intraluminal lesion.
  • the quick conversion of the low-solubility pharmaceutical prodrug into the constituent pharmaceutically active compounds insures a steady, controlled, dose of the pharmaceutically active compounds near the site of the lesion to be treated.
  • a suitable first pharmaceutically active compound examples include immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), anticancer/anti-proliferative prodrugs such as 5-fluorouracil (5FU) and BCNU, and non-steroidal anti-inflammatory prodrugs such as naproxen, diclofenac, indomethacin and flurbiprofen.
  • immune response modifiers such as cyclosporin A and FK 506
  • corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide
  • angiostatic steroids such as trihydroxy steroids
  • the preferred first pharmaceutically active compound is 5FU.
  • 5-Fluorouracil examples include immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), anticancer/anti-proliferative prodrugs such as 5-fluorouracil (5FU) and BCNU, and non-steroidal anti-inflammatory prodrugs such as naproxen, diclofenac, indomethacin and flurbiprofen.
  • immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antibiotics including
  • the second pharmaceutically active compound is selected from fluocinolone acetonide, triamcinolone acetonide, diclofenac, and naproxen.
  • the low-solubility pharmaceutically active prodrug according to the present invention may comprise further residues of pharmaceutically active compounds.
  • Such further pharmaceutically active compounds include immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), anticancer/anti-proliferative prodrugs such as 5-fluorouracil (5FU) and BCNU, and non-steroidal anti-inflammatory prodrugs such as naproxen, diclofenac, indomethacin and flurbiprofen.
  • immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone ace
  • the low-solubility pharmaceutical prodrug comprises a moiety of at least two pharmaceutically active compounds that can be covalently bonded, connected through a linker, ionically combined, or combined as a mixture.
  • the first and second pharmaceutically active compounds are covalently bonded directly to one another.
  • the bond may be formed by forming a suitable covalent linkage through an active group on each active compound. For instance, an acid group on the first pharmaceutically active compound may be condensed with an amine, an acid or an alcohol on the second pharmaceutically active compound to form the corresponding amide, anhydride or ester, respectively.
  • Suitable active groups for forming linkages between pharmaceutically active moieties include sulfonyl groups, sulfhydryl groups, and the haloic acid and acid anhydride derivatives of carboxylic acids.
  • the pharmaceutically active compounds may be covalently linked to one another through an intermediate linker.
  • the linker advantageously possesses two active groups, one of which is complementary to an active group on the first pharmaceutically active compound, and the other of which is complementary to an active group on the second pharmaceutically active compound.
  • the linker may suitably be a diacid, which will react with both compounds to form a diether linkage between the two residues.
  • Suitable active groups for forming linkages between pharmaceutically active moieties include sulfonyl groups, sulfhydryl groups, and the haloic acid and acid anhydride derivatives of carboxylic acids.
  • Suitable linkers are set forth in Table 1 below.
  • Suitable diacid linkers include oxalic, malonic, succinic, glutaric, adipic, pimelic, suberic, azelaic, sebacic, maleic, fumaric, tartaric, phthalic, isophthalic, and terephthalic acids. While diacids are named, the skilled artisan will recognize that in certain circumstances the corresponding acid halides or acid anhydrides (either unilateral or bilateral) are preferred as linker reprodrugs.
  • a preferred anhydride is succinic anhydride.
  • Another preferred anhydride is maleic anhydride.
  • Other anhydrides and/or acid halides may be employed by the skilled artisan to good effect.
  • Suitable amino acids include ⁇ -butyric acid, 2-aminoacetic acid, 3- aminopropanoic acid, 4-aminobutanoic acid, 5-aminopentanoic acid, 6- aminohexanoic acid, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
  • the acid group of the suitable amino acids may be converted to the anhydride or acid halide form prior to their use as linker groups.
  • Suitable diamines include 1, 2-diaminoethane, 1,3-diaminopropane, 1,4- diaminobutane, 1,5-diaminopentane, 1,6-diaminohexane.
  • Suitable aminoalcohols include 2-hydroxy-l-aminoethane, 3-hydroxy-l- aminoethane, 4-hydroxy-l-aminobutane, 5-hydroxy-l-aminopentane, 6-hydroxy-l- aminohexane.
  • Suitable hydroxyalkyl acids include 2-hydroxyacetic acid, 3- hydroxypropanoic acid, 4-hydroxybutanoic acid, 5-hydroxypentanoic acid, 5- hydroxyhexanoic acid.
  • first and second pharmaceutical moieties and optionally third, etc. pharmaceutical moieties having suitable active groups, and by matching them to suitable linkers, a broad palette of inventive compounds may be prepared within the scope of the present invention.
  • Exemplary preferred low-solubility pharmaceutically active prodrugs include 5FU covalently bonded to fluocinolone acetonide, 5FU covalently bonded to diclofenac, and 5FU covalently bonded to naproxen.
  • Illustrative examples include the following:
  • exemplary codrugs include the following:
  • TC-32 codrug of triamcinolone acetonide with 5-FU via formaldehyde linkage
  • the first and second pharmaceutically active compounds may be combined to form a salt.
  • the first pharmaceutically active compound may be an acid
  • the second pharmaceutically active compound may be a base, such as an amine.
  • the first pharmaceutically active compound may be diclofenac or naproxen (acids)
  • the second pharmaceutically active compound may be ciprofloxacin (a base). The combination of diclofenac and ciprofloxacin would for instance form the salt:
  • the rate of release of the prodrug is essentially the rate at which the prodrug is solubilized in the sunounding aqueous medium. This rate of release is nearly approximately linear with respect to time (so-called zero-order kinetics.).
  • the system of the present invention may be formed by mixing one or more suitable monomers and a suitable low-solubility pharmaceutical prodrug, then polymerizing the monomer to form the polymer system.
  • the prodrug is dissolved or dispersed in the polymer.
  • the prodrug is mixed into a liquid polymer or polymer dispersion and then the polymer is further processed to form the inventive system.
  • Suitable further processing includes crosslinking with suitable crosslinking prodrugs, further polymerization of the liquid polymer or polymer dispersion, copolymerization with a suitable monomer, block copolymerization with suitable polymer blocks, etc.
  • the further processing traps the drug in the polymer so that the drug is suspended or dispersed in the polymer vehicle.
  • monomers for forming a polymer are combined with an inventive low-solubility compound and are mixed to make a homogeneous dispersion of the inventive compound in the monomer solution.
  • the dispersion is then applied to a stent according to a conventional coating process, after which the crosslinking process is initiated by a conventional initiator, such as UV light.
  • a polymer composition is combined with an inventive low- solubility compound to form a dispersion.
  • the dispersion is then applied to a stent and the polymer is cross-linked to form a solid coating.
  • a polymer and an inventive low-solubility compound are combined with a suitable solvent to form a dispersion, which is then applied to a stent in a conventional fashion.
  • the solvent is then removed by a conventional process, such as heat evaporation, with the result that the polymer and inventive low-solubility drug (together forming a sustained-release drug delivery system) remain on the stent as a coating.
  • a conventional process such as heat evaporation
  • the system comprises a polymer that is relatively rigid. In other embodiments, the system comprises a polymer that is soft and malleable. In still other embodiments, the system includes a polymer that has an adhesive character. Hardness, elasticity, adhesive, and other characteristics of the polymer are widely variable, depending upon the particular final physical form of the system, as discussed in more detail below.
  • the system consists of the low solubility prodrug, i.e., the prodrug suspended or dispersed in the polymer.
  • the system consists of a prodrug and a semi-solid or gel polymer, which is adapted to be injected via a syringe into a body.
  • the system consists of a prodrug and a soft-flexible polymer, which is adapted to be inserted or implanted into a body by a suitable surgical method.
  • the system consists of a hard, solid polymer, which is adapted to be inserted or implanted into a body by a suitable surgical method.
  • the system comprises a polymer having the low solubility prodrug suspended or dispersed therein which is suitable for inhalation.
  • the system comprises a polymer having the prodrug suspended or dispersed therein, wherein the prodrug and polymer mixture forms a coating on a surgical implement, such as a screw, stent, pacemaker, etc.
  • the device consists of a hard, solid polymer, which is shaped in the form of a surgical implement such as a surgical screw, plate, stent, etc., or some part thereof.
  • the system includes a polymer that is in the form of a suture having the drug dispersed or suspended therein.
  • a medical device comprising a substrate having a surface, such as an exterior surface, and a coating on the exterior surface.
  • the coating comprises a polymer and a prodrug having a low solubility dispersed in the polymer, wherein the polymer is permeable to the prodrug and is essentially non-release rate limiting with respect to the rate of release of the prodrug from the polymer.
  • the device comprises a prodrug suspended or dispersed in a suitable polymer, wherein the prodrug and polymer are coated onto an entire substrate, e.g., a surgical implement. Such coating may be accomplished by spray coating or dip coating.
  • the device comprises a prodrug and polymer suspension or dispersion, wherein the polymer is rigid, and forms a constituent part of a device to be inserted or implanted into a body.
  • the device is a surgical screw, stent, pacemaker, etc. coated with the prodrug suspended or dispersed in the polymer.
  • the polymer in which the prodrug is suspended forms a tip or a head, or part thereof, of a surgical screw.
  • the polymer in which prodrug is suspended or dispersed is coated onto a surgical implement such as surgical tubing (such as colostomy, peritoneal lavage, catheter, and intravenous tubing).
  • the device is an intravenous needle having the polymer and prodrug (for instance, a prodrug of an anticoagulant such as heparin or codrug thereof) coated thereon.
  • a device according to the present invention comprises a polymer that is bioerodible or non-bioerodible. The choice of bioerodible versus non-bioerodible polymer is made based upon the intended end use of the system or device.
  • the polymer is advantageously bioerodible.
  • the system is a coating on a surgically implantable device, such as a screw, stent, pacemaker, etc.
  • the polymer is advantageously bioerodible.
  • Other embodiments according to the present invention in which the polymer is advantageously bioerodible include devices that are implantable, inhalable, or injectable suspensions or dispersions of prodrug in a polymer, wherein the further elements (such as screws or anchors) are not utilized.
  • the rate of bioerosion of the polymer is advantageously sufficiently slower than the rate of drug release so that the polymer remains in place for a substantial period of time after the drug has been released, but is eventually bioeroded and resorbed into the surrounding tissue.
  • the rate of bioerosion of the polymer is advantageously slow enough that the drug is released in a linear manner over a period of about three to about 14 days, but the sutures persist for a period of about three weeks to about six months.
  • Similar devices according to the present invention include surgical staples comprising a prodrug suspended or dispersed in a bioerodible polymer.
  • the rate of bioerosion of the polymer is advantageously on the same order as the rate of drug release.
  • the system comprises a prodrug suspended or dispersed in a polymer that is coated onto a surgical implement, such as an orthopedic screw, a stent, a pacemaker, or a non-bioerodible suture
  • the polymer advantageously bioerodes at such a rate that the surface area of the prodrug that is directly exposed to the surrounding body tissue remains substantially constant over time.
  • the polymer is non- bioerodible, or is bioerodible only at a rate slower than a dissolution rate of the low- solubility pharmaceutical prodrug, and the diameter of the granules is such that when the coating is applied to the stent, the granules' surfaces are exposed to the ambient tissue.
  • dissolution of the low-solubility pharmaceutical prodrug is proportional to the exposed surface area of the granules.
  • the polymer vehicle is permeable to water in the surrounding tissue, e.g. in blood plasma.
  • water solution may permeate the polymer, thereby contacting the low-solubility pharmaceutical prodrug.
  • the rate of dissolution may be governed by a complex set of variables, such as the polymer's permeability, the solubility of the low-solubility pharmaceutical prodrug, the pH, ionic strength, and protein composition, etc. of the physiologic fluid. In certain embodiments, however the permeability may be adjusted so that the rate of dissolution is governed primarily, or in some cases practically entirely, by the solubility of the low-solubility pharmaceutical prodrug in the ambient liquid phase.
  • the polymer is non- bioerodible.
  • Non-bioerodible polymers are especially useful where the system includes a polymer intended to be coated onto, or form a constituent part, of a surgical implement that is adapted to be permanently, or semi-permanently, inserted or implanted into a body.
  • Exemplary devices in which the polymer advantageously forms a permanent coating on a surgical implement include an orthopedic screw, a stent, a prosthetic joint, an artificial valve, a permanent suture, a pacemaker, etc.
  • a surgical system according to the present invention is used in a manner suitable for the desired therapeutic effect. For instance in some embodiments according to the invention, the mode of administration is advantageously by injection.
  • the system is a liquid, and is introduced into the desired locus by taking the system up into the barrel of a syringe and injecting the system through a needle into the desired locus.
  • a mode of administration is suitable for intramuscular injection, for instance intramuscular injection of sustained-release formulations of microbicides, including antibiotics, antivirals, and steroids.
  • This mode of administration is also useful where the desired therapeutic effect is the sustained release of hormones such as thyroid medication, birth control prodrugs, estrogen for estrogen therapy, etc.
  • hormones such as thyroid medication, birth control prodrugs, estrogen for estrogen therapy, etc.
  • the skilled clinician will appreciate that this mode of administration is adaptable to various therapeutic milieus, and will adapt the particular polymer and drug of the system to the desired therapeutic effect.
  • the system is advantageously a relatively non-polar drug suspended or dispersed in a viscous polymer vehicle.
  • the system is, in such cases, a stable suspension or dispersion of non-polar drug in liquid polymer vehicle.
  • the polymer vehicle will be either non-bioerodible or will bioerode at a rate slower than the rate of diffusion of the drug into the surrounding tissue. In such cases, the system stays in place in place relative to the surrounding tissue, preventing the drug from being prematurely released into the surrounding tissue.
  • the system is a relatively non-polar liquid suspended or dispersed in a liquid polymer.
  • the system further comprises an emulsifier that maintains the relatively non-polar drug in a stable, dispersed, state within the polymer.
  • the polymer vehicle advantageously is non-bioerodible, or is bioerodible at a slower rate than the rate of diffusion of the drug, so that the system maintains the location of the drug relative to the surrounding tissue over the full period of drug release.
  • the precise properties of the system according to the present invention depend upon the therapeutic use intended, the physical state of the drug to incorporated into the system under physiologic conditions, etc.
  • the system according to the present invention is advantageously a solid device of a shape and form suitable for implantation, for instance subcutaneously, etc.
  • the system is in the shape of an elongated ovoid
  • the prodrug is of a non-polar drug, such as a hormone
  • the polymer is a solid polymer whose permeability is such that it is not the primary rate-determining factor in the rate of release of the drug.
  • the polymer is bioerodible. In other embodiments according to the present invention, the polymer is non-bioerodible.
  • the device comprises a substrate and a coating on the substrate, such as a screw, stent, pacemaker, prosthetic joint, etc.
  • the device is used in substantially the manner of the corresponding prior art surgical implement.
  • a device according to the present invention that comprises a screw coated with a composition comprising a low solubility prodrug, such as an antibiotic or FU-naproxen, suspended or dispersed in a polymer, is screwed into a bone in the same manner as a prior art screw.
  • the screw according to the present invention then releases drug, in a sustained time-wise fashion, thereby conferring therapeutic benefits, such as antibiotic, anti- inflammatory, and antiviral effects, to the tissue surrounding the device, such as muscle, bone, blood, etc.
  • sustained release means release via rate kinetics such that the permeability of the polymer is non-rate limiting with respect to the rate of release of the drug.
  • the polymer is advantageously a solid having physical properties appropriate for the particular application of the device. For instance, where the device is a suture, the polymer will have strength and bioerodibility properties suitable for the particular surgical situation. Where the device is a screw, stent, etc, the polymer is advantageously a rigid solid forming at least part of the surgical implement. In particular embodiments according to the present invention, such as where the system is part of a prosthetic joint, the polymer advantageously is non-bioerodible and remains in place after the prodrug has been released into the surrounding tissue.
  • the polymer bioerodes after release of substantially all the prodrug.
  • exemplary embodiments of the invention will be described with respect to the treatment of restenosis and related complications following percutaneous transluminal coronary angioplasty, it is important to note that the local delivery of drug/drug combinations may be utilized to treat a wide variety of conditions utilizing any number of medical devices, or to enhance the function and/or life of the device.
  • intraocular lenses placed to restore vision after cataract surgery is often compromised by the formation of a secondary cataract. The latter is often a result of cellular overgrowth on the lens surface and can be potentially minimized by combining a drug or drugs with the device.
  • Devices which serve to improve the structure and function of tissue or organ may also show benefits when combined with the appropriate prodrug or codrugs.
  • improved osteointegration of orthopedic devices to enhance stabilization of the implanted device could potentially be achieved by combining it with prodrugs such as bone morphogenic protein.
  • other surgical devices sutures, staples, anastomosis devices, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds, various types of dressings, bone substitutes, intraluminal devices, and vascular supports could also provide enhanced patient benefit using this drug-device combination approach.
  • any type of medical device may be coated in some fashion with a prodrug or codrug which enhances treatment over use of the singular use of the device or pharmaceutical prodrug.
  • the subject devices can be used to deliver such pharmaceutical drugs as: antiproliferative/antimitotic prodrugs including natural products such as vinca alkaloids (i.e. vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (i.e.
  • antibiotics dactinomycin (actinomycin D) daunorubicin, doxorubicin and idarubicin
  • anthracyclines mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin
  • enzymes L- asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine
  • antiplatelet prodrugs antiproliferative/antimitotic alkylating prodrugs such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nirtosoureas (carmustine (BCNU) and analogs,
  • anticoagulants heparin, synthetic heparin salts and other inhibitors of thrombin
  • fibrinolytic prodrugs such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory; antisecretory (breveldin); antiinflammatory: such as adrenocortical steroids (cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6U-methylprednisolone, triamcinolone, betamethasone, and dexamethasone), non-steroidal prodrugs (salicylic acid derivatives i.e.
  • the prodrug is formed using an opiod.
  • opioids include morophine derivatives, such as apomorphine, buprenorphine, codeine, dihydrocodeine, dihydroetorphine, diprenorphine, etorphine, hydrocodone, hydromorphone, levorphanol, meperidine, metopon, o-methylnaltrexone, morphine, naloxone, naltrexone, normorphine, oxycodone, and oxymorphone.
  • the opiod is a fentanyl derivative which can be deritized to form the prodrug, such as ⁇ -hydroxy-3-methylfentanyl.
  • low-solubility relates to the solubility of the pharmaceutical prodrug in biological fluids, such as blood plasma, lymphatic fluid, peritoneal fluid, etc.
  • biological fluids such as blood plasma, lymphatic fluid, peritoneal fluid, etc.
  • low- solubility means that the pharmaceutical prodrug is only very slightly soluble in aqueous solutions having pH in the range of about 5 to about 8, and in particular to physiologic solutions, such as blood, blood plasma, etc.
  • Some low-solubility prodrugs according to the present invention will have solubilities of less than about 1 mg/ml, less than about 100 ⁇ g/ml, preferably less than about 20 ⁇ g/ml, more preferably less than about 15 ⁇ g/ml, and more preferably less than about 10 ⁇ g/ml.
  • Solubility is in water at a temperature of 25°C as measured by the procedures set forth in the 1995 USP, unless otherwise stated. This includes compounds which are slightly soluble (about lOmg/ml to about 1 mg/ml), very slightly soluble (about 1 mg/ml to about 0.1 mg/ml) and practically insoluble or insoluble compounds (less than about 0.01 mg/ml).
  • Suitable prodrugs useful in the present invention include prodrugs of immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antiparasitic prodrugs such as atovaquone, anti-glaucoma prodrugs such as ethacrynic acid, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), antiviral prodrugs including high molecular weight low (10-mers), anti-sense compounds, anticancer prodrugs such as BCNU, non-steroidal anti-inflammatory prodrugs such as indomethacin and flurbiprofen, and prodrugs comprising a conjugate of at least two compounds linked via a reversible covalent or ionic bond that is cleaved at a desired site in
  • the prodrug is relatively insoluble in aqueous media, including physiological fluids, such as blood serum, mucous, peritoneal fluid, limbic fluid, etc.
  • suitable prodrugs include drugs, which are lipophilic derivatives of hydrophilic drugs, that are easily converted into their hydrophilic drugs under physiological accessible conditions. Reference may be made to any standard pharmaceutical textbook for the procedures to obtain a low solubility form of a drug.
  • the present invention is especially suitable for prodrugs that heretofore have not found broad application due to their inherent low solubility, or have found only limited application in oil-based or other lipid-based delivery vehicles.
  • the present invention provides an intraluminal medical device for implantation into a lumen of a blood vessel, in particular adjacent an intraluminal lesion such as an atherosclerotic lesion, for maintaining patency of the vessel.
  • an intraluminal lesion such as an atherosclerotic lesion
  • the present invention provides an elongate radially expandable tubular stent having an interior luminal surface and an opposite exterior surface extending along a longitudinal stent axis, the stent having a coating on at least a portion of the interior or exterior surface thereof.
  • the local delivery of drug combinations from a stent has the following advantages; namely, the prevention of vessel recoil and remodeling through the scaffolding action of the stent and the prevention of multiple components of neointimal hyperplasia or restenosis as well as a reduction in inflammation and thrombosis.
  • This local administration of drugs to stented coronary arteries may also have additional therapeutic benefit. For example, higher tissue concentrations of the drugs may be achieved utilizing local delivery, rather than systemic administration. In addition, reduced systemic toxicity may be achieved utilizing local delivery rather than systemic administration while maintaining higher tissue concentrations. Also in utilizing local delivery from a stent rather than systemic administration, a single procedure may suffice with better patient compliance.
  • An additional benefit of combination drug therapy may be to reduce the dose of each of the therapeutic drugs, prodrugs or compounds, thereby limiting their toxicity, while still achieving a reduction in restenosis, inflammation and thrombosis.
  • Local stent-based therapy is therefore a means of improving the therapeutic ratio (efficacy/toxicity) of anti-restenosis, anti-inflammatory, anti- thrombotic drugs, prodrugs or compounds.
  • a stent is commonly used as a tubular structure left inside the lumen of a duct to relieve an obstruction. Commonly, stents are inserted into the lumen in a non-expanded form and are then expanded autonomously, or with the aid of a second device in situ.
  • a typical method of expansion occurs through the use of a catheter-mounted angioplasty balloon which is inflated within the stenosed vessel or body passageway in order to shear and disrupt the obstructions associated with the wall components of the vessel and to obtain an enlarged lumen.
  • the stents of the present invention may be fabricated utilizing any number of methods.
  • the stent may be fabricated from a hollow or formed stainless steel tube that may be machined using lasers, electric discharge milling, chemical etching or other means.
  • the stent is inserted into the body and placed at the desired site in an unexpanded form.
  • expansion may be effected in a blood vessel by a balloon catheter, where the final diameter of the stent is a function of the diameter of the balloon catheter used.
  • a stent in accordance with the present invention may be embodied in a shape-memory material, including, for example, an appropriate alloy of nickel and titanium or stainless steel.
  • Structures formed from stainless steel may be made self-expanding by configuring the stainless steel in a predetermined manner, for example, by twisting it into a braided configuration.
  • the stent after the stent has been formed it may be compressed so as to occupy a space sufficiently small as to permit its insertion in a blood vessel or other tissue by insertion means, wherein the insertion means include a suitable catheter, or flexible rod.
  • the stent On emerging from the catheter, the stent may be configured to expand into the desired configuration where the expansion is automatic or triggered by a change in pressure, temperature or electrical stimulation. Regardless of the design of the stent, it is preferable to have the drug combination dosage applied with enough specificity and a sufficient concentration to provide an effective dosage in the lesion area.
  • the "reservoir size" in the coating is preferably sized to adequately apply the drug combination dosage at the desired location and in the desired amount.
  • the entire inner and outer surface of the stent may be coated with drug/drug combinations in therapeutic dosage amounts. It is, however, important to note that the coating techniques may vary depending on the drug combinations. Also, the coating techniques may vary depending on the material comprising the stent or other intraluminal medical device. An embodiment of an intraluminal device (stent) according to the present invention is depicted in FIGs. 3 and 4.
  • FIG. 3 shows a side plan view of a preferred elongate radially expandable tubular stent 13 having a surface coated with a sustained release drug delivery system in a non-deployed state.
  • the stent 13 has its radially outer boundaries 14A, 14B at a non-deployed state.
  • the interior luminal surface 15, the exterior surface 16, or an entire surface of the stent 13 may be coated with a sustained release drug delivery system or comprise a sustained release drug delivery system.
  • the interior luminal surface 15 is to contact a body fluid, such as blood in a vascular stenting procedure, while the exterior surface 16 is to contact tissue when the stent 13 is deployed to support and enlarge the biological vessel or duct.
  • an optional reinforcing wire 17 that connects two or more of the adjacent members or loops of the stent structure 13 is used to lock-in and/or maintain the stent at its expanded state when a stent is deployed.
  • This reinforcing wire 17 may be made of a Nitinol or other high-strength material.
  • a Nitinol device is well known to have a preshape and a transition temperature for said Nitinol device to revert to its preshape.
  • One method for treating an intraluminal tissue of a patient using a surface coated stent 13 of the present invention comprises collapsing the radially expandable tubular stent and retracting the collapsed stent from a body of a patient.
  • the operation for collapsing a radially expandable tubular stent may be accomplished by elevating the temperature so that the reinforcing wire 17 is reversed to its straightened state or other appropriate state to cause the stent 13 to collapse for removing said stent from the body of a patient.
  • FIG. 4 shows an overall view of an elongate radially expandable tubular stent 13 having a sustained release drug delivery system coated stent surface at a deployed state.
  • the stent 13 has its radially outer boundaries 24A, 24B at a deployed state.
  • the interior luminal surface 14, the exterior surface 16, or an entire surface of the stent 13 may be coated or may comprise the sustained release drug delivery system.
  • the interior luminal surface 15 is to contact a body fluid, such as blood in a vascular stenting procedure, while the exterior surfacel ⁇ is to contact tissue when the stent 13 is deployed to support and enlarge the biological vessel.
  • the reinforcing wire 17 may be used to maintain the expanded stent at its expanded state as a permanent stent or as a temporary stent. In the case of the surface coated stent 13 functioning as a temporary stent, the reinforcing wire 17 may have the capability to cause collapsing of the expanded stent.
  • the deployment of a stent can be accomplished by a balloon on a delivery catheter or by self-expanding after a pre-stressed stent is released from a delivery catheter. Delivery catheters and methods for deployment of stents are well known to one who is skilled in the art.
  • the expandable stent 13 may be a self-expandable stent, a balloon-expandable stent, or an expandable-retractable stent.
  • the expandable stent may be made of memory coil, mesh material, and the like. III. Examples
  • Prodrug TC-112 comprising a conjugate of 5-fluorouracil and naproxen linked via a reversible covalent bond
  • prodrug G.531.1 comprising a conjugate of 5-fluorouracil and fluocinolone acetonide were prepared in accordance with the methods set forth in U.S. Patent No. 6,051,576. The structure of these compounds is reproduced below.
  • FIG. 1 shows the total cumulative release of TC-112 from PVA coated glass plates.
  • the slope of the curve demonstrates that TC- 112 is released at 10 ⁇ g/day.
  • the data represent both intact and constituents of the compound TC-112.
  • silicone part A 12.0 gm of silicone part A (Med-6810A) were mixed with 1.2 gm of silicone part B (Med-6810B), and degassed in sonicator for 10 min, followed by water aspirator. 41.2 mg of (TC-112) were dispersed in this degassed silicone, and degassed again. 0.2 gm of the mixture was spread on one surface of a glass plate. The glass plates (total 5) were then placed in oven and heated at 105 °C for 20 min. to cure. After removing from the oven and cooled to room temperature, 0.2 gm of the mixture was spread on the other uncoated surface of each glass plate. The coated glass plates were then heat treated again at 105 °C for 20 min.
  • the glass plates were individually placed in 20 ml of 0.1 M phosphate buffer (pH 7.4, 37 °C) for release test. Samples were taken daily, and the entire release media was replaced with fresh media at each sampling time.
  • the drugs (5FU and TA) and TC-112 released in the media were determined by HPLC.
  • the total TC-112 release for silicone coating was calculated as follows.
  • the molecular weight of Naproxen is 230.3, and the molecular weight for 5-Fluorouracil is 130.1, while the inventive compound (TC-112) generated from these two drugs has a molecular weight of 372.4. To detect x mg of naproxen, this means that x*372.4/230.3 mg of TC-112 was hydrolyzed.
  • the total TC-112 released equals the sum of TC-112 detected in the release media and the TC-112 hydrolyzed. For example, up to day 6, 43.9 mg of naproxen is detected, this means 71.0 (43.9*372.4/230.3) mg of TC-112 was hydrolyzed, at the same time, 51.4 mg of TC- 112 is detected in buffer, therefore a total of 122.4mg (51.4 plus 71.0) of TC-112 is released up to day 6.
  • FIG. 2 shows the total cumulative release of
  • TC-112 is released at 13.3 ⁇ g/day. Again, the data represent both intact and constituents of the inventive compound. The similarity in the slopes demonstrates that the polymers have little effect on the release of the drug.
  • DMAC dimethyl acetamide
  • the coating and air-drying process was repeated a few times till a total of about 2.0 mg of polymer/TC-32 were applied to each stent.
  • the coated stents were air-dried under ambient temperature in a biological safety cabinet over night.
  • the stents were then vacuum dried at 80°C for two hour to remove the residue of the solvent. Afterwards they were placed individually in 5.0 ml of 0.1 m phosphate buffer, pH 7.4, in glass tube and monitoring of the release of compounds from the stents was at 37 °C was begun. Samples were taken daily, and the entire media was replaced with a fresh one at each sampling time.
  • the drugs released in the media were determined by HPLC. The release profiles were shown in the Figure 8. No TC-32 was detectable in the release media.
  • Example 5 Polyurethane (PU) was first dissolved in tetrahydrofuran. Into this solution bioreversible conjugates of 5-FU and TA were dissolved and the resulting solution spray coated onto coronary Tetra stents produced by Guidant. After air-drying, the stents were vacuum dried at 50 °C for 2 hours to remove solvent residue, and subjected to plasma treatment and gamma-irradiation. Two different levels of drug loading were applied to stents: 80 ug Low Dose (13%) and 600 ug High Dose (60%). The release rate was determined in vitro by placing the coated stents (expanded) in 0.1M phosphate buffer (pH 7.4) at 37°C. Samples of the buffer solution were periodically removed for analysis by HPLC, and the buffer was replaced to avoid any saturation effects. The results shown in Figure 9 illustrate the release pattern in vitro for a High
  • Dose coated stent The pattern followed a pseudo logarithmic pattern with approximately 70% being released in 10 weeks. A similar pattern is seen in both High Dose and Low Dose loaded stents.
  • TA and 5-FU were released in an equimolar fashion at all times during the experiments. No co-drugs of 5-FU/TA were detectable in the release media.
  • Polyurethane (1.008 gm) was added to 50.0 gm of tetrahydrofuran (THF).
  • the mixture was stirred overnight to dissolve the polymer.
  • 5.0 gm of the polymer solution was diluted with 10.0 gm of THF.
  • 150.2 mg of a co-drug of 5-fluorouracil (5FU) and triamcinolone acetonide (TA) (the co-drug being defined as "TC-32") was added to the polymer solution and dissolved.
  • the coating solution was prepared with 60% codrug loading.
  • a 13% codrug loaded coating solution was also prepared.
  • Bare stents Tetra, Guidant, Lot# 1092154, 13mm Tetra
  • the coating was repeated until approximately 1.0 mg of total coating had been applied to each stent.
  • the coated stents were vacuum dried for two hours at 50°C to remove solvent residue, then subjected to plasma treatment and gamma-irradiation.
  • Co-drug coated stents were test in two groups. Group One stents were placed individually into a glass tube containing 5.0 ml of 0.1 M phosphate buffer (pH 7.4). Samples were taken periodically and the concentration of co-drug in the buffer was tested by HPLC. The entire release media was replaced after each sample.
  • Group Two stents were placed in vivo. Three common swine had TC-32 coated stents implanted into the left anterior descending (LAD) coronary artery on study day 1. The stents were harvested on study day 5 and then placed in 0.1 M phosphate buffer as describe for Group One stents. The amount of each drug released into the media was determined by HPLC. The intact codrug was not detectable in release media.
  • Fig. 10 The results are shown in Fig. 10, showing the comparative drug release profiles between explanted stents and non-implanted stents.
  • the release patterns for both explanted and pre-implanted stents indicate that in-vivo release may be predicted by in vitro release patterns.
  • FIGS. 11A and 11B are graphs showing the effect of gamma irradiation and plasma treatment on drug release.
  • the stents were inflated with a dilatation catheter (3.0 mm balloon size, 20mm long) and placed individually into a glass tube containing 5.0 ml of 0.1 M phosphate buffer (pH 7.4). Samples were taken periodically and the entire release media was replaced after each sample. The amount of each drug released into the media was determined by HPLC. The intact codrug was not detectable in release media.
  • Example 9 Coating Example A
  • EMM poly(ethyl acrylate and methyl methacrylate)copolymer
  • Eudragit NE30D aqueous dispersion obtained by evaporating the Eudragit NE30D aqueous dispersion and air drying, was added in 9.0 gm acetone.
  • 51.5 mg of codrug of 5-Fluorouracil and Fluocinolone acetonide (G.531.1) were added and dissolved after stirring. By dipping them in the codrug/polymer solution, followed by air-drying, 10 HPLC inserts were coated with the codrug/polymer. The coating process was repeated several times until about 30 mg of codrug/polymer were coated on each of the glass tube.
  • the coated inserts were then individually placed in 10.0 ml of 0.1 M phosphate buffer (pH 7.4, 37 °C) for release test. Sample was taken daily and entire release media were replaced with fresh media at each sampling time. The drugs and codrug released in the media were determined by HPLC.
  • Example 10 Coating Example B 441.8 mg poly(ethylene-co-vinyl acetate) (EVA) is weighed and transferred to 15.0 ml of THF. The EVA is slowly swollen and then partly dissolved in the THF by ultrasonic and magnetic stirring. 88.2 mg of codrug (TC32) is added and dissolved into the polymer solution. 9 HPLC inserts are then coated with the polymer/codrug solution by dipping, followed by air-drying under ambient temperature. The coating and air-drying process is repeated a few times until a total of about 10 mg of polymer/codrug is applied to each insert. The inserts are then placed in oven at 50°C for one hour to remove the residue of the solvent.
  • EVA poly(ethylene-co-vinyl acetate)
  • the weight and diameter of the inserts are checked before and after completion of the coating and recorded.
  • the coated inserts were then individually placed in 10.0 ml of 0.1 M phosphate buffer (pH 7.4, 37 °C) for release test. Sample was taken daily and entire release media were replaced with fresh media at each sampling time. The drugs and codrug released in the media were determined by HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed is a sustained release system that includes a polymer and a prodrug having a solubility less than about 1 mg/ml dispersed in the polymer. Advantageously, the polymer is permeable to the prodrug and may be non-release rate limiting with respect to the rate of release of the prodrug from the polymer. This permits improved drug delivery within a body in the vicinity of a surgery via sustained release rate kinetics over a prolonged period of time, while not requiring complicated manufacturing processes.

Description

SUSTAINED RELEASE DRUG DELIVERY SYSTEM CONTAINING CODRUGS.
Field Of The Invention The present invention relates generally to an improved system of delivering drugs. In particular, the present invention relates to a polymer-based, sustained-release drug delivery system and methods of delivering drugs using the same.
Background Of The Invention The desirability of sustained release has long been recognized in the pharmaceutical field. Many polymer-based systems have been proposed to accomplish the goal of sustained release. These systems generally have relied upon either degradation of the polymer or diffusion through the polymer as a means to control release. Implantable drug delivery devices offer an attractive alternative to oral, parenteral, suppository, and topical modes of administration. For example, as compared to oral, parenteral and suppository modes of administration, implantable drug delivery permits more localized administration of drug than do other modes of administration. Thus, implantable drug delivery devices are especially desirable where a clinician wishes to elicit a more localized therapeutic pharmaceutical effect. Additionally, the ability of implantable drug delivery devices to deliver the drug directly to the desired site of action permits the clinician to use drugs that are relatively poorly absorbed, or labile in biological fluids, often to great advantage. Implantable drug delivery devices allow achievement of therapeutic doses at the desired site of action, while maintaining low or negligible systemic levels. Thus implantable drug delivery devices are especially attractive in situations where the drugs in question are toxic or have poor clearance characteristics, or both.
As compared to topical modes of administration, implantable drug delivery devices have the advantage that they can be applied subcutaneously. They can be surgically implanted and thereby deliver drug locally and in high concentrations over a protracted period of time. In comparison, topical application of drugs generally is limited to the epidermis, and must be repeated periodically to maintain concentration of the drug in its therapeutically effective range. Delivery by a transdermal route, such as by a transdermal patch, has the disadvantage of delivering drug systemically. Despite the obvious advantages of implantable drug delivery devices, there are several needs left to be satisfied by implantable devices. For instance, there is a need for a simple drug delivery device that releases drug at a constant rate. Prior art attempts to solve this problem have met with limited success because they were difficult to construct and inconvenient to use.
There is therefore a need for an improved drug delivery device that provides sustained-release drug delivery within a body over a prolonged period of time that does not require complicated manufacturing processes.
Modern surgical methods employ various and numerous devices that are routinely placed within the body and left there for extended periods of time. Such devices include, but are not limited to sutures, stents, surgical screws, prosthetic joints, artificial valves, plates, pacemakers, etc. Such devices have proven useful over time, however some problems associated with implanted surgical devices remain. For instance, stents, artificial valves, and to some extent even sutures may be associated with restenosis after vascular surgery. It is therefore often necessary to use systemic drugs in conjunction with implantation of surgical devices, which increases the risk of post-operative hemorrhage. Occasionally, surgical implants may be subject to immune response or rejection. Consequently, it is sometimes necessary to abandon surgical implant therapy, or to use immune suppressant drugs in conjunction with certain surgical implants. In an effort to avoid systemic treatment the use of drugs in rate controlling bioerodible polymers has been frequently reported. Such systems are designed to release drug as the polymer erodes. This severely limits the selection of drug and polymer.
There is therefore a need for an improved drug delivery device that is capable of delivering a drug having anti-restenosis or immune suppressive activity in the vicinity of a surgical implant over a prolonged period at a sustained concentration within the therapeutically effective concentration range for the drug.
Many advances have been made to reduce the exposure of patients to pathogenic microbes during surgery, implantation of surgical devices nonetheless involves introducing into the body a foreign object that has the potential to infect patients with various viruses and/or bacteria. Accordingly, surgical procedures often result in infections to which a patient would not ordinarily be exposed, and which may compromise or negate the effectiveness of implantation therapy. Administration of antibiotics, corticosteroids and/or antivirals is therefore a common adjunct to implantation therapy, either for prophylaxis or in response to infection. However, systemic administration of such antimicrobial compositions often leads to undesirable side effects.
There is therefore a need for an improved drug delivery device that is capable of delivering a drug having antimicrobial activity in the vicinity of a surgical implant over a prolonged period at a sustained concentration within the therapeutically effective concentration range for the drug.
Surgical implantation often leads to other deleterious side effects such as pain and swelling. It is routine to treat surgical implant patients with anti-inflammatory and analgesic drugs, such as steroidal anti-inflammatories, non-steroidal anti-inflammatories (NSAIDs), such as aspirin, cefacoxib, rofecoxib, or indomethacin, other analgesics, such as acetaminophen, and opiates. As some post operative patients experience fever, it is common to treat such patients with antipyretics, such as aspirin, ibuprofen, naproxen, or acetaminophen. It is not uncommon for patients to show poor tolerance for systemic administration of certain NSAIDs, steroids and opiates. Moreover, several NSAIDs act as blood thinners and anticoagulants, which may increase the risk of postoperative hemorrhage.
There is therefore a need for an improved drug delivery device that is capable of delivering a drug having anti-inflammatory, analgesic, and/or antipyretic activity in the vicinity of a surgical implant over a prolonged period at a sustained concentration within the therapeutically effective concentration range for the drug.
Summary of the Invention
Certain embodiments of the present invention provide a sustained release system comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A-L-B in which: A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient; L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A. In certain embodiments, the linkage L is hydrolyzed in bodily fluid. In other embodiments, the linkage L is enzymatically cleaved. Examples of linkages which can be used include one or more hydrolyzable groups selected from the group consisting of an ester, an amide, a carbamate, a carbonate, a cyclic ketal, a thioester, a thioamide, a thiocarbamate, a thiocarbonate, a xanthate and a phosphate ester. Other embodiments of the present invention provide a sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A::B in which A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient; :: represents a ionic bond between A and B that dissociates under physiological conditions to generate said therapeutically active form of A; and B represents a moiety which, when ionically bonded to A, results in the prodrug having a lower solubility than the therapeutically active form of A.
In certain preferred embodiments, the solubility of therapeutically active form of A in water is greater than 1 mg/ml and the solubility of the prodrug in water is less than 1 mg/ml, and even more preferably less than 0.1 mg/ml, 0.01 mg/ml or even less than 0.001 mg/ml.
In certain preferred embodiments, the therapeutically active form of A is at least 10 times more soluble in water relative to said prodrug, and even more preferably at least 100, 1000 or even 10000 times more soluble in water relative to said prodrug.
In certain preferred embodiments, when disposed in biological fluid (such as serum, synovial fluid, cerebral spinal fluid, lymph, urine, etc), the sustained release formulation provides sustained release of the therapeutically active form of A for a period of at least 24 hours, and over that period of release, the concentration of the prodrug in fluid outside the polymer is less than 10% of the concentration of the therapeutically active form of A, and even more preferably less than 5%, 1% or even 0.1% of the concentration of the therapeutically active form of A.
In certain preferred embodiments, the therapeutically active form of A has a logP value at least 1 logP unit less than the logP value of the prodrug, and even more preferably at least 2, 3 or even 4 logP unit less than the logP value of the prodrug.
In certain preferred embodiments, the the prodrug, in its linked form, has an ED50 for producing the clinical response at least 10 times greater than the ED50 of the therapeutically active form of A, and even more preferably at least 100, 1000 or even 10000 times greater than the ED50 of the therapeutically active form of A. That is, in many embodiments, the prodrug per se is inert with respect to inducing the clinical response.
In certain embodiments, B is a hydrophobic aliphatic moiety. In some instances, B is drug moiety having a therapeutically active form generated upon cleavage of said linker L or dissociates of said ionic bond, and may be the same drug or a different drug than A.
In other embodiments, B, after cleavage from the prodrug, is a biologically inert moiety.
In many preferred embodiments, the duration of release from the polymer matrix of a therapeutically effective amount of the therapeutically active form of A is at least 24 hours, and even more preferably may be at least 72 hours, 100, 250, 500 or even 750 hours. In certain embodiments, the duration of release of the therapeutically active form of A from the polymer matrix is at least one week, more preferably two weeks, or even more preferably at least three weeks. In certain embodiments, the duration of release of the therapeutically active form of A from the polymer matrix is at least one month, more preferably two months, and even more preferably six months. In certain embodiments, the pro-drug has an ED50 at least 10 times greater than the ED50 of the therapeutically active form of A. In preferred embodiments, the pro-drug has an ED50 at least 100 times, or more preferably at least 1000 times, greater than the ED50 of the therapeutically active form of A.
In some embodiments, the therapeutically active form of A is at least 10 times more soluble in water relative to said pro-drug. In preferred embodiments, the therapeutically active form of A is at least 100 times, or more preferably at least 1000 times, more soluble in water relative to said prodrug.
The A (and optionally B) moiety can be selected from amongst such drugs as immune response modifiers, anti-proliferatives, corticosteroids, angiostatic steroids, anti-parasitic drugs, anti-glaucoma drugs, antibiotics, anti-sense compounds, differentiation modulators, antiviral drugs, anticancer drugs, and non-steroidal anti- inflammatory drugs.
In certain embodiments, the polymer matrix is non-bioerodible, while in other embodiments it is bioerodible. Exemplary non-bioerodible polymer matrices can be formed from polyurethane, polysilicone, poly(ethylene-co-vinyl acetate), polyvinyl alcohol, and derivatives and copolymers thereof.
Exemplary bioerodible polymer matrices can be formed polyanhydride, polylactic acid, polyglycolic acid, polyorthoester, polyalkylcyanoacrylate, and derivatives and copolymers thereof. In certain embodiments, the polymer matrix is chosen so as reduce interaction between the prodrug in the matrix and proteinaceous components in surrounding bathing fluid, e.g., by forming a matrix have physical (pore size, etc) and/or chemical (ionized groups, hydrophobicity, etc) characteristics which exclude proteins from the inner matrix, e.g., exclude proteins of greater than lOOkD, and even more preferably exclude proteins greater in size than 50kD, 25kD, lOkD or even 5kD.
In certain embodiments, the polymer matrix is essentially non-release rate limiting with respect to the rate of release of the therapeutically active form of A from the matrix.
In other embodiments, the subject polymer matrices influence the rate of release. For instance, the matrices can be derived to have charge or hydrophobicity characteristics which favor sequestration of the prodrug over the released monomers (A and B). Likewise, the polymer matrix can influence the pH-dependency of the hydrolysis reaction, or create a microenvironment having a pH different than the bathing bodily fluid, such that hydrolysis and/or solubility of the prodrug is different within the matrix than in the surrounding fluids. In such a manner, the polymer can influence the rate of release, and the rate of hydrolysis of the prodrug, by differential electronic, hydrophobic or chemical interactions with the prodrug. In certain embodiments, at least one of A or B is an antineoplastic agent.
Exemplary antineoplastic agent include anthracyclines, vincaalkaloids, purine analogs, pyrimidine analogs, inhibitors of pyrimidine biosynthesis, and or alkylating agents. Exemplary antineoplastic drugs include 5-fluorouracil (5FU), 5'-deoxy-5- fluorouridine 5-fluorouridine, 2'-deoxy-5-fluorouridine, fluorocytosine, 5- trifluoromethyl-2'-deoxyuridine, arabinoxyl cytosine, cyclocytidine, 5-aza-2'- deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine, N-phosphonoacetyl-L- aspartic acid, pyrazofurin, 6-azauridine, azaribine, 3-deazauridine, arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5-azacytosine, 6- azacytidine, Cladribine, 6-mercaptopurine, pentostatin, 6-thioguanine, and fludarabin phosphate.
In certain preferred embodiments, the antineoplastic drug is a fluorinated pyrimidine, and even more preferably 5-fluorouracil, e.g., A is preferably 5- fluorouracil in certain embodiments.
In certain embodiments, at least one of A or B is an anti-inflammatory agent, such as, to illustrate, an a non-steroidal anti-inflammatory (diclofenac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, ketorolac, nahumstone, naproxen, piroxicam and the like) or an a glucocorticoid (such as aclometasone, beclomethasone, betamethasone, budesonide, clobetasol, clobetasone, cortisone, desonide, desoximetasone, diflorosane, flumethasone, flunisolide, fluocinolone acetonide, fluocinolone, fluocortolone, fluprednidene, flurandrenolide, fluticasone, hydrocortisone, methylprednisolone aceponate,mometasone furdate, prednisolone, prednisone and rofleponide).
In certain preferred embodiments, A is an antineoplastic fluorinated pyrimidine, such as 5-fluorouracil, and is an B is anti-inflammatory, such as fluocinolone acetonide, triamcinolone acetonide, diclofenac, or naproxen.
In some embodiments, the prodrug is selected from 5FU covalently bonded to fluocinolone acetonide (Hi), 5FU covalently bonded to naproxen (IV), and 5FU covalently bonded to diclofenac (V). Exemplary produgs include:
Figure imgf000009_0001
5FU-flucinolone acetonide (III),
Figure imgf000009_0002
5FU-Naproxen (IV), and
Figure imgf000010_0001
5FU-Diclofenac (V).
Another aspect of the invention relates to coated medical devices. For instance, in certain embodiments, the subject invention provides a medical device having a coating adhered to at least one surface, wherein the coating includes the subject polymer matrix and a low solubility prodrug. Such coatings can be applied to surgical implements such as screws, plates, washers, sutures, prosthesis anchors, tacks, staples, electrical leads, valves, membranes. The devices can be catheters, implantable vascular access ports, blood storage bags, blood tubing, central venous catheters, arterial catheters, vascular grafts, intraaortic balloon pumps, heart valves, cardiovascularsutures, artificial hearts, a pacemaker, ventricular assist pumps, extracorporeal devices, blood filters, hemodialysis units, hemoperfasion units, plasmapheresis units, and filters adapted for deployment in a blood vessel.
In a preferred embodiment, the subject coatings are applied to a vascular stent. In certain instances, particularly where the stent is an expandable stent, the coating is flexible to accommodate compressed and expanded states of the stent.
In certain embodiments, the weight of the coating attributable to the prodrug is in the range of about 0.05 mg to about 50 mg of prodrug per cm2 of the surface coated with said polymer matrix, and even more preferably 5 to 25 mg/cm . In certain embodiments, the coating has a thickness is in the range of 5 micrometers to 100 micrometers.
In certain embodiments, the prodrug is present in the coating in an amount between 5% and 70% by weight of the coating, and even more preferably 25 to 50% by weight. Yet another aspect of the invention provides a method for treating an intraluminal tissue of a patient. In general, the method comprising the steps of:
(a) providing a stent having an interior surface and an exterior surface, said stent having a coating on at least a part of the interior surface, the exterior surface, or both; said coating comprising a low-solubility pharmaceutical prodrug dissolved or dispersed in a biologically- tolerated polymer;
(b) positioning the stent at an appropriate intraluminal tissue site; and (c) deploying the stent.
Another aspect of the invention relates to a coating composition for use in delivering a medicament from the surface of a medical device positioned in vivo. The composition comprises a polymer matrix and low solubility prodrug as described above. The coating composition can be provided in liquid or suspension form for application to the surface of a medical device by spraying and/or dipping the device in the composition. In other embodiments, the coating composition is provided in powdered form and, upon addition of a solvent, can reconstitute a liquid or suspension form for application to the surface of a medical device by spraying and/or dipping the device in the composition. Another aspect of the invention relates to an injectable composition for use in delivering a medicament to a patient. The composition includes a polymer matrix and low solubility prodrug as described above, and is provided in liquid or suspension form adapted for delivery by injection through a needle.
Additional advantages of the present invention will become readily apparent to those skilled in the art from the following detailed description, wherein only a preferred embodiment of the invention is shown and described by way of illustration of the best mode contemplated for carrying out the invention. As will be realized, the present invention is capable of other and different embodiments, and its several details are capable of modifications in various respects, all without departing from the scope of the present invention. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
Brief Description Of The Drawings
FIG. 1 is a time-dependent graph of the release of a prodrug from a polymer- prodrug dispersion according to the present invention. FIG. 2 is a time-dependent graph of the release of a prodrug from a polymer- prodrug dispersion according to the present invention.
FIG. 3 is a side plan view of a non-deployed stent according to the present invention. FIG. 4 is a side plan view of a deployed stent according to the present invention.
FIG. 5 is a release profile of TC-112 from PVA-coated glass slides into pH 7.4 buffer. FIG. 6 is a release profile of TC-112 from silicone-coated glass plates into pH 7.4 buffer.
FIG. 7 is a release profile of 5-Fluroruracil (5FU) and triamcinolone acetonide (TA) from coated inserts.
FIG. 8 is a release profile of 5-Flurouracil (5FU) and triamcinolone acetonide (TA) from coated inserts.
FIG. 9 illustrate the release pattern in vitro for a High Dose coated stent.
FIG. 10 shows the comparative drug release profiles between explanted stents and non-implanted stents.
FIGS. 11 A and 11B are graphs showing the effect of gamma irradiation and plasma treatment on drug release. Group B: with plasma treatment, with gamma irradiation. Group C: no plasma treatment, with gamma irradiation. Group D: with plasma treatment, no gamma irradiation. Group F: no plasma, no gamma irradiation
Best Mode for Carrying Out the Invention Detailed Description Of The Invention
/. Definitions
The term "active" as used herein means therapeutically or pharmacologically active.
The term "ED5o" means the dose of a drug that produces 50% of its maximum response or effect.
The term "IC50" means the dose of a drug that inhibits a biological activity by 50%.
The term "LD50" means the dose of a drug that is lethal in 50% of test subjects. The term "therapeutic index" refers to the therapeutic index of a drug defined as LD50/ED50. A "patient" or "subject" to be treated by the subject method can mean either a human or non-human animal.
"Physiological conditions" describe the conditions inside an organism, i.e., in vivo. Physiological conditions include the acidic and basic environments of body cavities and organs, enzymatic cleavage, metabolism, and other biological processes, and preferably refer to physiological conditions in a vertebrate, such as a mammal.
"LogP" refers to the logarithm of P (Partition Coefficient). P is a measure of how well a substance partitions between a lipid (oil) and water. P itself is a constant. It is defined as the ratio of concentration of compound in aqueous phase to the concentration of compound in an immiscible solvent, as the neutral molecule.
Partition Coefficient, P = [Organic] / [Aqueous] where [] = concentration
LogP = logjo (Partition Coefficient) = logioP
In practice, the LogP value will vary according to the conditions under which it is measured and the choice of partitioning solvent. A LogP value of 1 means that the concentration of the compound is ten times greater in the organic phase than in the aqueous phase. The increase in a logP value of 1 indicates a ten fold increase in the concentration of the compound in the organic phase as compared to the aqueous phase. Thus, a compound with a logP value of 3 is 10 times more soluble in water than a compound with a logP value of 4 and a compound with a logP value of 3 is 100 times more soluble in water than a compound with a logP value of 5. In general, compounds having logP values between 7-10 are considered low solubility compounds.
//. Exemplary Embodiments
The present invention provides a drug delivery system that can provide various release profiles, e.g., varying doses and/or varying lengths of time. The present invention thereby addresses the need for an insertable, injectable, inhalable, or implantable drug delivery system that provides controlled time-release kinetics of drug, particularly in the vicinity of a desired locus of drug activity, while avoiding complications associated with prior art devices. The system of the present invention includes a polymer and a prodrug having a low solubility dispersed in the polymer. The polymer is permeable to the prodrug and is essentially non-release rate limiting with respect to the rate of release of the prodrug from the polymer, and provides sustained release of the drug. Once administered, the system gives a continuous supply of the prodrug to the desired locus of activity without necessarily requiring additional invasive penetrations into these regions. Instead, the system remains in the body and serves as a continuous source of the prodrug to the affected area. The system according to the present invention permits prolonged release of drugs over a specific period of days, weeks, months (e.g., about 3 months to about 6 months) or years (e.g., about 1 year to about 20 years, such as from about 5 years to about 10 years) until the prodrug is used up.
The intraluminal medical device comprises the sustained release drug delivery coating. The inventive stent coating may be applied to the stent via a conventional coating process, such as impregnating coating, spray coating and dip coating.
In one embodiment, an intraluminal medical device comprises an elongate radially expandable tubular stent having an interior luminal surface and an opposite exterior surface extending along a longitudinal stent axis. The stent may include a permanent implantable stent, an implantable grafted stent, or a temporary stent, wherein the temporary stent is defined as a stent that is expandable inside a vessel and is thereafter retractable from the vessel. The stent configuration may comprise a coil stent, a memory coil stent, a Nitinol stent, a mesh stent, a scaffold stent, a sleeve stent, a permeable stent, a stent having a temperature sensor, a porous stent, and the like. The stent may be deployed according to conventional methodology, such as by an inflatable balloon catheter, by a self-deployment mechanism (after release from a catheter), or by other appropriate means. The elongate radially expandable tubular stent may be a grafted stent, wherein the grafted stent is a composite device having a stent inside or outside of a graft. The graft may be a vascular graft, such as an ePTFE graft, a biological graft, or a woven graft.
The drug combinations may be incorporated onto or affixed to the stent in a number of ways. In the exemplary embodiment, the drug combination is directly incorporated into a polymeric matrix and sprayed onto the outer surface of the stent. The drug combination elutes from the polymeric matrix over time and enters the surrounding tissue. The drug combination preferably remains on the stent for at least three days up to approximately six months, and more preferably between seven and thirty days.
The prodrugs are slowly dissolved in physiologic fluids, but are relatively quickly dissociated into at least one pharmaceutically active compound upon dissolution in physiologic fluids. In some embodiments the dissolution rate of the prodrug is in the range of about 0.001 μg/day to about 10 μg/day. In certain embodiments, the prodrugs have dissolution rates in the range of about 0.01 to about 1 μg/day. In particular embodiments, the prodrugs have dissolution rates of about 0.1 μg/day.
The low-solubility pharmaceutical prodrug is incorporated into a biocompatable (i.e., biologically tolerated) polymer vehicle. In some embodiments according to the present invention, the low-solubility pharmaceutical prodrug is present as a plurality of granules dispersed within the polymer vehicle. In such cases, it is preferred that the low-solubility pharmaceutical prodrug be relatively insoluble in the polymer vehicle, however the low-solubility pharmaceutical prodrug may possess a finite solubility coefficient with respect to the polymer vehicle and still be within the scope of the present invention. In either case, the polymer vehicle solubility of the low-solubility pharmaceutical prodrug should be such that the prodrug will disperse throughout the polymer vehicle, while remaining in substantially granular form.
In some embodiments according to the present invention, the low-solubility pharmaceutical prodrug is dissolved within the polymer vehicle. In such cases, it is preferred that the polymer vehicle be a relatively non-polar or hydrophobic polymer which acts as a good solvent for the relatively hydrophobic low-solubility pharmaceutical prodrug. In such cases, the solubility of the low-solubility pharmaceutical prodrug in the polymer vehicle should be such that the prodrug will dissolve thoroughly in the polymer vehicle, being distributed homogeneously throughout the polymer vehicle. The polymer according to the present invention comprises any biologically tolerated polymer that is permeable to the prodrug and while having a permeability such that it is not the principal rate determining factor in the rate of release of the prodrug from the polymer.
In some embodiments according to the present invention, the polymer is non- bioerodible. Examples of non-bioerodible polymers useful in the present invention include poly(ethylene-co-vinyl acetate) (EVA), polyvinylalcohol and polyurethanes, such as polycarbonate-based polyurethanes. In other embodiments of the present invention, the polymer is bioerodible. Examples of bioerodible polymers useful in the present invention include polyanhydride, polylactic acid, polyglycolic acid, polyorthoester, polyalkylcyanoacrylate or derivatives and copolymers thereof. The skilled artisan will recognize that the choice of bioerodibility or non-bioerodibility of the polymer depends upon the final physical form of the system, as described in greater detail below. Other exemplary polymers include polysilicone and polymers derived from hyaluronic acid. The skilled artisan will understand that the polymer according to the present invention is prepared under conditions suitable to impart permeability such that it is not the principal rate determining factor in the release of the low solubility prodrug from the polymer.
Moreover, suitable polymers include naturally occurring (collagen, hyaluronic acid, etc.) or synthetic materials that are biologically compatible with bodily fluids and mammalian tissues, and essentially insoluble in bodily fluids with which the polymer will come in contact. In addition, the suitable polymers essentially prevent interaction between the low solubility prodrug dispersed/suspended in the polymer and proteinaceous components in the bodily fluid. The use of rapidly dissolving polymers or polymers highly soluble in bodily fluid or which permit interaction between the low solubility prodrug and proteinaceous components are to be avoided in certain instances since dissolution of the polymer or interaction with proteinaceous components would affect the constancy of drug release.
Other suitable polymers include polypropylene, polyester, polyethylene vinyl acetate (PVA or EVA), polyethylene oxide (PEO), polypropylene oxide, polycarboxylic acids, polyalkylacrylates, cellulose ethers, silicone, poly(dl-lactide-co glycolide), various Eudragrits (for example, NE30D, RS PO and RL PO), polyalkyl- alkyacrylate copolymers, polyester-polyurethane block copolymers, polyether- polyurethane block copolymers, polydioxanone, poly-(β-hydroxybutyrate), polylactic acid (PLA), polycaprolactone, polyglycolic acid, and PEO-PLA copolymers.
The coating of the present invention may be formed by mixing one or more suitable monomers and a suitable low-solubility pharmaceutical prodrug, then polymerizing the monomer to form the polymer system. In this way, the prodrug is dissolved or dispersed in the polymer. In other embodiments, the prodrug is mixed into a liquid polymer or polymer dispersion and then the polymer is further processed to form the inventive coating. Suitable further processing may include crosslinking with suitable crosslinking prodrugs, further polymerization of the liquid polymer or polymer dispersion, copolymerization with a suitable monomer, block copolymerization with suitable polymer blocks, etc. The further processing traps the drug in the polymer so that the drug is suspended or dispersed in the polymer vehicle. Any number of non-erodible polymers may be utilized in conjunction with the drug combination. Film-forming polymers that can be used for coatings in this application can be absorbable or non-absorbable and must be biocompatible to minimize irritation to the vessel wall. The polymer may be either biostable or bioabsorbable depending on the desired rate of release or the desired degree of polymer stability, but a bioabsorbable polymer may be preferred since, unlike biostable polymer, it will not be present long after implantation to cause any adverse, chronic local response. Furthermore, bioabsorbable polymers do not present the risk that over extended periods of time there could be an adhesion loss between the stent and coating caused by the stresses of the biological environment that could dislodge the coating and introduce further problems even after the stent is encapsulated in tissue.
Suitable film-forming bioabsorbable polymers that could be used include polymers selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amido groups, poly(anhydrides), polyphosphazenes, biomolecules and blends thereof. For the purpose of this invention aliphatic polyesters include homopolymers and copolymers of lactide (which includes lactic acid d-,1- and meso lactide), ε-caprolactone, glycolide (including glycolic acid), hydroxybutyrate, hydroxyvalerate, para-dioxanone, trimethylene carbonate (and its alkyl derivatives), l,4-dioxepan-2-one, l,5-dioxepan-2-one, 6,6-dimethyl-l,4- dioxan-2-one and polymer blends thereof. Poly(iminocarbonate) for the purpose of this invention include as described by Kemnitzer and Kohn, in the Handbook of Biodegradable Polymers, edited by Domb, Kost and Wisemen, Hardwood Academic Press, 1997, pages 251-272. Copoly(ether-esters) for the purpose of this invention include those copolyester-ethers described in Journal of Biomaterials Research, Vol. 22, pages 993-1009, 1988 by Cohn and Younes and Cohn, Polymer Preprints (ACS Division of Polymer Chemistry) Vol. 30(1), page 498, 1989 (e.g. PEO/PLA). Polyalkylene oxalates for the purpose of this invention include U.S. Pat. Nos. 4,208,511; 4,141,087; 4,130,639; 4,140,678; 4,105,034; and 4,205,399 (incorporated by reference herein). Polyphosphazenes, co-, ter- and higher order mixed monomer based polymers made from L-lactide, D,L-lactide, lactic acid, glycolide, glycolic acid, para-dioxanone, trimethylene carbonate and ε-caprolactone such as are described by Allcock in The Encyclopedia of Polymer Science, Vol. 13, pages 31- 41, Wiley Intersciences, John Wiley & Sons, 1988 and by Vandorpe, Schacht, Dejardin and Lemmouchi in the Handbook of Biodegradable Polymers, edited by Domb, Kost and Wisemen, Hardwood Academic Press, 1997, pages 161-182 (which are hereby incorporated by reference herein). Polyanhydrides from diacids of the form HOOC— C6H4-O-(CH2)m-O-C6H4-COOH where m is an integer in the range of from 2 to 8 and copolymers thereof with aliphatic alpha-omega diacids of up to 12 carbons. Polyoxaesters polyoxaamides and polyoxaesters containing amines and/or amido groups are described in one or more of the following U.S. Pat. Nos. 5,464,929; 5,595,751; 5,597,579; 5,607,687; 5,618,552; 5,620,698; 5,645,850; 5,648,088; 5,698,213 and 5,700,583; (which are incorporated herein by reference). Polyorthoesters such as those described by Heller in Handbook of Biodegradable Polymers, edited by Domb, Kost and Wisemen, Hardwood Academic Press, 1997, pages 99-118 (hereby incorporated herein by reference). Film-forming polymeric biomolecules for the purpose of this invention include naturally occurring materials that may be enzymatically degraded in the human body or are hydrolytically unstable in the human body such as fibrin, fibrinogen, collagen, elastin, and absorbable biocompatable polysaccharides such as chitosan, starch, fatty acids (and esters thereof), glucoso-glycans and hyaluronic acid.
Suitable film-forming biostable polymers with relatively low chronic tissue response, such as polyurethanes, silicones, poly(meth)acrylates, polyesters, polyalkyl oxides (polyethylene oxide), polyvinyl alcohols, polyethylene glycols and polyvinyl pyrrolidone, as well as, hydrogels such as those formed from crosslinked polyvinyl pyrrolidinone and polyesters could also be used. Other polymers could also be used if they can be dissolved, cured or polymerized on the stent. These include polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers (including methacrylate) and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics such as polystyrene; polyvinyl esters such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as etheylene-methyl methacrylate copolymers, acrylonitrile- styrene copolymers, ABS resins and ethylene-vinyl acetate copolymers; polyamides,such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins, polyurethanes; rayon; rayon-triacetate, cellulose, cellulose acetate, cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers (i.e. carboxymethyl cellulose and hydoxyalkyl celluloses); and combinations thereof. Polyamides for the purpose of this application would also include polyamides of the form -NH-(CH2)n-CO- and NH-(CH2)x-NH-CO-(CH2)y-CO, wherein n is preferably an integer in from 6 to 13; x is an integer in the range of form 6 to 12; and y is an integer in the range of from 4 to 16. The list provided above is illustrative but not limiting. The polymers used for coatings can be film-forming polymers that have molecular weight high enough as to not be waxy or tacky. The polymers also should adhere to the stent and should not be so readily deformable after deposition on the stent as to be able to be displaced by hemodynamic stresses. The polymers molecular weight be high enough to provide sufficient toughness so that the polymers will not to be rubbed off during handling or deployment of the stent and must not crack during expansion of the stent. In certain embodiments, the polymer has a melting temperature above 40°C, preferably above about 45°C, more preferably above 50°C and most preferably above 55°C.
Coating may be formulated by mixing one or more of the therapeutic prodrugs with the coating polymers in a coating mixture. The therapeutic prodrug may be present as a liquid, a finely divided solid, or any other appropriate physical form. Optionally, the mixture may include one or more additives, e.g., nontoxic auxiliary substances such as diluents, carriers, excipients, stabilizers or the like. Other suitable additives may be formulated with the polymer and pharmaceutically active prodrug or compound. For example, hydrophilic polymers selected from the previously described lists of biocompatible film forming polymers maybe added to a biocompatible hydrophobic coating to modify the release profile (or a hydrophobic polymer may be added to a hydrophilic coating to modify the release profile). One example would be adding a hydrophilic polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyethylene glycol, carboxylmethyl cellulose, hydroxymethyl cellulose and combination thereof to an aliphatic polyester coating to modify the release profile. Appropriate relative amounts can be determined by monitoring the in vitro and/or in vivo release profiles for the therapeutic prodrugs. The thickness of the coating can determine the rate at which the active drug(s) or prodrug elutes from the matrix. Essentially, the active drug(s) or prodrug elutes from the matrix by diffusion through the polymer matrix. Polymers are permeable, thereby allowing solids, liquids and gases to escape therefrom. The total thickness of the polymeric matrix is in the range from about one micron to about twenty microns or greater. It is important to note that primer layers and metal surface treatments may be utilized before the polymeric matrix is affixed to the medical device. For example, acid cleaning, alkaline (base) cleaning, salinization and parylene deposition may be used as part of the overall process described.
In certain embodiments, multiple coatings can be used. For instance, the various coatings can differ in the concentration of prodrug, the identity of the prodrugs (active ingredients, linkers, etc), the characteristics of the polymer matrix (composition, porosity, etc) and/or the presence of other drugs or release modifiers.
To further illustrate, a poly(ethylene-co-vinylacetate), polybutylmethacrylate and drug combination solution may be incorporated into or onto the stent in a number of ways. For example, the solution may be sprayed onto the stent or the stent may be dipped into the solution. Other methods include spin coating and RF plasma polymerization. In one exemplary embodiment, the solution is sprayed onto the stent and then allowed to dry. In another exemplary embodiment, the solution may be electrically charged to one polarity and the stent electrically changed to the opposite polarity. In this manner, the solution and stent will be attracted to one another. In using this type of spraying process, waste may be reduced and more precise control over the thickness of the coat may be achieved.
In another exemplary embodiment, the drug combination or other therapeutic prodrug may be incorporated into a film-forming polyfluoro copolymer comprising an amount of a first moiety selected from the group consisting of polymerized vinylidenefluoride and polymerized tetrafluoroethylene, and an amount of a second moiety other than the first moiety and which is copolymerized with the first moiety, thereby producing the polyfluoro copolymer, the second moiety being capable of providing toughness or elastomeric properties to the polyfluoro copolymer, wherein the relative amounts of the first moiety and the second moiety are effective to provide the coating and film produced therefrom with properties effective for use in treating implantable medical devices.
In one embodiment according to the present invention, the exterior surface of the expandable tubular stent of the intraluminal medical device of the present invention comprises a coating according to the present invention. The exterior surface of a stent having a coating is the tissue-contacting surface and is biocompatible. The "sustained release drug delivery system coated surface" is synonymous with "coated surface", which surface is coated, covered or impregnated with sustained release drug delivery system according to the present invention.
In an alternate embodiment, the interior luminal surface or entire surface (i.e. both interior and exterior surfaces) of the elongate radially expandable tubular stent of the intraluminal medical device of the present invention has the coated surface. The interior luminal surface having the inventive sustained release drug delivery system coating is also the fluid contacting surface, and is biocompatible and blood compatible. U.S. Pat. No. 5,773,019, U.S. Pat. No. 6,001,386, and U.S. Pat. No.
6,051,576 disclose implantable controlled-release devices and drugs and are incorporated in their entireties herein by reference. The inventive process for making a surface coated stent includes deposition onto the stent of a coating by, for example, dip coating or spray coating. In the case of coating one side of the stent, only the surface to be coated is exposed to the dip or spray. The treated surface may be all or part of an interior luminal surface, an exterior surface, or both interior and exterior surfaces of the intraluminal medical device. The stent may be made of a porous material to enhance deposition or coating into a plurality of micropores on or in the applicable stent surface, wherein the microporous size is preferably about 100 microns or less.
Problems associated with treating restinosis and neointimal hyperplasia can be addressed by the choice of pharmaceutical prodrug used to coat the medical device. In certain preferred embodiments of the present invention, the chosen pharmaceutical prodrug is a moiety of low-solubility and comprises at least two pharmaceutically active compounds. The pharmaceutically active compounds can be the same or different chemical species, and can be formed, as desired, in equi-molar or non-equi-molar concentrations to provide optimal treatment based on the relative activities and other pharmaco-kinetic properties of the compounds. The drug combination, particularly where co-drug formulations are used, may itself be advantageously relatively insoluble in physiologic fluids, such as blood and blood plasma, and has the property of regenerating any or all of the pharmaceutically active compounds when dissolved in physiologic fluids. In other words, to the extent that the low-solubility prodrug dissolves in physiologic fluids, it is quickly and efficiently converted into the constituent pharmaceutically active compounds upon dissolution. The low-solubility of the pharmaceutical prodrug thus insures persistence of the prodrug in the vicinity of an intraluminal lesion. The quick conversion of the low-solubility pharmaceutical prodrug into the constituent pharmaceutically active compounds insures a steady, controlled, dose of the pharmaceutically active compounds near the site of the lesion to be treated. Examples of a suitable first pharmaceutically active compound include immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), anticancer/anti-proliferative prodrugs such as 5-fluorouracil (5FU) and BCNU, and non-steroidal anti-inflammatory prodrugs such as naproxen, diclofenac, indomethacin and flurbiprofen.
In some embodiments according to the present invention, the preferred first pharmaceutically active compound is 5FU.
Figure imgf000022_0001
5-Fluorouracil (5FU). Examples of a suitable second pharmaceutically active compound include immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), anticancer/anti-proliferative prodrugs such as 5-fluorouracil (5FU) and BCNU, and non-steroidal anti-inflammatory prodrugs such as naproxen, diclofenac, indomethacin and flurbiprofen.
In some embodiments according to the present invention, the second pharmaceutically active compound is selected from fluocinolone acetonide, triamcinolone acetonide, diclofenac, and naproxen.
Figure imgf000022_0002
Triamcinolone acetonide Diclofenac
Figure imgf000023_0001
Naproxen
The low-solubility pharmaceutically active prodrug according to the present invention may comprise further residues of pharmaceutically active compounds. Such further pharmaceutically active compounds include immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone, fluocinolone acetonide and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), anticancer/anti-proliferative prodrugs such as 5-fluorouracil (5FU) and BCNU, and non-steroidal anti-inflammatory prodrugs such as naproxen, diclofenac, indomethacin and flurbiprofen.
In certain embodiments, the low-solubility pharmaceutical prodrug comprises a moiety of at least two pharmaceutically active compounds that can be covalently bonded, connected through a linker, ionically combined, or combined as a mixture. In some embodiments according to the present invention, the first and second pharmaceutically active compounds are covalently bonded directly to one another. Where the first and second pharmaceutically active compounds are directly bonded to one another by a covalent bond, the bond may be formed by forming a suitable covalent linkage through an active group on each active compound. For instance, an acid group on the first pharmaceutically active compound may be condensed with an amine, an acid or an alcohol on the second pharmaceutically active compound to form the corresponding amide, anhydride or ester, respectively.
In addition to carboxylic acid groups, amine groups, and hydroxyl groups, other suitable active groups for forming linkages between pharmaceutically active moieties include sulfonyl groups, sulfhydryl groups, and the haloic acid and acid anhydride derivatives of carboxylic acids.
In other embodiments, the pharmaceutically active compounds may be covalently linked to one another through an intermediate linker. The linker advantageously possesses two active groups, one of which is complementary to an active group on the first pharmaceutically active compound, and the other of which is complementary to an active group on the second pharmaceutically active compound. For example, where the first and second pharmaceutically active compounds both possess free hydroxyl groups, the linker may suitably be a diacid, which will react with both compounds to form a diether linkage between the two residues. In addition to carboxylic acid groups, amine groups, and hydroxyl groups, other suitable active groups for forming linkages between pharmaceutically active moieties include sulfonyl groups, sulfhydryl groups, and the haloic acid and acid anhydride derivatives of carboxylic acids.
Suitable linkers are set forth in Table 1 below.
Figure imgf000024_0001
Suitable diacid linkers include oxalic, malonic, succinic, glutaric, adipic, pimelic, suberic, azelaic, sebacic, maleic, fumaric, tartaric, phthalic, isophthalic, and terephthalic acids. While diacids are named, the skilled artisan will recognize that in certain circumstances the corresponding acid halides or acid anhydrides (either unilateral or bilateral) are preferred as linker reprodrugs. A preferred anhydride is succinic anhydride. Another preferred anhydride is maleic anhydride. Other anhydrides and/or acid halides may be employed by the skilled artisan to good effect.
Suitable amino acids include γ-butyric acid, 2-aminoacetic acid, 3- aminopropanoic acid, 4-aminobutanoic acid, 5-aminopentanoic acid, 6- aminohexanoic acid, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. Again, the acid group of the suitable amino acids may be converted to the anhydride or acid halide form prior to their use as linker groups. Suitable diamines include 1, 2-diaminoethane, 1,3-diaminopropane, 1,4- diaminobutane, 1,5-diaminopentane, 1,6-diaminohexane.
Suitable aminoalcohols include 2-hydroxy-l-aminoethane, 3-hydroxy-l- aminoethane, 4-hydroxy-l-aminobutane, 5-hydroxy-l-aminopentane, 6-hydroxy-l- aminohexane. Suitable hydroxyalkyl acids include 2-hydroxyacetic acid, 3- hydroxypropanoic acid, 4-hydroxybutanoic acid, 5-hydroxypentanoic acid, 5- hydroxyhexanoic acid.
The person having skill in the art will recognize that by selecting first and second pharmaceutical moieties (and optionally third, etc. pharmaceutical moieties) having suitable active groups, and by matching them to suitable linkers, a broad palette of inventive compounds may be prepared within the scope of the present invention.
Exemplary preferred low-solubility pharmaceutically active prodrugs include 5FU covalently bonded to fluocinolone acetonide, 5FU covalently bonded to diclofenac, and 5FU covalently bonded to naproxen. Illustrative examples include the following:
Figure imgf000025_0001
5FU-fluocinolone acetonide (via oxalate linker).
Figure imgf000026_0001
5FU-Naproxen
Figure imgf000026_0002
5FU-Diclofenac
Other exemplary codrugs include the following:
Figure imgf000027_0001
-TC-70.1 (codrug of fluocinolone acetonide with 5-FU via formaldehyde linkage)
Figure imgf000027_0002
5-TC-63.1 (codrug of naproxen with floxuridine via oxa acid linkage)
Figure imgf000027_0003
3-TC-112 (codrug of naproxen with 5-FU via formaldehyde linkage)
Figure imgf000027_0004
G-427.1 (direct codrug of triamcinolone acetonide with 5-FU)
Figure imgf000027_0005
TC-32 (codrug of triamcinolone acetonide with 5-FU via formaldehyde linkage) Some exemplary co-drugs which join the first and second pharmaceutically active compounds with different linkages include:
Figure imgf000028_0001
Co-drug of Floxuridine with Diclofenac (1:1)
Figure imgf000028_0002
Figure imgf000029_0001
Figure imgf000030_0001
Co-drug of Floxuridine with Fluocinolone acetonide (1:1)
Figure imgf000031_0001
Co-drug of Floxuridine with Naproxen (1:1)
Figure imgf000031_0002
Co-drug of Floxuridine with Naproxen (1:2)
In other embodiments, the first and second pharmaceutically active compounds may be combined to form a salt. For instance, the first pharmaceutically active compound may be an acid, and the second pharmaceutically active compound may be a base, such as an amine. As a specific example, the first pharmaceutically active compound may be diclofenac or naproxen (acids), and the second pharmaceutically active compound may be ciprofloxacin (a base). The combination of diclofenac and ciprofloxacin would for instance form the salt:
Figure imgf000032_0001
Ciprofloxacin-Diclofenac
For the system of present invention to deliver a prodrug in desired fashion, e.g., constant or substantially linear in some embodiments, he solubility of the drug and the permeability of the polymer must be balanced so that the permeability of the polymer is not the principal rate determining factor in the delivery of the drug. As a result, the rate of release of the prodrug is essentially the rate at which the prodrug is solubilized in the sunounding aqueous medium. This rate of release is nearly approximately linear with respect to time (so-called zero-order kinetics.). The system of the present invention may be formed by mixing one or more suitable monomers and a suitable low-solubility pharmaceutical prodrug, then polymerizing the monomer to form the polymer system. In this way, the prodrug is dissolved or dispersed in the polymer. In other embodiments, the prodrug is mixed into a liquid polymer or polymer dispersion and then the polymer is further processed to form the inventive system. Suitable further processing includes crosslinking with suitable crosslinking prodrugs, further polymerization of the liquid polymer or polymer dispersion, copolymerization with a suitable monomer, block copolymerization with suitable polymer blocks, etc. The further processing traps the drug in the polymer so that the drug is suspended or dispersed in the polymer vehicle.
In some embodiments according to the present invention, monomers for forming a polymer are combined with an inventive low-solubility compound and are mixed to make a homogeneous dispersion of the inventive compound in the monomer solution. The dispersion is then applied to a stent according to a conventional coating process, after which the crosslinking process is initiated by a conventional initiator, such as UV light. In other embodiments according to the present invention, a polymer composition is combined with an inventive low- solubility compound to form a dispersion. The dispersion is then applied to a stent and the polymer is cross-linked to form a solid coating. In other embodiments according to the present invention, a polymer and an inventive low-solubility compound are combined with a suitable solvent to form a dispersion, which is then applied to a stent in a conventional fashion. The solvent is then removed by a conventional process, such as heat evaporation, with the result that the polymer and inventive low-solubility drug (together forming a sustained-release drug delivery system) remain on the stent as a coating. An analogous process may be used where the inventive low-solubility pharmaceutical compound is dissolved in the polymer composition.
In some embodiments according to the invention, the system comprises a polymer that is relatively rigid. In other embodiments, the system comprises a polymer that is soft and malleable. In still other embodiments, the system includes a polymer that has an adhesive character. Hardness, elasticity, adhesive, and other characteristics of the polymer are widely variable, depending upon the particular final physical form of the system, as discussed in more detail below.
Embodiments of the system according to the present invention take many different forms. In some embodiments, the system consists of the low solubility prodrug, i.e., the prodrug suspended or dispersed in the polymer. In certain other embodiments, the system consists of a prodrug and a semi-solid or gel polymer, which is adapted to be injected via a syringe into a body. In other embodiments according to the present invention, the system consists of a prodrug and a soft-flexible polymer, which is adapted to be inserted or implanted into a body by a suitable surgical method. In still further embodiments according to the present invention, the system consists of a hard, solid polymer, which is adapted to be inserted or implanted into a body by a suitable surgical method. In additional embodiments of the present invention, the system comprises a polymer having the low solubility prodrug suspended or dispersed therein which is suitable for inhalation. In further embodiments, the system comprises a polymer having the prodrug suspended or dispersed therein, wherein the prodrug and polymer mixture forms a coating on a surgical implement, such as a screw, stent, pacemaker, etc. In particular embodiments according to the present invention, the device consists of a hard, solid polymer, which is shaped in the form of a surgical implement such as a surgical screw, plate, stent, etc., or some part thereof. In other embodiments according to the present invention, the system includes a polymer that is in the form of a suture having the drug dispersed or suspended therein. In some embodiments according to the present invention, provided is a medical device comprising a substrate having a surface, such as an exterior surface, and a coating on the exterior surface. The coating comprises a polymer and a prodrug having a low solubility dispersed in the polymer, wherein the polymer is permeable to the prodrug and is essentially non-release rate limiting with respect to the rate of release of the prodrug from the polymer. In certain embodiments according to the present invention, the device comprises a prodrug suspended or dispersed in a suitable polymer, wherein the prodrug and polymer are coated onto an entire substrate, e.g., a surgical implement. Such coating may be accomplished by spray coating or dip coating.
In other embodiments according to the present invention, the device comprises a prodrug and polymer suspension or dispersion, wherein the polymer is rigid, and forms a constituent part of a device to be inserted or implanted into a body. For instance, in particular embodiments according to the present invention, the device is a surgical screw, stent, pacemaker, etc. coated with the prodrug suspended or dispersed in the polymer. In other particular embodiments according to the present invention, the polymer in which the prodrug is suspended forms a tip or a head, or part thereof, of a surgical screw. In other embodiments according to the present invention, the polymer in which prodrug is suspended or dispersed is coated onto a surgical implement such as surgical tubing (such as colostomy, peritoneal lavage, catheter, and intravenous tubing). In still further embodiments according to the present invention, the device is an intravenous needle having the polymer and prodrug (for instance, a prodrug of an anticoagulant such as heparin or codrug thereof) coated thereon. As discussed above, a device according to the present invention comprises a polymer that is bioerodible or non-bioerodible. The choice of bioerodible versus non-bioerodible polymer is made based upon the intended end use of the system or device. In some embodiments according to the present invention, the polymer is advantageously bioerodible. For instance, where the system is a coating on a surgically implantable device, such as a screw, stent, pacemaker, etc., the polymer is advantageously bioerodible. Other embodiments according to the present invention in which the polymer is advantageously bioerodible include devices that are implantable, inhalable, or injectable suspensions or dispersions of prodrug in a polymer, wherein the further elements (such as screws or anchors) are not utilized. In some embodiments according to the present invention wherein the polymer is poorly permeable and bioerodible, the rate of bioerosion of the polymer is advantageously sufficiently slower than the rate of drug release so that the polymer remains in place for a substantial period of time after the drug has been released, but is eventually bioeroded and resorbed into the surrounding tissue. For example, where the device is a bioerodible suture comprising the drug suspended or dispersed in a bioerodible polymer, the rate of bioerosion of the polymer is advantageously slow enough that the drug is released in a linear manner over a period of about three to about 14 days, but the sutures persist for a period of about three weeks to about six months. Similar devices according to the present invention include surgical staples comprising a prodrug suspended or dispersed in a bioerodible polymer. In other embodiments according to the present invention, the rate of bioerosion of the polymer is advantageously on the same order as the rate of drug release. For instance, where the system comprises a prodrug suspended or dispersed in a polymer that is coated onto a surgical implement, such as an orthopedic screw, a stent, a pacemaker, or a non-bioerodible suture, the polymer advantageously bioerodes at such a rate that the surface area of the prodrug that is directly exposed to the surrounding body tissue remains substantially constant over time.
In some embodiments according to the present invention, the polymer is non- bioerodible, or is bioerodible only at a rate slower than a dissolution rate of the low- solubility pharmaceutical prodrug, and the diameter of the granules is such that when the coating is applied to the stent, the granules' surfaces are exposed to the ambient tissue. In such embodiments, dissolution of the low-solubility pharmaceutical prodrug is proportional to the exposed surface area of the granules.
In other embodiments according to the present invention, the polymer vehicle is permeable to water in the surrounding tissue, e.g. in blood plasma. In such cases, water solution may permeate the polymer, thereby contacting the low-solubility pharmaceutical prodrug. The rate of dissolution may be governed by a complex set of variables, such as the polymer's permeability, the solubility of the low-solubility pharmaceutical prodrug, the pH, ionic strength, and protein composition, etc. of the physiologic fluid. In certain embodiments, however the permeability may be adjusted so that the rate of dissolution is governed primarily, or in some cases practically entirely, by the solubility of the low-solubility pharmaceutical prodrug in the ambient liquid phase.
In some embodiments according to the present invention, the polymer is non- bioerodible. Non-bioerodible polymers are especially useful where the system includes a polymer intended to be coated onto, or form a constituent part, of a surgical implement that is adapted to be permanently, or semi-permanently, inserted or implanted into a body. Exemplary devices in which the polymer advantageously forms a permanent coating on a surgical implement include an orthopedic screw, a stent, a prosthetic joint, an artificial valve, a permanent suture, a pacemaker, etc. A surgical system according to the present invention is used in a manner suitable for the desired therapeutic effect. For instance in some embodiments according to the invention, the mode of administration is advantageously by injection. In such cases, the system is a liquid, and is introduced into the desired locus by taking the system up into the barrel of a syringe and injecting the system through a needle into the desired locus. Such a mode of administration is suitable for intramuscular injection, for instance intramuscular injection of sustained-release formulations of microbicides, including antibiotics, antivirals, and steroids. This mode of administration is also useful where the desired therapeutic effect is the sustained release of hormones such as thyroid medication, birth control prodrugs, estrogen for estrogen therapy, etc. The skilled clinician will appreciate that this mode of administration is adaptable to various therapeutic milieus, and will adapt the particular polymer and drug of the system to the desired therapeutic effect.
In embodiments according to the present invention in which the mode of administration is to be by injection, the system is advantageously a relatively non-polar drug suspended or dispersed in a viscous polymer vehicle. The system is, in such cases, a stable suspension or dispersion of non-polar drug in liquid polymer vehicle. Advantageously, the polymer vehicle will be either non-bioerodible or will bioerode at a rate slower than the rate of diffusion of the drug into the surrounding tissue. In such cases, the system stays in place in place relative to the surrounding tissue, preventing the drug from being prematurely released into the surrounding tissue.
In other embodiments according to the present invention, the system is a relatively non-polar liquid suspended or dispersed in a liquid polymer. In such cases, the system further comprises an emulsifier that maintains the relatively non-polar drug in a stable, dispersed, state within the polymer. The polymer vehicle advantageously is non-bioerodible, or is bioerodible at a slower rate than the rate of diffusion of the drug, so that the system maintains the location of the drug relative to the surrounding tissue over the full period of drug release. The precise properties of the system according to the present invention depend upon the therapeutic use intended, the physical state of the drug to incorporated into the system under physiologic conditions, etc.
In some embodiments according to the present invention, the system according to the present invention is advantageously a solid device of a shape and form suitable for implantation, for instance subcutaneously, etc. In some embodiments according to the present invention, the system is in the shape of an elongated ovoid, the prodrug is of a non-polar drug, such as a hormone, and the polymer is a solid polymer whose permeability is such that it is not the primary rate-determining factor in the rate of release of the drug. In particular embodiments according to the present invention, the polymer is bioerodible. In other embodiments according to the present invention, the polymer is non-bioerodible.
In embodiments according to the present invention wherein the device comprises a substrate and a coating on the substrate, such as a screw, stent, pacemaker, prosthetic joint, etc., the device is used in substantially the manner of the corresponding prior art surgical implement. For instance, a device according to the present invention that comprises a screw coated with a composition comprising a low solubility prodrug, such as an antibiotic or FU-naproxen, suspended or dispersed in a polymer, is screwed into a bone in the same manner as a prior art screw. The screw according to the present invention then releases drug, in a sustained time-wise fashion, thereby conferring therapeutic benefits, such as antibiotic, anti- inflammatory, and antiviral effects, to the tissue surrounding the device, such as muscle, bone, blood, etc.
As used in this specification and the appended claims, sustained release means release via rate kinetics such that the permeability of the polymer is non-rate limiting with respect to the rate of release of the drug.
In embodiments according to the present invention wherein the device is a surgical implement into which the prodrug and polymer have been incorporated as a constituent part, the polymer is advantageously a solid having physical properties appropriate for the particular application of the device. For instance, where the device is a suture, the polymer will have strength and bioerodibility properties suitable for the particular surgical situation. Where the device is a screw, stent, etc, the polymer is advantageously a rigid solid forming at least part of the surgical implement. In particular embodiments according to the present invention, such as where the system is part of a prosthetic joint, the polymer advantageously is non-bioerodible and remains in place after the prodrug has been released into the surrounding tissue. In other embodiments according to the present invention, such as in the case of bioerodible sutures, the polymer bioerodes after release of substantially all the prodrug. While exemplary embodiments of the invention will be described with respect to the treatment of restenosis and related complications following percutaneous transluminal coronary angioplasty, it is important to note that the local delivery of drug/drug combinations may be utilized to treat a wide variety of conditions utilizing any number of medical devices, or to enhance the function and/or life of the device. For example, intraocular lenses, placed to restore vision after cataract surgery is often compromised by the formation of a secondary cataract. The latter is often a result of cellular overgrowth on the lens surface and can be potentially minimized by combining a drug or drugs with the device. Other medical devices which often fail due to tissue in-growth or accumulation of proteinaceous material in, on and around the device, such as shunts for hydrocephalus, dialysis grafts, colostomy bag attachment devices, ear drainage tubes, leads for pace makers and implantable defibrillators can also benefit from the device-drug combination approach.
Devices which serve to improve the structure and function of tissue or organ may also show benefits when combined with the appropriate prodrug or codrugs. For example, improved osteointegration of orthopedic devices to enhance stabilization of the implanted device could potentially be achieved by combining it with prodrugs such as bone morphogenic protein. Similarly other surgical devices, sutures, staples, anastomosis devices, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds, various types of dressings, bone substitutes, intraluminal devices, and vascular supports could also provide enhanced patient benefit using this drug-device combination approach. Essentially, any type of medical device may be coated in some fashion with a prodrug or codrug which enhances treatment over use of the singular use of the device or pharmaceutical prodrug.
The subject devices can be used to deliver such pharmaceutical drugs as: antiproliferative/antimitotic prodrugs including natural products such as vinca alkaloids (i.e. vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (i.e. etoposide, teniposide), antibiotics (dactinomycin (actinomycin D) daunorubicin, doxorubicin and idarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (L- asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet prodrugs; antiproliferative/antimitotic alkylating prodrugs such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nirtosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes - dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate), pyrimidine analogs (fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine fcladribinel); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones (i.e. estrogen); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic prodrugs (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory; antisecretory (breveldin); antiinflammatory: such as adrenocortical steroids (cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6U-methylprednisolone, triamcinolone, betamethasone, and dexamethasone), non-steroidal prodrugs (salicylic acid derivatives i.e. aspirin; para-aminophenol derivatives i.e. acetominophen; indole and indene acetic acids (indomethacin, sulindact and etodalac), heteroaryl acetic acids (tolmetin, diclofenac, and ketorolac), arylpropionic acids (ibuprofen and derivatives), anthranilic acids (mefenamic acid, and meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone, and oxyphenthatrazone), nabumetone, gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); angiogenic prodrugs: vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF); angiotensin receptor blocker; nitric oxide donors; anti-sense oligionucleotides and combinations thereof; cell cycle inhibitors, mTOR inhibitors, and growth factor signal transduction kinase inhibitors. In certain embodiments, the prodrug is formed using an opiod. Exemplary opioids include morophine derivatives, such as apomorphine, buprenorphine, codeine, dihydrocodeine, dihydroetorphine, diprenorphine, etorphine, hydrocodone, hydromorphone, levorphanol, meperidine, metopon, o-methylnaltrexone, morphine, naloxone, naltrexone, normorphine, oxycodone, and oxymorphone. In other embodiments, the opiod is a fentanyl derivative which can be deritized to form the prodrug, such as β-hydroxy-3-methylfentanyl. As used in regard to the low-solubility pharmaceutical prodrug, the term "low-solubility" relates to the solubility of the pharmaceutical prodrug in biological fluids, such as blood plasma, lymphatic fluid, peritoneal fluid, etc. In general, "low- solubility" means that the pharmaceutical prodrug is only very slightly soluble in aqueous solutions having pH in the range of about 5 to about 8, and in particular to physiologic solutions, such as blood, blood plasma, etc. Some low-solubility prodrugs according to the present invention will have solubilities of less than about 1 mg/ml, less than about 100 μg/ml, preferably less than about 20 μg/ml, more preferably less than about 15 μg/ml, and more preferably less than about 10 μg/ml. Solubility is in water at a temperature of 25°C as measured by the procedures set forth in the 1995 USP, unless otherwise stated. This includes compounds which are slightly soluble (about lOmg/ml to about 1 mg/ml), very slightly soluble (about 1 mg/ml to about 0.1 mg/ml) and practically insoluble or insoluble compounds (less than about 0.01 mg/ml). Suitable prodrugs useful in the present invention include prodrugs of immune response modifiers such as cyclosporin A and FK 506, corticosteroids such as dexamethasone and triamcinolone acetonide, angiostatic steroids such as trihydroxy steroids, antiparasitic prodrugs such as atovaquone, anti-glaucoma prodrugs such as ethacrynic acid, antibiotics including ciprofloxacin, differentiation modulators such as retinoids (e.g., trans-retinoic acid, cis-retinoic acid and analogues), antiviral prodrugs including high molecular weight low (10-mers), anti-sense compounds, anticancer prodrugs such as BCNU, non-steroidal anti-inflammatory prodrugs such as indomethacin and flurbiprofen, and prodrugs comprising a conjugate of at least two compounds linked via a reversible covalent or ionic bond that is cleaved at a desired site in a body to regenerate an active form of each compound. In embodiments of the present invention, the prodrug is relatively insoluble in aqueous media, including physiological fluids, such as blood serum, mucous, peritoneal fluid, limbic fluid, etc. In still further embodiments according to the present invention, suitable prodrugs include drugs, which are lipophilic derivatives of hydrophilic drugs, that are easily converted into their hydrophilic drugs under physiological accessible conditions. Reference may be made to any standard pharmaceutical textbook for the procedures to obtain a low solubility form of a drug. In this regard, the present invention is especially suitable for prodrugs that heretofore have not found broad application due to their inherent low solubility, or have found only limited application in oil-based or other lipid-based delivery vehicles. In certain embodiments, the present invention provides an intraluminal medical device for implantation into a lumen of a blood vessel, in particular adjacent an intraluminal lesion such as an atherosclerotic lesion, for maintaining patency of the vessel. In particular the present invention provides an elongate radially expandable tubular stent having an interior luminal surface and an opposite exterior surface extending along a longitudinal stent axis, the stent having a coating on at least a portion of the interior or exterior surface thereof. The local delivery of drug combinations from a stent has the following advantages; namely, the prevention of vessel recoil and remodeling through the scaffolding action of the stent and the prevention of multiple components of neointimal hyperplasia or restenosis as well as a reduction in inflammation and thrombosis. This local administration of drugs to stented coronary arteries may also have additional therapeutic benefit. For example, higher tissue concentrations of the drugs may be achieved utilizing local delivery, rather than systemic administration. In addition, reduced systemic toxicity may be achieved utilizing local delivery rather than systemic administration while maintaining higher tissue concentrations. Also in utilizing local delivery from a stent rather than systemic administration, a single procedure may suffice with better patient compliance. An additional benefit of combination drug therapy may be to reduce the dose of each of the therapeutic drugs, prodrugs or compounds, thereby limiting their toxicity, while still achieving a reduction in restenosis, inflammation and thrombosis. Local stent-based therapy is therefore a means of improving the therapeutic ratio (efficacy/toxicity) of anti-restenosis, anti-inflammatory, anti- thrombotic drugs, prodrugs or compounds.
There are a multiplicity of different stents that may be utilized following percutaneous transluminal coronary angioplasty. Although any number of stents may be utilized in accordance with the present invention, for simplicity, a limited number of stents will be described in exemplary embodiments of the present invention. The skilled artisan will recognize that any number of stents may be utilized in connection with the present invention. In addition, as stated above, other medical devices may be utilized. A stent is commonly used as a tubular structure left inside the lumen of a duct to relieve an obstruction. Commonly, stents are inserted into the lumen in a non-expanded form and are then expanded autonomously, or with the aid of a second device in situ. A typical method of expansion occurs through the use of a catheter-mounted angioplasty balloon which is inflated within the stenosed vessel or body passageway in order to shear and disrupt the obstructions associated with the wall components of the vessel and to obtain an enlarged lumen. The stents of the present invention may be fabricated utilizing any number of methods. For example, the stent may be fabricated from a hollow or formed stainless steel tube that may be machined using lasers, electric discharge milling, chemical etching or other means. The stent is inserted into the body and placed at the desired site in an unexpanded form. In one exemplary embodiment, expansion may be effected in a blood vessel by a balloon catheter, where the final diameter of the stent is a function of the diameter of the balloon catheter used.
It should be appreciated that a stent in accordance with the present invention may be embodied in a shape-memory material, including, for example, an appropriate alloy of nickel and titanium or stainless steel.
Structures formed from stainless steel may be made self-expanding by configuring the stainless steel in a predetermined manner, for example, by twisting it into a braided configuration. In this embodiment after the stent has been formed it may be compressed so as to occupy a space sufficiently small as to permit its insertion in a blood vessel or other tissue by insertion means, wherein the insertion means include a suitable catheter, or flexible rod.
On emerging from the catheter, the stent may be configured to expand into the desired configuration where the expansion is automatic or triggered by a change in pressure, temperature or electrical stimulation. Regardless of the design of the stent, it is preferable to have the drug combination dosage applied with enough specificity and a sufficient concentration to provide an effective dosage in the lesion area. In this regard, the "reservoir size" in the coating is preferably sized to adequately apply the drug combination dosage at the desired location and in the desired amount. In an alternate exemplary embodiment, the entire inner and outer surface of the stent may be coated with drug/drug combinations in therapeutic dosage amounts. It is, however, important to note that the coating techniques may vary depending on the drug combinations. Also, the coating techniques may vary depending on the material comprising the stent or other intraluminal medical device. An embodiment of an intraluminal device (stent) according to the present invention is depicted in FIGs. 3 and 4.
FIG. 3 shows a side plan view of a preferred elongate radially expandable tubular stent 13 having a surface coated with a sustained release drug delivery system in a non-deployed state. As shown in FIG. 3, the stent 13 has its radially outer boundaries 14A, 14B at a non-deployed state. The interior luminal surface 15, the exterior surface 16, or an entire surface of the stent 13 may be coated with a sustained release drug delivery system or comprise a sustained release drug delivery system. The interior luminal surface 15 is to contact a body fluid, such as blood in a vascular stenting procedure, while the exterior surface 16 is to contact tissue when the stent 13 is deployed to support and enlarge the biological vessel or duct.
In an alternate embodiment, an optional reinforcing wire 17 that connects two or more of the adjacent members or loops of the stent structure 13 is used to lock-in and/or maintain the stent at its expanded state when a stent is deployed. This reinforcing wire 17 may be made of a Nitinol or other high-strength material. A Nitinol device is well known to have a preshape and a transition temperature for said Nitinol device to revert to its preshape. One method for treating an intraluminal tissue of a patient using a surface coated stent 13 of the present invention comprises collapsing the radially expandable tubular stent and retracting the collapsed stent from a body of a patient. The operation for collapsing a radially expandable tubular stent may be accomplished by elevating the temperature so that the reinforcing wire 17 is reversed to its straightened state or other appropriate state to cause the stent 13 to collapse for removing said stent from the body of a patient.
FIG. 4 shows an overall view of an elongate radially expandable tubular stent 13 having a sustained release drug delivery system coated stent surface at a deployed state. As shown in FIG. 4, the stent 13 has its radially outer boundaries 24A, 24B at a deployed state. The interior luminal surface 14, the exterior surface 16, or an entire surface of the stent 13 may be coated or may comprise the sustained release drug delivery system. The interior luminal surface 15 is to contact a body fluid, such as blood in a vascular stenting procedure, while the exterior surfacelό is to contact tissue when the stent 13 is deployed to support and enlarge the biological vessel.
The reinforcing wire 17 may be used to maintain the expanded stent at its expanded state as a permanent stent or as a temporary stent. In the case of the surface coated stent 13 functioning as a temporary stent, the reinforcing wire 17 may have the capability to cause collapsing of the expanded stent.
The deployment of a stent can be accomplished by a balloon on a delivery catheter or by self-expanding after a pre-stressed stent is released from a delivery catheter. Delivery catheters and methods for deployment of stents are well known to one who is skilled in the art. The expandable stent 13 may be a self-expandable stent, a balloon-expandable stent, or an expandable-retractable stent. The expandable stent may be made of memory coil, mesh material, and the like. III. Examples
The present invention can be more fully understood with reference to the following examples.
Prodrug TC-112 comprising a conjugate of 5-fluorouracil and naproxen linked via a reversible covalent bond, and prodrug G.531.1 comprising a conjugate of 5-fluorouracil and fluocinolone acetonide were prepared in accordance with the methods set forth in U.S. Patent No. 6,051,576. The structure of these compounds is reproduced below.
Figure imgf000044_0001
5-Fluorouracil (5-FU)
Figure imgf000044_0002
Naproxen
Figure imgf000045_0001
TC-1 12
Figure imgf000045_0002
G.531.1
The following examples are intended to be illustrative of the disclosed invention. The examples are non-limiting, and the skilled artisan will recognize that other embodiments are within the scope of the disclosed invention.
Example 1
To 20 gm of 10% (w/v) aqueous poly( vinyl alcohol) (PVA) solution, 80.5 mg of prodrug TC-112 was dispersed. 5 pieces of glass plates were then dipping coated with this TC-112/PVA suspension and followed by air-drying. The coating and air- drying was repeated four more times. At the end about 100 mg of TC-112/PVA was coated on each glass plates. The coated glass plates were then heat treated at 135°C for 5 hours. After cooling to room temperature, the glass plates were individually placed in 20 ml of 0.1 M mol phosphate buffer (pH 7.4, 37 °C) for release test. Sample was taken daily and entire release media were replaced with fresh one at each sampling time. The drugs and TC-112 released in the media were determined by reverse-phase HPLC. The half-life for TC-112 in pH 7.4 buffer is 456 min, in serum is 14 min.
The results are shown in FIG. 1, which shows the total cumulative release of TC-112 from PVA coated glass plates. The slope of the curve demonstrates that TC- 112 is released at 10 μg/day. The data represent both intact and constituents of the compound TC-112.
Example 2
12.0 gm of silicone part A (Med-6810A) were mixed with 1.2 gm of silicone part B (Med-6810B), and degassed in sonicator for 10 min, followed by water aspirator. 41.2 mg of (TC-112) were dispersed in this degassed silicone, and degassed again. 0.2 gm of the mixture was spread on one surface of a glass plate. The glass plates (total 5) were then placed in oven and heated at 105 °C for 20 min. to cure. After removing from the oven and cooled to room temperature, 0.2 gm of the mixture was spread on the other uncoated surface of each glass plate. The coated glass plates were then heat treated again at 105 °C for 20 min. After cooling to room temperature, the glass plates were individually placed in 20 ml of 0.1 M phosphate buffer (pH 7.4, 37 °C) for release test. Samples were taken daily, and the entire release media was replaced with fresh media at each sampling time. The drugs (5FU and TA) and TC-112 released in the media were determined by HPLC. The total TC-112 release for silicone coating was calculated as follows. The molecular weight of Naproxen is 230.3, and the molecular weight for 5-Fluorouracil is 130.1, while the inventive compound (TC-112) generated from these two drugs has a molecular weight of 372.4. To detect x mg of naproxen, this means that x*372.4/230.3 mg of TC-112 was hydrolyzed. The total TC-112 released equals the sum of TC-112 detected in the release media and the TC-112 hydrolyzed. For example, up to day 6, 43.9 mg of naproxen is detected, this means 71.0 (43.9*372.4/230.3) mg of TC-112 was hydrolyzed, at the same time, 51.4 mg of TC- 112 is detected in buffer, therefore a total of 122.4mg (51.4 plus 71.0) of TC-112 is released up to day 6. The results are shown in FIG. 2, which shows the total cumulative release of
TC-112 from silicone coated glass plates. The slope of the curve demonstrates that
TC-112 is released at 13.3 μg/day. Again, the data represent both intact and constituents of the inventive compound. The similarity in the slopes demonstrates that the polymers have little effect on the release of the drug.
Example 3
A mixture of 3.3 gm Chronoflex C(65D) (Lot# CTB-G25B-1234) dispersion containing 0.3 gm of Chronoflex C(65D) and 2.2 gm Chronoflex C(55D) (Lot# CTB-121B-1265) dispersion containing 0.2 gm of Chronoflex C (55D), both in dimethyl acetamide (DMAC) (1:10, w/w) was prepared by mixing the two dispersions together. To this mixture, 6.0 gm of tetrahydrofurane (HPLC grade) were added and mixed. The final mixture was not a clear solution. Then 101.5 mg of a co-drug of 5-fluorouracil (5FU) and triamcinolone acetonide (TA) (the co-drug being defined as "TC-32") was added and dissolved into the polymer solution. Ten (10) HPLC inserts were then coated with the polymer/TC-32 solution by dipping, which was then followed by air-drying under ambient temperature. The coating and air-drying process was repeated four (4) times (5 times total) until a total of about 10 mg of polymer/TC-32 was applied to each insert. The inserts were then placed in an oven at 80°C for two hour to remove the residue of the solvent. The inserts were placed individually in 20 ml of 0.1 m phosphate buffer, pH
7.4, in glass tube and monitoring of the release of compounds from the inserts at 37°C was begun. Samples were taken daily, and the entire media was replaced with fresh media at each sampling time. The drugs released in the media were determined by HPLC. Because of the short half-life of TC-32 in buffer, no TC-32 was detectable in the release media; only amounts of parent drugs, 5-FU and TA, could be determined. The release profiles are displayed in Figure 7.
Example 4
To 5.0 gm of stirred dimethyl acetamide (DMAC), 300 mg of Chronoflex C(65D) (Lot# CTB-G25B-1234) and 200 mg of Chronoflex C(55D) (Lot# CTB- 121B-1265) were added. The polymer was slowly dissolved in DMAC (about 4 hours). Then 5.0 gm of THF was added to the polymer dispersion. The mixture was not a clear solution. Then 100.9 mg of TC-32 was added and dissolved in the mixture. Three (3) Stents, supplied by Guidant Corp, were coated then with the polymer/TC-32 solution by dipping and followed by air-drying under ambient temperature. The coating and air-drying process was repeated a few times till a total of about 2.0 mg of polymer/TC-32 were applied to each stent. The coated stents were air-dried under ambient temperature in a biological safety cabinet over night. The stents were then vacuum dried at 80°C for two hour to remove the residue of the solvent. Afterwards they were placed individually in 5.0 ml of 0.1 m phosphate buffer, pH 7.4, in glass tube and monitoring of the release of compounds from the stents was at 37 °C was begun. Samples were taken daily, and the entire media was replaced with a fresh one at each sampling time. The drugs released in the media were determined by HPLC. The release profiles were shown in the Figure 8. No TC-32 was detectable in the release media.
Example 5 Polyurethane (PU) was first dissolved in tetrahydrofuran. Into this solution bioreversible conjugates of 5-FU and TA were dissolved and the resulting solution spray coated onto coronary Tetra stents produced by Guidant. After air-drying, the stents were vacuum dried at 50 °C for 2 hours to remove solvent residue, and subjected to plasma treatment and gamma-irradiation. Two different levels of drug loading were applied to stents: 80 ug Low Dose (13%) and 600 ug High Dose (60%). The release rate was determined in vitro by placing the coated stents (expanded) in 0.1M phosphate buffer (pH 7.4) at 37°C. Samples of the buffer solution were periodically removed for analysis by HPLC, and the buffer was replaced to avoid any saturation effects. The results shown in Figure 9 illustrate the release pattern in vitro for a High
Dose coated stent. The pattern followed a pseudo logarithmic pattern with approximately 70% being released in 10 weeks. A similar pattern is seen in both High Dose and Low Dose loaded stents. TA and 5-FU were released in an equimolar fashion at all times during the experiments. No co-drugs of 5-FU/TA were detectable in the release media.
Example 6
Polyurethane (1.008 gm) was added to 50.0 gm of tetrahydrofuran (THF).
The mixture was stirred overnight to dissolve the polymer. 5.0 gm of the polymer solution was diluted with 10.0 gm of THF. 150.2 mg of a co-drug of 5-fluorouracil (5FU) and triamcinolone acetonide (TA) (the co-drug being defined as "TC-32") was added to the polymer solution and dissolved. The coating solution was prepared with 60% codrug loading. A 13% codrug loaded coating solution was also prepared. Bare stents (Tetra, Guidant, Lot# 1092154, 13mm Tetra) were washed with isopropanol, air-dried, and spray coated with the coating solution using a precision airbrush. The coating was repeated until approximately 1.0 mg of total coating had been applied to each stent. The coated stents were vacuum dried for two hours at 50°C to remove solvent residue, then subjected to plasma treatment and gamma-irradiation.
Co-drug coated stents were test in two groups. Group One stents were placed individually into a glass tube containing 5.0 ml of 0.1 M phosphate buffer (pH 7.4). Samples were taken periodically and the concentration of co-drug in the buffer was tested by HPLC. The entire release media was replaced after each sample.
Group Two stents were placed in vivo. Three common swine had TC-32 coated stents implanted into the left anterior descending (LAD) coronary artery on study day 1. The stents were harvested on study day 5 and then placed in 0.1 M phosphate buffer as describe for Group One stents. The amount of each drug released into the media was determined by HPLC. The intact codrug was not detectable in release media.
The results are shown in Fig. 10, showing the comparative drug release profiles between explanted stents and non-implanted stents. The release patterns for both explanted and pre-implanted stents indicate that in-vivo release may be predicted by in vitro release patterns.
Example 7
Fourteen (14) domestic swine received a maximum of three (3) stents deployed in any of the three-epicardial coronaries (LAD, LCX, and RCA). Some animals were given only control stents, comprising either Bare Metal Tetra Coronary Stent on Cross Sail Rx balloon delivery system (Control), or PU Coated Tetra Coronary Stent on Cross Sail Rx balloon delivery system (Control). Other animals were given drug-coated stents either in Low Dose (80μg TA+5FU (13%)) or High Dose (600μg TA+5FU (60%)). The stents were implanted into arteries of the animals. Each stent was advanced to the desired location in the artery, and was deployed using an inflation device. The pressure of the inflation device was chosen to achieve a balloon to artery ratio of 1.1 - 1.2 : 1.
After 28 days, arterial sections directly adjacent to the stents were surgically excised and embedded in a methacrylate resin. Histologic 5-μm sections were cut and stained with Verhoeffs elastin and Hematoxylin and Eosin stains, and the thickness of each excised section was measured. The results are shown in the table below for both High and Low Dose drug-coated stents. The response at 28 days in both low-dose and high-dose experimental groups shows a profound reduction in intimal thickness attributed to the co-release of TA and 5FU from polymer coated Tetra stents.
Figure imgf000050_0001
ξ p=0.0008 Bare Metal vs. Low Dose, p=0.03 Polymer vs. Low Dose
§ p=0.002 Bare Metal vs. Low Dose, p=0.04 Polymer vs. Low Dose p p=0.02 Bare Metal vs. High Dose, p=0.07 Polymer vs. High Dose ς p=0.01 Bare Metal vs. High Dose, p=0.07 Polymer vs. High Dose
Example 8
FIGS. 11A and 11B are graphs showing the effect of gamma irradiation and plasma treatment on drug release. Following plasma treatment and gamma- irradiation, the stents were inflated with a dilatation catheter (3.0 mm balloon size, 20mm long) and placed individually into a glass tube containing 5.0 ml of 0.1 M phosphate buffer (pH 7.4). Samples were taken periodically and the entire release media was replaced after each sample. The amount of each drug released into the media was determined by HPLC. The intact codrug was not detectable in release media. Example 9: Coating Example A
1.Ogm of EMM (poly(ethyl acrylate and methyl methacrylate)copolymer), obtained by evaporating the Eudragit NE30D aqueous dispersion and air drying, was added in 9.0 gm acetone. To this dispersion, 51.5 mg of codrug of 5-Fluorouracil and Fluocinolone acetonide (G.531.1) were added and dissolved after stirring. By dipping them in the codrug/polymer solution, followed by air-drying, 10 HPLC inserts were coated with the codrug/polymer. The coating process was repeated several times until about 30 mg of codrug/polymer were coated on each of the glass tube. The coated inserts were then individually placed in 10.0 ml of 0.1 M phosphate buffer (pH 7.4, 37 °C) for release test. Sample was taken daily and entire release media were replaced with fresh media at each sampling time. The drugs and codrug released in the media were determined by HPLC.
Example 10: Coating Example B 441.8 mg poly(ethylene-co-vinyl acetate) (EVA) is weighed and transferred to 15.0 ml of THF. The EVA is slowly swollen and then partly dissolved in the THF by ultrasonic and magnetic stirring. 88.2 mg of codrug (TC32) is added and dissolved into the polymer solution. 9 HPLC inserts are then coated with the polymer/codrug solution by dipping, followed by air-drying under ambient temperature. The coating and air-drying process is repeated a few times until a total of about 10 mg of polymer/codrug is applied to each insert. The inserts are then placed in oven at 50°C for one hour to remove the residue of the solvent. The weight and diameter of the inserts are checked before and after completion of the coating and recorded. The coated inserts were then individually placed in 10.0 ml of 0.1 M phosphate buffer (pH 7.4, 37 °C) for release test. Sample was taken daily and entire release media were replaced with fresh media at each sampling time. The drugs and codrug released in the media were determined by HPLC.
The purpose of the above description and examples is to illustrate some embodiments of the present invention without implying any limitation. It will be apparent to those of skill in the art that various modifications and variations may be made to the systems, devices and methods of the present invention without departing from the spirit or scope of the invention. All patents and publications cited herein are incorporated by reference in their entireties.

Claims

Claims:
1. A sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A-L-B in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and
B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A; wherein the solubility of therapeutically active form of A in water is greater than 1 mg/ml and the solubility of the prodrug in water is less than 1 mg/ml.
2. A sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A: :B in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
:: represents a ionic bond between A and B that dissociates under physiological conditions to generate said therapeutically active form of A;
B represents a moiety .which, when ionically bonded to A, results in the prodrug having a lower solubility than the therapeutically active form of A; and wherein the solubility of therapeutically active form of A in water is greater than 1 mg/ml and the solubility of the prodrug in water is less than 1 mg/ml.
3. A sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A-L-B in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient; L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A; wherein, when disposed in biological fluid, said sustained release formulation provides sustained release of the therapeutically active form of A for a period of at least 24 hours, and, over the period of release, the concentration of the prodrug in fluid outside the polymer is less than 10% of the concentration of the therapeutically active form of A.
4. A sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A::B in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
:: represents a ionic bond between A and B that dissociates under physiological conditions to generate said therapeutically active form of A;
B represents a moiety which, when ionically bonded to A, results in the prodrug having a lower solubility than the therapeutically active form of A; and wherein, when disposed in biological fluid, said sustained release formulation provides sustained release of the therapeutically active form of A for a period of at least 24 hours, and, over the period of release, the concentration of the prodrug in fluid outside the polymer is less than 10% of the concentration of the therapeutically active form of A.
5. A sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A-L-B in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and
B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A; wherein the therapeutically active form of A has a logP value at least 1 logP unit less than the logP value of the prodrug.
6. A sustained release formulation comprising a polymer matrix and a prodrug, dispersed in the polymer, having a general formula of A::B in which A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
:: represents a ionic bond between A and B that dissociates under physiological conditions to generate said therapeutically active form of A; B represents a moiety which, when ionically bonded to A, results in the prodrug having a lower solubility than the therapeutically active form of A; and wherein the therapeutically active form of A has a logP value at least 1 logP unit less than the logP value of the prodrug.
7. The sustained release formulation of claims 1 or 2, wherein the solubility of the prodrug is less than 100 μg/ml in water.
8. The sustained release formulation of any of claims 1-6, wherein B is a hydrophobic aliphatic moiety.
9. The sustained release formulation of any of claims 1-6, wherein B is a drug moiety having a therapeutically active form generated upon cleavage of said linker L or dissociation of said ionic bond.
10. The sustained release formulation of claim 9, wherein A and B are the same drug moiety.
11. The sustained release formulation of claim 9, wherein A and B are different drug moieties.
12. The sustained release formulation of any of claims 1-6, wherein B, after cleavage from the prodrug, is a biologically inert moiety.
13. The sustained release formulation of any of claims 1-6, wherein A is selected from immune response modifiers, anti-proliferatives, corticosteroids, angiostatic steroids, anti-parasitic drugs, anti-glaucoma drugs, antibiotics, anti-sense compounds, differentiation modulators, antiviral drugs, anticancer drugs, and non-steroidal anti-inflammatory drugs.
14. The sustained release formulation of 9, wherein B is selected from immune response modifiers, anti-proliferatives, corticosteroids, angiostatic steroids, anti-parasitic drugs, anti-glaucoma drugs, antibiotics, anti-sense compounds, differentiation modulators, antiviral drugs, anticancer drugs, and non- steroidal anti-inflammatory drugs.
15. The sustained release formulation of any of claims 1-6, wherein the duration of release of the therapeutically active form of A from the polymer matrix is at least 24 hours.
16. The sustained release formulation of claim 9, wherein A is 5-fluorouracil (5FU) and B is naproxen.
17. The sustained release formulation of any of claims 1-6 or 9, wherein at least one of A or B is an antineoplastic agent.
18. The sustained release formulation of claim 17, wherein said antineoplastic agent selected from the group consisting of anthracyclines, vincaalkaloids, purine analogs, pyrimidine analogs, inhibitors of pyrimidine biosynthesis, and alkylating agents.
19. The sustained release formulation of claim 17, wherein said antineoplastic drug is a fluorinated pyrimidine.
20. The sustained release formulation of claim 17, wherein said antineoplastic drug is selected from the group consisting of 5-fluorouracil (5FU), 5'-deoxy-
5-fluorouridine 5-fluorouridine, 2'-deoxy-5-fluorouridine, fluorocytosine, 5- trifluoromethyl-2'-deoxyuridine, arabinoxyl cytosine, cyclocytidine, 5-aza-2'- deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine, N-phosphonoacetyl- L-aspartic acid, pyrazofurin, 6-azauridine, azaribine, and 3-deazauridine.
21. The sustained release formulation of claim 17, wherein said antineoplastic drug is a pyrimidine nucleoside analog selected from the group consisting of arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5- azacytosine, and 6-azacytidine.
22. The sustained release formulation of claim 17, wherein said antineoplastic drug is selected from the group consisting of Cladribine, 6-mercaptopurine, pentostatin, 6-thioguanine, and fludarabin phosphate.
23. The sustained release formulation of any of claims 1 -6, wherein the therapeutically active form of A is 5-fluorouracil.
24. The sustained release formulation of claim 1-6 or 9, wherein at least one of A or B is an anti-inflammatory agent.
25. The sustained release formulation of claim 24, wherein said anti- inflammatory agent is a non-steroidal anti-inflammatory.
26. The sustained release formulation of claim 25, wherein said anti- inflammatory agent is selected from the group consisting of diclofenac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, ketorolac, nahumstone, naproxen and piroxicam.
27. The sustained release formulation of claim 24, wherein anti-inflammatory agent is a glucocorticoid.
28. The sustained release formulation of claim 27, wherein said glucocorticoid is selected from the group consisting of aclometasone, beclomethasone, betamethasone, budesonide, clobetasol, clobetasone, cortisone, desonide, desoximetasone, diflorosane, flumethasone, flunisolide, fluocinolone acetonide, fluocinolone, fluocortolone, fluprednidene, flurandrenolide, fluticasone, hydrocortisone, methylprednisolone aceponate,mometasone furdate, prednisolone, prednisone and rofleponide.
29. The sustained release formulation of claim 9, wherein the therapeutically active form of B is selected from fluocinolone acetonide, triamcinolone acetonide, diclofenac, and naproxen.
30. The sustained release formulation of claim 1, wherein the linkage L is hydrolyzed in bodily fluid.
31. The sustained release formulation of claim 1 , wherein the linkage L includes one or more hydrolyzable groups selected from the group consisting of an ester, an amide, a carbamate, a carbonate, a cyclic ketal, a thioester, a thioamide, a thiocarbamate, a thiocarbonate, a xanthate and a phosphate ester.
32. The sustained release formulation of claim 1, wherein the linkage L is enzymatically cleaved.
33. The sustained release formulation of claim 1, wherein the prodrug, in its linked form, has an ED50 for producing said clinical response at least 10 times greater than the ED5o of the therapeutically active form of A.
34. The sustained release formulation of claim 1, wherein the prodrug, in its linked form, has an ED5o for producing said clinical response at least 1000 times greater than the ED5o of the therapeutically active form of A.
35. The sustained release formulation of claim 1, wherein the therapeutically active form of A is at least 10 times more soluble in water relative to said prodrug.
36. The sustained release formulation of claim 29, wherein the prodrug is selected from 5FU covalently bonded to fluocinolone acetonide, 5FU covalently bonded to naproxen, and 5FU covalently bonded to diclofenac.
37. The sustained release formulation of claim 9, wherein the prodrug is selected from ciprofloxacin-diclofenac (VI) and ciprofloxacin-naproxen.
Figure imgf000057_0001
Ciprofloxacin-Diclofenac (VI)
38. The sustained release formulation of any of claims 1-6, wherein the polymer is non-bioerodible.
39. The sustained release formulation of claim 38, wherein the non-bioerodible polymer is selected from polyurethane, polysilicone, poly(ethylene-co-vinyl acetate), polyvinyl alcohol, and derivatives and copolymers thereof.
40. The sustained release formulation of any of claims 1-6, wherein the polymer is bioerodible.
41. The sustained release formulation of claim 40, wherein the bioerodible polymer is selected from polyanhydride, polylactic acid, polyglycolic acid, polyorthoester, polyalkylcyanoacrylate, and derivatives and copolymers thereof.
42. The sustained release formulation of any of claims 1-6, wherein the polymer holds the prodrug in a particular anatomic position and prevents disintegration of the prodrug.
43. The sustained release formulation of any of claims 1-6, wherein the polymer reduces interaction between the prodrug in the polymer and proteinaceous components in surrounding bathing fluid.
44. The sustained release formulation of any of claims 1-6, wherein the system is adapted to be injected or implanted into a body.
45. A medical device comprising: (i) a substrate having a surface; and,
(ii) a coating adhered to the surface, said coating comprising a polymer matrix having a low solubility prodrug dispersed therein, wherein said low solubility prodrug is represented by the general formula A- L-B, in which A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A.
46. The device of claim 45, wherein the polymer matrix is essentially non-release rate limiting with respect to the rate of release of the therapeutically active form of A from the coating.
47. The device of claim 45, wherein the substrate is a surgical implement selected from a screw, a plate, a washer, a suture, a prosthesis anchor, a tack, a staple, an electrical lead, a valve, and a membrane.
48. The device of claim 45, selected from the group consisting of catheters, implantable vascular access ports, blood storage bags, blood tubing, central venous catheters, arterial catheters, vascular grafts, intraaortic balloon pumps, heart valves, cardiovascularsutures, artificial hearts, a pacemaker, ventricular assist pumps, extracorporeal devices, blood filters, hemodialysis units, hemoperfasion units, plasmapheresis units, and filters adapted for deployment in a blood vessel.
49. The device of claim 45, which is a vascular stent.
50. The device of claim 49, which is an expandable stent, and said coating is flexible to accommodate compressed and expanded states of said expandable stent.
51. The device of claim 45, wherein the weight of the coating attributable to the prodrug is in the range of about 0.05 mg to about 50 mg of prodrug per cm2 of the surface coated with said polymer matrix.
52. The device of claim 45, wherein the coating has a thickness is in the range of 5 micrometers to 100 micrometers.
53. The device of claim 45, wherein prodrug is present in an amount between 5% and 70% by weight of the coating.
54. A coated device combination, comprising a medical device for implantation within a patient's body, said medical device having one or more surfaces coated with a polymer formulation of any of claims 1-6 in a manner that permits the coated surface to release the therapeutically active form of A over a period of time when implanted in the patient.
55. The coated device of claim 54, wherein the device is an elongate radially expandable tubular stent having an interior luminal surface and an opposite exterior surface extending along a longitudinal stent axis.
56. A stent having at least a portion which is insertable or implantable into the body of a patient, wherein the portion has a surface which is adapted for exposure to body tissue and wherein at least a part of the surface is covered with a coating for releasing at least one biologically active material, the coating comprising a polymer matrix having a low solubility prodrug dispersed therein, wherein said low solubility prodrug is represented by the general formula A-L-B, in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A.
57. An intraluminal medical device coated with a sustained release system comprising a biologically tolerated polymer and a low-solubility prodrug dispersed in the polymer, said device having an interior surface and an exterior surface; said device having said system applied to at least a part of the interior surface, the exterior surface, or both.
58. A method for treating an intraluminal tissue of a patient, the method comprising the steps of:
(a) providing a stent having an interior surface and an exterior surface, said stent having a coating on at least a part of the interior surface, the exterior surface, or both; said coating comprising a low-solubility pharmaceutical prodrug dissolved or dispersed in a biologically- tolerated polymer;
(b) positioning the stent at an appropriate intraluminal tissue site; and
(c) deploying the stent.
59. A coating composition for use in delivering a medicament from the surface of a medical device positioned in vivo, the composition comprising a polymer matrix having a low solubility prodrug dispersed therein, wherein said low solubility prodrug is represented by the general formula A-L-B, in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient; L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A; and
B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form ofA; which coating composition is provided in liquid or suspension form for application to the surface of said medical device by spraying and/or dipping the device in said composition.
60. A coating composition for use in delivering a medicament from the surface of a medical device positioned in vivo, the composition comprising a polymer matrix having a low solubility prodrug dispersed therein, wherein said low solubility prodrug is represented by the general formula A-L-B, in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A;
B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A; which coating composition is provided in powdered form and, upon addition of a solvent, can reconstitute a liquid or suspension form for application to the surface of said medical device by spraying and/or dipping the device in said composition.
61. An injectable composition for use in delivering a medicament to a patient, the composition comprising a polymer matrix having a low solubility prodrug dispersed therein, wherein said low solubility prodrug is represented by the general formula A-L-B, in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient; L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A;
B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A; which composition is provided in liquid or suspension form adapted for delivery by injection through a needle.
62. A method of manufacturing a sustained release system, comprising admixing a polymer matrix and a therapeutically effective amount of a low solubility prodrug, wherein
(i) said low solubility prodrug is represented by the general formula A- L-B, in which
A represents a drug moiety having a therapeutically active form for producing a clinical response in a patient;
L represents a covalent linker linking A and B to form a prodrug, said linker being cleaved under physiological conditions to generate said therapeutically active form of A;
B represents a moiety which, when linked to A, results in the prodrug having a lower solubility than the therapeutically active form of A; and
(ii) the polymer matrix is permeable to the therapeutically active form of A, and is essentially non-release rate limiting with respect to a rate of release of therapeutically active form of A from the polymer matrix.
63. The method of claim 62, further comprising the step of applying the mixture of polymer matrix and prodrug to a surface of a surgical implement.
64. A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect, comprising: administering a therapeutically effective amount of The sustained release formulation of any of claims 1-6 to a mammal.
65. A use of a sustained release system of any of claims 1 -6 in the manufacture of a medication for treating a patient with a sustained dosage regimen of the therapeutically active form of A.
66. The sustained release formulation of claim 5 or 6, wherein the therapeutically active form of A has a logP value at least 2 logP unit less than the logP value of the prodrug.
PCT/US2002/013385 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs WO2002087586A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA2444894A CA2444894C (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs
JP2002584931A JP2004536799A (en) 2001-04-26 2002-04-26 Sustained release drug delivery systems containing co-drugs
KR10-2003-7014032A KR20040005936A (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs
EP02729028A EP1383504A1 (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs
MXPA03009727A MXPA03009727A (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs.
AU2002259045A AU2002259045B2 (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs
IN10834DEN2014 IN2014DN10834A (en) 2001-09-17 2002-04-26
IL15852702A IL158527A0 (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs
BR0209198-4A BR0209198A (en) 2001-04-26 2002-04-26 Synthesis methods of phenol-containing compounds
NZ528994A NZ528994A (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs
US10/449,855 US20040022853A1 (en) 2001-04-26 2003-05-30 Polymer-based, sustained release drug delivery system
US12/082,520 US20090123546A1 (en) 2001-04-26 2008-04-11 Polymer-based, sustained release drug delivery system
US13/228,774 US20120045513A1 (en) 2001-04-26 2011-09-09 Polymer-based, sustained release drug delivery system
US13/937,844 US20140037746A1 (en) 2001-04-26 2013-07-09 Polymer-based, sustained release drug delivery system

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US28634301P 2001-04-26 2001-04-26
US60/286,343 2001-04-26
US32242801P 2001-09-17 2001-09-17
US60/322,428 2001-09-17
US37276102P 2002-04-15 2002-04-15
US60/372,761 2002-04-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/449,855 Continuation-In-Part US20040022853A1 (en) 2001-04-26 2003-05-30 Polymer-based, sustained release drug delivery system

Publications (1)

Publication Number Publication Date
WO2002087586A1 true WO2002087586A1 (en) 2002-11-07

Family

ID=27403607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013385 WO2002087586A1 (en) 2001-04-26 2002-04-26 Sustained release drug delivery system containing codrugs

Country Status (12)

Country Link
US (2) US20030039689A1 (en)
EP (3) EP1383504A1 (en)
JP (2) JP2004536799A (en)
KR (1) KR20040005936A (en)
CN (1) CN1520297A (en)
AU (1) AU2002259045B2 (en)
BR (1) BR0209198A (en)
CA (1) CA2444894C (en)
IL (1) IL158527A0 (en)
MX (1) MXPA03009727A (en)
NZ (1) NZ528994A (en)
WO (1) WO2002087586A1 (en)

Cited By (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
EP1350526A1 (en) * 2002-04-03 2003-10-08 Poly-Med Inc. Conjugated drug-polymer coated stent
WO2003024455A3 (en) * 2001-09-17 2003-10-30 Control Delivery Sys Inc Stent coated with a sustained-release drug delivery and method for use thereof
EP1360966A1 (en) * 2002-04-18 2003-11-12 Poly-Med Inc. Drug-polymer coated stents with segmented homochain copolyesters
WO2004043511A1 (en) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Method and apparatus for treating vulnerable artherosclerotic plaque
WO2005011741A3 (en) * 2003-07-10 2005-04-14 Allergan Inc Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
WO2005009480A3 (en) * 2003-06-11 2005-07-14 Control Delivery Sys Inc Implants containing codrugs
JP2005199058A (en) * 2003-12-19 2005-07-28 Cordis Corp Local vascular delivery of trichostatin alone or in combination with sirolimus to prevent restenosis after vascular injury
WO2005105046A1 (en) * 2004-04-30 2005-11-10 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
JP2006506191A (en) * 2002-11-18 2006-02-23 ポリメリックス・コーポレーション Medical devices using new polymers
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
EP1461122A4 (en) * 2001-12-10 2006-08-23 Control Delivery Sys Inc Treatment of genitourinary tract disorders
US7135464B2 (en) 2002-06-05 2006-11-14 Supergen, Inc. Method of administering decitabine
JP2007505039A (en) * 2003-09-08 2007-03-08 マイラス バイオ コーポレーション Improved delivery by hydrophobic modification of easily denatured drugs
US7199151B2 (en) 1996-05-22 2007-04-03 Luitpold Pharmaceuticals, Inc. DHA-pharmaceutical agent conjugates of taxanes
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
JP2007530733A (en) * 2004-03-22 2007-11-01 アドヴァンスド カーディオヴァスキュラー システムズ， インコーポレイテッド Phosphorylcholine coating composition
WO2008093086A1 (en) 2007-01-31 2008-08-07 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
EP1628597A4 (en) * 2003-05-28 2008-12-10 Conor Medsystems Inc METHODS OF ADMINISTERING ANTI-RESTENOSE AGENTS FROM A STENT
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US7816398B2 (en) 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US7819912B2 (en) 1998-03-30 2010-10-26 Innovational Holdings Llc Expandable medical device with beneficial agent delivery mechanism
US7850728B2 (en) 2000-10-16 2010-12-14 Innovational Holdings Llc Expandable medical device for delivery of beneficial agent
US7985415B2 (en) 1997-09-10 2011-07-26 Rutgers, The State University Of New Jersey Medical devices employing novel polymers
US8314077B2 (en) 1996-05-22 2012-11-20 Luitpold Pharmaceuticals, Inc. Fatty acid-pharmaceutical agent conjugates
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US8349390B2 (en) 2002-09-20 2013-01-08 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US8361537B2 (en) 1998-03-30 2013-01-29 Innovational Holdings, Llc Expandable medical device with beneficial agent concentration gradient
US8372420B2 (en) 2002-05-24 2013-02-12 Angiotech International Ag Compositions and methods for coating medical implants
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
WO2014004199A1 (en) * 2012-03-28 2014-01-03 Ethicon Endo-Surgery, Inc. Tissue stapler having a thickness compensator incorporating an anti-inflammatory agent
US8668703B2 (en) 2006-12-01 2014-03-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
US20140256651A1 (en) * 2013-03-08 2014-09-11 Allergan, Inc. Cyclosporine A steroid conjugates
US8864009B2 (en) 2010-09-30 2014-10-21 Ethicon Endo-Surgery, Inc. Tissue thickness compensator for a surgical stapler comprising an adjustable anvil
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US8925788B2 (en) 2007-03-15 2015-01-06 Ethicon Endo-Surgery, Inc. End effectors for surgical stapling instruments
US8931682B2 (en) 2007-06-04 2015-01-13 Ethicon Endo-Surgery, Inc. Robotically-controlled shaft based rotary drive systems for surgical instruments
US8973804B2 (en) 2006-09-29 2015-03-10 Ethicon Endo-Surgery, Inc. Cartridge assembly having a buttressing member
US8991677B2 (en) 2008-02-14 2015-03-31 Ethicon Endo-Surgery, Inc. Detachable motor powered surgical instrument
US9028494B2 (en) 2012-06-28 2015-05-12 Ethicon Endo-Surgery, Inc. Interchangeable end effector coupling arrangement
US9033204B2 (en) 2011-03-14 2015-05-19 Ethicon Endo-Surgery, Inc. Circular stapling devices with tissue-puncturing anvil features
US9044230B2 (en) 2012-02-13 2015-06-02 Ethicon Endo-Surgery, Inc. Surgical cutting and fastening instrument with apparatus for determining cartridge and firing motion status
US9050084B2 (en) 2011-09-23 2015-06-09 Ethicon Endo-Surgery, Inc. Staple cartridge including collapsible deck arrangement
US9055941B2 (en) 2011-09-23 2015-06-16 Ethicon Endo-Surgery, Inc. Staple cartridge including collapsible deck
US9060770B2 (en) 2003-05-20 2015-06-23 Ethicon Endo-Surgery, Inc. Robotically-driven surgical instrument with E-beam driver
US9072515B2 (en) 2008-02-14 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus
US9072536B2 (en) 2012-06-28 2015-07-07 Ethicon Endo-Surgery, Inc. Differential locking arrangements for rotary powered surgical instruments
US9072535B2 (en) 2011-05-27 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling instruments with rotatable staple deployment arrangements
US9078653B2 (en) 2012-03-26 2015-07-14 Ethicon Endo-Surgery, Inc. Surgical stapling device with lockout system for preventing actuation in the absence of an installed staple cartridge
US9101358B2 (en) 2012-06-15 2015-08-11 Ethicon Endo-Surgery, Inc. Articulatable surgical instrument comprising a firing drive
US9101385B2 (en) 2012-06-28 2015-08-11 Ethicon Endo-Surgery, Inc. Electrode connections for rotary driven surgical tools
US9113874B2 (en) 2006-01-31 2015-08-25 Ethicon Endo-Surgery, Inc. Surgical instrument system
US9119657B2 (en) 2012-06-28 2015-09-01 Ethicon Endo-Surgery, Inc. Rotary actuatable closure arrangement for surgical end effector
US9125662B2 (en) 2012-06-28 2015-09-08 Ethicon Endo-Surgery, Inc. Multi-axis articulating and rotating surgical tools
US9138225B2 (en) 2007-06-22 2015-09-22 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with an articulatable end effector
US9192579B2 (en) 2000-04-26 2015-11-24 Psivida Us, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US9204878B2 (en) 2008-02-14 2015-12-08 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with interlockable firing system
US9204880B2 (en) 2012-03-28 2015-12-08 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising capsules defining a low pressure environment
US9204879B2 (en) 2012-06-28 2015-12-08 Ethicon Endo-Surgery, Inc. Flexible drive member
US9211120B2 (en) 2011-04-29 2015-12-15 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising a plurality of medicaments
US9220501B2 (en) 2010-09-30 2015-12-29 Ethicon Endo-Surgery, Inc. Tissue thickness compensators
US9220500B2 (en) 2010-09-30 2015-12-29 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising structure to produce a resilient load
US9226751B2 (en) 2012-06-28 2016-01-05 Ethicon Endo-Surgery, Inc. Surgical instrument system including replaceable end effectors
US9232945B2 (en) 2010-09-09 2016-01-12 Ethicon Endo-Surgery, Inc. Surgical stapling head assembly with firing lockout for a surgical stapler
US9272406B2 (en) 2010-09-30 2016-03-01 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a cutting member for releasing a tissue thickness compensator
US9282966B2 (en) 2004-07-28 2016-03-15 Ethicon Endo-Surgery, Inc. Surgical stapling instrument
US9282974B2 (en) 2012-06-28 2016-03-15 Ethicon Endo-Surgery, Llc Empty clip cartridge lockout
US9283054B2 (en) 2013-08-23 2016-03-15 Ethicon Endo-Surgery, Llc Interactive displays
US9289212B2 (en) 2010-09-17 2016-03-22 Ethicon Endo-Surgery, Inc. Surgical instruments and batteries for surgical instruments
US9289256B2 (en) 2012-06-28 2016-03-22 Ethicon Endo-Surgery, Llc Surgical end effectors having angled tissue-contacting surfaces
US9289210B2 (en) 2008-09-19 2016-03-22 Ethicon Endo-Surgery, Llc Surgical stapler with apparatus for adjusting staple height
US9301759B2 (en) 2006-03-23 2016-04-05 Ethicon Endo-Surgery, Llc Robotically-controlled surgical instrument with selectively articulatable end effector
US9301752B2 (en) 2010-09-30 2016-04-05 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising a plurality of capsules
US9307987B2 (en) 2009-12-24 2016-04-12 Ethicon Endo-Surgery, Llc Surgical cutting instrument that analyzes tissue thickness
US9307986B2 (en) 2013-03-01 2016-04-12 Ethicon Endo-Surgery, Llc Surgical instrument soft stop
US9307988B2 (en) 2005-08-31 2016-04-12 Ethicon Endo-Surgery, Llc Staple cartridges for forming staples having differing formed staple heights
US9320521B2 (en) 2006-06-27 2016-04-26 Ethicon Endo-Surgery, Llc Surgical instrument
US9320523B2 (en) 2012-03-28 2016-04-26 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising tissue ingrowth features
US9326770B2 (en) 2006-01-31 2016-05-03 Ethicon Endo-Surgery, Llc Surgical instrument
US9326768B2 (en) 2005-08-31 2016-05-03 Ethicon Endo-Surgery, Llc Staple cartridges for forming staples having differing formed staple heights
US9332987B2 (en) 2013-03-14 2016-05-10 Ethicon Endo-Surgery, Llc Control arrangements for a drive member of a surgical instrument
US9332984B2 (en) 2013-03-27 2016-05-10 Ethicon Endo-Surgery, Llc Fastener cartridge assemblies
US9332974B2 (en) 2010-09-30 2016-05-10 Ethicon Endo-Surgery, Llc Layered tissue thickness compensator
US9345481B2 (en) 2013-03-13 2016-05-24 Ethicon Endo-Surgery, Llc Staple cartridge tissue thickness sensor system
US9358005B2 (en) 2010-09-30 2016-06-07 Ethicon Endo-Surgery, Llc End effector layer including holding features
US9364233B2 (en) 2010-09-30 2016-06-14 Ethicon Endo-Surgery, Llc Tissue thickness compensators for circular surgical staplers
US9370358B2 (en) 2006-01-31 2016-06-21 Ethicon Endo-Surgery, Llc Motor-driven surgical cutting and fastening instrument with tactile position feedback
US9370364B2 (en) 2008-10-10 2016-06-21 Ethicon Endo-Surgery, Llc Powered surgical cutting and stapling apparatus with manually retractable firing system
US9381207B2 (en) 2011-08-30 2016-07-05 Astex Pharmaceuticals, Inc. Drug formulations
US9386984B2 (en) 2013-02-08 2016-07-12 Ethicon Endo-Surgery, Llc Staple cartridge comprising a releasable cover
US9386985B2 (en) 2012-10-15 2016-07-12 Ethicon Endo-Surgery, Llc Surgical cutting instrument
US9393015B2 (en) 2009-02-06 2016-07-19 Ethicon Endo-Surgery, Llc Motor driven surgical fastener device with cutting member reversing mechanism
US9402626B2 (en) 2006-03-23 2016-08-02 Ethicon Endo-Surgery, Llc Rotary actuatable surgical fastener and cutter
US9402912B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
US9486214B2 (en) 2009-02-06 2016-11-08 Ethicon Endo-Surgery, Llc Motor driven surgical fastener device with switching system configured to prevent firing initiation until activated
US9522029B2 (en) 2008-02-14 2016-12-20 Ethicon Endo-Surgery, Llc Motorized surgical cutting and fastening instrument having handle based power source
US9549735B2 (en) 2013-12-23 2017-01-24 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a firing member including fastener transfer surfaces
US9561038B2 (en) 2012-06-28 2017-02-07 Ethicon Endo-Surgery, Llc Interchangeable clip applier
US9572577B2 (en) 2013-03-27 2017-02-21 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a tissue thickness compensator including openings therein
US9574644B2 (en) 2013-05-30 2017-02-21 Ethicon Endo-Surgery, Llc Power module for use with a surgical instrument
US9585660B2 (en) 2010-01-07 2017-03-07 Ethicon Endo-Surgery, Llc Method for testing a surgical tool
US9585657B2 (en) 2008-02-15 2017-03-07 Ethicon Endo-Surgery, Llc Actuator for releasing a layer of material from a surgical end effector
US9592052B2 (en) 2005-08-31 2017-03-14 Ethicon Endo-Surgery, Llc Stapling assembly for forming different formed staple heights
US9597075B2 (en) 2010-07-30 2017-03-21 Ethicon Endo-Surgery, Inc. Tissue acquisition arrangements and methods for surgical stapling devices
US9603598B2 (en) 2007-01-11 2017-03-28 Ethicon Endo-Surgery, Llc Surgical stapling device with a curved end effector
US9603991B2 (en) 2004-07-28 2017-03-28 Ethicon Endo-Surgery, Llc Surgical stapling instrument having a medical substance dispenser
US9629629B2 (en) 2013-03-14 2017-04-25 Ethicon Endo-Surgey, LLC Control systems for surgical instruments
US9629814B2 (en) 2010-09-30 2017-04-25 Ethicon Endo-Surgery, Llc Tissue thickness compensator configured to redistribute compressive forces
US9642620B2 (en) 2013-12-23 2017-05-09 Ethicon Endo-Surgery, Llc Surgical cutting and stapling instruments with articulatable end effectors
US9649110B2 (en) 2013-04-16 2017-05-16 Ethicon Llc Surgical instrument comprising a closing drive and a firing drive operated from the same rotatable output
US9655614B2 (en) 2008-09-23 2017-05-23 Ethicon Endo-Surgery, Llc Robotically-controlled motorized surgical instrument with an end effector
US9681870B2 (en) 2013-12-23 2017-06-20 Ethicon Llc Articulatable surgical instruments with separate and distinct closing and firing systems
US9690362B2 (en) 2014-03-26 2017-06-27 Ethicon Llc Surgical instrument control circuit having a safety processor
US9687236B2 (en) 2010-10-01 2017-06-27 Ethicon Endo-Surgery, Inc. Surgical instrument having a power control circuit
US9687231B2 (en) 2008-02-13 2017-06-27 Ethicon Llc Surgical stapling instrument
US9693777B2 (en) 2014-02-24 2017-07-04 Ethicon Llc Implantable layers comprising a pressed region
US9724092B2 (en) 2013-12-23 2017-08-08 Ethicon Llc Modular surgical instruments
US9724098B2 (en) 2012-03-28 2017-08-08 Ethicon Endo-Surgery, Llc Staple cartridge comprising an implantable layer
US9724094B2 (en) 2014-09-05 2017-08-08 Ethicon Llc Adjunct with integrated sensors to quantify tissue compression
US9743929B2 (en) 2014-03-26 2017-08-29 Ethicon Llc Modular powered surgical instrument with detachable shaft assemblies
US9743928B2 (en) 2006-01-31 2017-08-29 Ethicon Endo-Surgery, Inc. Surgical instrument having a feedback system
US9757123B2 (en) 2007-01-10 2017-09-12 Ethicon Llc Powered surgical instrument having a transmission system
US9795384B2 (en) 2013-03-27 2017-10-24 Ethicon Llc Fastener cartridge comprising a tissue thickness compensator and a gap setting element
US9795382B2 (en) 2005-08-31 2017-10-24 Ethicon Llc Fastener cartridge assembly comprising a cam and driver arrangement
US9801628B2 (en) 2014-09-26 2017-10-31 Ethicon Llc Surgical staple and driver arrangements for staple cartridges
US9808246B2 (en) 2015-03-06 2017-11-07 Ethicon Endo-Surgery, Llc Method of operating a powered surgical instrument
US9814462B2 (en) 2010-09-30 2017-11-14 Ethicon Llc Assembly for fastening tissue comprising a compressible layer
US9820738B2 (en) 2014-03-26 2017-11-21 Ethicon Llc Surgical instrument comprising interactive systems
US9826978B2 (en) 2010-09-30 2017-11-28 Ethicon Llc End effectors with same side closure and firing motions
US9833241B2 (en) 2014-04-16 2017-12-05 Ethicon Llc Surgical fastener cartridges with driver stabilizing arrangements
US9839427B2 (en) 2005-08-31 2017-12-12 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil and a staple driver arrangement
US9839428B2 (en) 2013-12-23 2017-12-12 Ethicon Llc Surgical cutting and stapling instruments with independent jaw control features
US9839429B2 (en) 2008-02-15 2017-12-12 Ethicon Endo-Surgery, Llc Stapling system comprising a lockout
US9844376B2 (en) 2014-11-06 2017-12-19 Ethicon Llc Staple cartridge comprising a releasable adjunct material
US9844375B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Drive arrangements for articulatable surgical instruments
US9844374B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member
US9861359B2 (en) 2006-01-31 2018-01-09 Ethicon Llc Powered surgical instruments with firing system lockout arrangements
US9895147B2 (en) 2005-11-09 2018-02-20 Ethicon Llc End effectors for surgical staplers
US9895148B2 (en) 2015-03-06 2018-02-20 Ethicon Endo-Surgery, Llc Monitoring speed control and precision incrementing of motor for powered surgical instruments
US9901342B2 (en) 2015-03-06 2018-02-27 Ethicon Endo-Surgery, Llc Signal and power communication system positioned on a rotatable shaft
US9913642B2 (en) 2014-03-26 2018-03-13 Ethicon Llc Surgical instrument comprising a sensor system
US9924961B2 (en) 2015-03-06 2018-03-27 Ethicon Endo-Surgery, Llc Interactive feedback system for powered surgical instruments
US9924944B2 (en) 2014-10-16 2018-03-27 Ethicon Llc Staple cartridge comprising an adjunct material
US9931118B2 (en) 2015-02-27 2018-04-03 Ethicon Endo-Surgery, Llc Reinforced battery for a surgical instrument
US9943309B2 (en) 2014-12-18 2018-04-17 Ethicon Llc Surgical instruments with articulatable end effectors and movable firing beam support arrangements
US9962161B2 (en) 2014-02-12 2018-05-08 Ethicon Llc Deliverable surgical instrument
US9987000B2 (en) 2014-12-18 2018-06-05 Ethicon Llc Surgical instrument assembly comprising a flexible articulation system
US9993248B2 (en) 2015-03-06 2018-06-12 Ethicon Endo-Surgery, Llc Smart sensors with local signal processing
US9993258B2 (en) 2015-02-27 2018-06-12 Ethicon Llc Adaptable surgical instrument handle
US10004498B2 (en) 2006-01-31 2018-06-26 Ethicon Llc Surgical instrument comprising a plurality of articulation joints
US10028744B2 (en) 2015-08-26 2018-07-24 Ethicon Llc Staple cartridge assembly including staple guides
US10039529B2 (en) 2010-09-17 2018-08-07 Ethicon Llc Power control arrangements for surgical instruments and batteries
US10045776B2 (en) 2015-03-06 2018-08-14 Ethicon Llc Control techniques and sub-processor contained within modular shaft with select control processing from handle
US10045781B2 (en) 2014-06-13 2018-08-14 Ethicon Llc Closure lockout systems for surgical instruments
US10052102B2 (en) 2015-06-18 2018-08-21 Ethicon Llc Surgical end effectors with dual cam actuated jaw closing features
US10052044B2 (en) 2015-03-06 2018-08-21 Ethicon Llc Time dependent evaluation of sensor data to determine stability, creep, and viscoelastic elements of measures
US10058963B2 (en) 2006-01-31 2018-08-28 Ethicon Llc Automated end effector component reloading system for use with a robotic system
US10076325B2 (en) 2014-10-13 2018-09-18 Ethicon Llc Surgical stapling apparatus comprising a tissue stop
US10076326B2 (en) 2015-09-23 2018-09-18 Ethicon Llc Surgical stapler having current mirror-based motor control
US10085748B2 (en) 2014-12-18 2018-10-02 Ethicon Llc Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors
US10085751B2 (en) 2015-09-23 2018-10-02 Ethicon Llc Surgical stapler having temperature-based motor control
US10105139B2 (en) 2015-09-23 2018-10-23 Ethicon Llc Surgical stapler having downstream current-based motor control
US10117649B2 (en) 2014-12-18 2018-11-06 Ethicon Llc Surgical instrument assembly comprising a lockable articulation system
US10130359B2 (en) 2006-09-29 2018-11-20 Ethicon Llc Method for forming a staple
US10130363B2 (en) 2010-09-29 2018-11-20 Ethicon Llc Staple cartridge
US10172620B2 (en) 2015-09-30 2019-01-08 Ethicon Llc Compressible adjuncts with bonding nodes
US10172619B2 (en) 2015-09-02 2019-01-08 Ethicon Llc Surgical staple driver arrays
US10180463B2 (en) 2015-02-27 2019-01-15 Ethicon Llc Surgical apparatus configured to assess whether a performance parameter of the surgical apparatus is within an acceptable performance band
US10188385B2 (en) 2014-12-18 2019-01-29 Ethicon Llc Surgical instrument system comprising lockable systems
US10206676B2 (en) 2008-02-14 2019-02-19 Ethicon Llc Surgical cutting and fastening instrument
US10211586B2 (en) 2017-06-28 2019-02-19 Ethicon Llc Surgical shaft assemblies with watertight housings
US10213201B2 (en) 2015-03-31 2019-02-26 Ethicon Llc Stapling end effector configured to compensate for an uneven gap between a first jaw and a second jaw
US10226249B2 (en) 2013-03-01 2019-03-12 Ethicon Llc Articulatable surgical instruments with conductive pathways for signal communication
US10238386B2 (en) 2015-09-23 2019-03-26 Ethicon Llc Surgical stapler having motor control based on an electrical parameter related to a motor current
US10245029B2 (en) 2016-02-09 2019-04-02 Ethicon Llc Surgical instrument with articulating and axially translatable end effector
US10245033B2 (en) 2015-03-06 2019-04-02 Ethicon Llc Surgical instrument comprising a lockable battery housing
US10258418B2 (en) 2017-06-29 2019-04-16 Ethicon Llc System for controlling articulation forces
US10258331B2 (en) 2016-02-12 2019-04-16 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10265068B2 (en) 2015-12-30 2019-04-23 Ethicon Llc Surgical instruments with separable motors and motor control circuits
US10271851B2 (en) 2016-04-01 2019-04-30 Ethicon Llc Modular surgical stapling system comprising a display
US10271849B2 (en) 2015-09-30 2019-04-30 Ethicon Llc Woven constructs with interlocked standing fibers
USD847989S1 (en) 2016-06-24 2019-05-07 Ethicon Llc Surgical fastener cartridge
US10278780B2 (en) 2007-01-10 2019-05-07 Ethicon Llc Surgical instrument for use with robotic system
US10285705B2 (en) 2016-04-01 2019-05-14 Ethicon Llc Surgical stapling system comprising a grooved forming pocket
US10292704B2 (en) 2015-12-30 2019-05-21 Ethicon Llc Mechanisms for compensating for battery pack failure in powered surgical instruments
US10299878B2 (en) 2015-09-25 2019-05-28 Ethicon Llc Implantable adjunct systems for determining adjunct skew
US10307170B2 (en) 2017-06-20 2019-06-04 Ethicon Llc Method for closed loop control of motor velocity of a surgical stapling and cutting instrument
USD850617S1 (en) 2016-06-24 2019-06-04 Ethicon Llc Surgical fastener cartridge
US10307159B2 (en) 2016-04-01 2019-06-04 Ethicon Llc Surgical instrument handle assembly with reconfigurable grip portion
USD851762S1 (en) 2017-06-28 2019-06-18 Ethicon Llc Anvil
US10327769B2 (en) 2015-09-23 2019-06-25 Ethicon Llc Surgical stapler having motor control based on a drive system component
US10327767B2 (en) 2017-06-20 2019-06-25 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10335145B2 (en) 2016-04-15 2019-07-02 Ethicon Llc Modular surgical instrument with configurable operating mode
USD854151S1 (en) 2017-06-28 2019-07-16 Ethicon Llc Surgical instrument shaft
US10357247B2 (en) 2016-04-15 2019-07-23 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10363037B2 (en) 2016-04-18 2019-07-30 Ethicon Llc Surgical instrument system comprising a magnetic lockout
US10363036B2 (en) 2015-09-23 2019-07-30 Ethicon Llc Surgical stapler having force-based motor control
US10368865B2 (en) 2015-12-30 2019-08-06 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10368864B2 (en) 2017-06-20 2019-08-06 Ethicon Llc Systems and methods for controlling displaying motor velocity for a surgical instrument
US10390841B2 (en) 2017-06-20 2019-08-27 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10398433B2 (en) 2007-03-28 2019-09-03 Ethicon Llc Laparoscopic clamp load measuring devices
US10398434B2 (en) 2017-06-29 2019-09-03 Ethicon Llc Closed loop velocity control of closure member for robotic surgical instrument
US10405859B2 (en) 2016-04-15 2019-09-10 Ethicon Llc Surgical instrument with adjustable stop/start control during a firing motion
US10413294B2 (en) 2012-06-28 2019-09-17 Ethicon Llc Shaft assembly arrangements for surgical instruments
US10420549B2 (en) 2008-09-23 2019-09-24 Ethicon Llc Motorized surgical instrument
US10426471B2 (en) 2016-12-21 2019-10-01 Ethicon Llc Surgical instrument with multiple failure response modes
US10426467B2 (en) 2016-04-15 2019-10-01 Ethicon Llc Surgical instrument with detection sensors
US10426481B2 (en) 2014-02-24 2019-10-01 Ethicon Llc Implantable layer assemblies
US10448948B2 (en) 2016-02-12 2019-10-22 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10448950B2 (en) 2016-12-21 2019-10-22 Ethicon Llc Surgical staplers with independently actuatable closing and firing systems
US10456137B2 (en) 2016-04-15 2019-10-29 Ethicon Llc Staple formation detection mechanisms
US10463370B2 (en) 2008-02-14 2019-11-05 Ethicon Llc Motorized surgical instrument
US10485764B2 (en) 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
US10492785B2 (en) 2016-12-21 2019-12-03 Ethicon Llc Shaft assembly comprising a lockout
US10499890B2 (en) 2006-01-31 2019-12-10 Ethicon Llc Endoscopic surgical instrument with a handle that can articulate with respect to the shaft
US10517596B2 (en) 2016-12-21 2019-12-31 Ethicon Llc Articulatable surgical instruments with articulation stroke amplification features
US10517594B2 (en) 2014-10-29 2019-12-31 Ethicon Llc Cartridge assemblies for surgical staplers
US10519190B2 (en) 2017-08-03 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US10517590B2 (en) 2007-01-10 2019-12-31 Ethicon Llc Powered surgical instrument having a transmission system
US10542979B2 (en) 2016-06-24 2020-01-28 Ethicon Llc Stamped staples and staple cartridges using the same
US10568625B2 (en) 2016-12-21 2020-02-25 Ethicon Llc Staple cartridges and arrangements of staples and staple cavities therein
US10568652B2 (en) 2006-09-29 2020-02-25 Ethicon Llc Surgical staples having attached drivers of different heights and stapling instruments for deploying the same
US10575868B2 (en) 2013-03-01 2020-03-03 Ethicon Llc Surgical instrument with coupler assembly
US10617412B2 (en) 2015-03-06 2020-04-14 Ethicon Llc System for detecting the mis-insertion of a staple cartridge into a surgical stapler
US10660640B2 (en) 2008-02-14 2020-05-26 Ethicon Llc Motorized surgical cutting and fastening instrument
US10687806B2 (en) 2015-03-06 2020-06-23 Ethicon Llc Adaptive tissue compression techniques to adjust closure rates for multiple tissue types
US10716614B2 (en) 2017-06-28 2020-07-21 Ethicon Llc Surgical shaft assemblies with slip ring assemblies with increased contact pressure
US10736636B2 (en) 2014-12-10 2020-08-11 Ethicon Llc Articulatable surgical instrument system
US10736628B2 (en) 2008-09-23 2020-08-11 Ethicon Llc Motor-driven surgical cutting instrument
US10758233B2 (en) 2009-02-05 2020-09-01 Ethicon Llc Articulatable surgical instrument comprising a firing drive
US10765429B2 (en) 2017-09-29 2020-09-08 Ethicon Llc Systems and methods for providing alerts according to the operational state of a surgical instrument
US10796471B2 (en) 2017-09-29 2020-10-06 Ethicon Llc Systems and methods of displaying a knife position for a surgical instrument
US10799464B2 (en) 2014-10-30 2020-10-13 Textile-Based Delivery, Inc. Delivery systems
US10828028B2 (en) 2016-04-15 2020-11-10 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10835249B2 (en) 2015-08-17 2020-11-17 Ethicon Llc Implantable layers for a surgical instrument
US10856868B2 (en) 2016-12-21 2020-12-08 Ethicon Llc Firing member pin configurations
US10881396B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Surgical instrument with variable duration trigger arrangement
US10945727B2 (en) 2016-12-21 2021-03-16 Ethicon Llc Staple cartridge with deformable driver retention features
US10973516B2 (en) 2016-12-21 2021-04-13 Ethicon Llc Surgical end effectors and adaptable firing members therefor
US10980539B2 (en) 2015-09-30 2021-04-20 Ethicon Llc Implantable adjunct comprising bonded layers
US11039836B2 (en) 2007-01-11 2021-06-22 Cilag Gmbh International Staple cartridge for use with a surgical stapling instrument
US11141153B2 (en) 2014-10-29 2021-10-12 Cilag Gmbh International Staple cartridges comprising driver arrangements
US11179150B2 (en) 2016-04-15 2021-11-23 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US11213293B2 (en) 2016-02-09 2022-01-04 Cilag Gmbh International Articulatable surgical instruments with single articulation link arrangements
US11224426B2 (en) 2016-02-12 2022-01-18 Cilag Gmbh International Mechanisms for compensating for drivetrain failure in powered surgical instruments
US11272927B2 (en) 2008-02-15 2022-03-15 Cilag Gmbh International Layer arrangements for surgical staple cartridges
US11284890B2 (en) 2016-04-01 2022-03-29 Cilag Gmbh International Circular stapling system comprising an incisable tissue support
US11517325B2 (en) 2017-06-20 2022-12-06 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval
US11564686B2 (en) 2017-06-28 2023-01-31 Cilag Gmbh International Surgical shaft assemblies with flexible interfaces
US12161328B2 (en) 2016-06-24 2024-12-10 Cilag Gmbh International Staple cartridge comprising wire staples and stamped staples

Families Citing this family (520)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7266725B2 (en) * 2001-09-03 2007-09-04 Pact Xpp Technologies Ag Method for debugging reconfigurable architectures
US6776792B1 (en) 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
DE69838731T2 (en) * 1997-09-10 2008-04-10 Rutgers, The State University POLYANHYDRIDE WITH THERAPEUTICALLY APPLICABLE ABBAUPRODUCTS
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US20020188037A1 (en) * 1999-04-15 2002-12-12 Chudzik Stephen J. Method and system for providing bioactive agent release coating
PT1019111E (en) * 1998-04-27 2002-10-31 Surmodics Inc COATING RELEASING A BIOACTIVE AGENT
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050238686A1 (en) * 1999-12-23 2005-10-27 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6953560B1 (en) * 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6783793B1 (en) 2000-10-26 2004-08-31 Advanced Cardiovascular Systems, Inc. Selective coating of medical devices
US7807210B1 (en) 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
GB0100761D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US6780424B2 (en) * 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US7923055B2 (en) * 2001-05-11 2011-04-12 Exogenesis Corporation Method of manufacturing a drug delivery system
US6743462B1 (en) * 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US6695920B1 (en) * 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US7247313B2 (en) 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US6565659B1 (en) 2001-06-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US8303651B1 (en) 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US20030229390A1 (en) * 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
US6753071B1 (en) * 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20030073961A1 (en) * 2001-09-28 2003-04-17 Happ Dorrie M. Medical device containing light-protected therapeutic agent and a method for fabricating thereof
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
ES2665999T3 (en) * 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US20030232087A1 (en) * 2002-06-18 2003-12-18 Lawin Laurie R. Bioactive agent release coating with aromatic poly(meth)acrylates
US7396539B1 (en) 2002-06-21 2008-07-08 Advanced Cardiovascular Systems, Inc. Stent coatings with engineered drug release rate
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7794743B2 (en) * 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7005137B1 (en) 2002-06-21 2006-02-28 Advanceed Cardiovascular Systems, Inc. Coating for implantable medical devices
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7491233B1 (en) 2002-07-19 2009-02-17 Advanced Cardiovascular Systems Inc. Purified polymers for coatings of implantable medical devices
US20040063805A1 (en) * 2002-09-19 2004-04-01 Pacetti Stephen D. Coatings for implantable medical devices and methods for fabrication thereof
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US6896965B1 (en) * 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
US7776926B1 (en) * 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7074276B1 (en) * 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US20060002968A1 (en) * 2004-06-30 2006-01-05 Gordon Stewart Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US7758881B2 (en) * 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8435550B2 (en) * 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7063884B2 (en) * 2003-02-26 2006-06-20 Advanced Cardiovascular Systems, Inc. Stent coating
US20080051866A1 (en) * 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
EP1610791B1 (en) 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US20040266806A1 (en) * 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation
US8791171B2 (en) * 2003-05-01 2014-07-29 Abbott Cardiovascular Systems Inc. Biodegradable coatings for implantable medical devices
US7563454B1 (en) 2003-05-01 2009-07-21 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
WO2004112838A2 (en) * 2003-05-21 2004-12-29 Control Delivery Systems, Inc. Codrugs of diclofenac
ZA200509063B (en) * 2003-05-30 2007-03-28 Titan Pharmaceuticals Inc Impiantable polymeric device for sustained release of nalmefene
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CA2530136C (en) 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US7357940B2 (en) * 2003-07-31 2008-04-15 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing graft copolymer for controlled delivery of therapeutic agents
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7261946B2 (en) * 2003-11-14 2007-08-28 Advanced Cardiovascular Systems, Inc. Block copolymers of acrylates and methacrylates with fluoroalkenes
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8192752B2 (en) * 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7220816B2 (en) * 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) * 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US7563324B1 (en) 2003-12-29 2009-07-21 Advanced Cardiovascular Systems Inc. System and method for coating an implantable medical device
US8685431B2 (en) * 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20060083772A1 (en) * 2004-04-06 2006-04-20 Dewitt David M Coating compositions for bioactive agents
US7541048B2 (en) * 2004-04-06 2009-06-02 Surmodics, Inc. Coating compositions for bioactive agents
US7553377B1 (en) 2004-04-27 2009-06-30 Advanced Cardiovascular Systems, Inc. Apparatus and method for electrostatic coating of an abluminal stent surface
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US9561309B2 (en) * 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
EP1761283A2 (en) * 2004-06-07 2007-03-14 California Institute Of Technology Biodegradable drug-polymer delivery system
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
US20050287184A1 (en) 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US11998198B2 (en) 2004-07-28 2024-06-04 Cilag Gmbh International Surgical stapling instrument incorporating a two-piece E-beam firing mechanism
US11896225B2 (en) 2004-07-28 2024-02-13 Cilag Gmbh International Staple cartridge comprising a pan
US7494665B1 (en) * 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US8357391B2 (en) 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US7311980B1 (en) 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US7648727B2 (en) 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US7244443B2 (en) * 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US7063720B2 (en) * 2004-09-14 2006-06-20 The Wallace Enterprises, Inc. Covered stent with controlled therapeutic agent diffusion
JP5081622B2 (en) * 2004-09-21 2012-11-28 山▲東緑▼叶制▲薬▼有限公司 Long-acting sustained-release preparation containing dopamine receptor agonist and method for producing the same
US8110211B2 (en) * 2004-09-22 2012-02-07 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices including polyacrylates
US9011831B2 (en) 2004-09-30 2015-04-21 Advanced Cardiovascular Systems, Inc. Methacrylate copolymers for medical devices
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US8603634B2 (en) * 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US20060089485A1 (en) * 2004-10-27 2006-04-27 Desnoyer Jessica R End-capped poly(ester amide) copolymers
US20060095122A1 (en) * 2004-10-29 2006-05-04 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US7390497B2 (en) * 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7481835B1 (en) 2004-10-29 2009-01-27 Advanced Cardiovascular Systems, Inc. Encapsulated covered stent
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
US7214759B2 (en) 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US8609123B2 (en) * 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US20060115449A1 (en) * 2004-11-30 2006-06-01 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US7892592B1 (en) 2004-11-30 2011-02-22 Advanced Cardiovascular Systems, Inc. Coating abluminal surfaces of stents and other implantable medical devices
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
EP1841808B1 (en) * 2004-12-22 2009-01-21 California Institute Of Technology Degradable p0lymers and methods of preparation thereof
US7604818B2 (en) * 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US7419504B2 (en) 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) * 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
BRPI0608818A2 (en) * 2005-03-07 2010-01-26 Univ Chicago use of opioid antagonist for attenuation of endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9381279B2 (en) 2005-03-24 2016-07-05 Abbott Cardiovascular Systems Inc. Implantable devices formed on non-fouling methacrylate or acrylate polymers
US7700659B2 (en) 2005-03-24 2010-04-20 Advanced Cardiovascular Systems, Inc. Implantable devices formed of non-fouling methacrylate or acrylate polymers
RU2007140909A (en) * 2005-04-04 2009-05-20 Синексус, Инк. (Us) DEVICE AND METHODS FOR TREATING DISEASES OF THE NANOLAIN SINUS
US7795467B1 (en) 2005-04-26 2010-09-14 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US8002730B2 (en) 2005-04-29 2011-08-23 Medtronic, Inc. Anti-thrombogenic venous shunt system and method
US7637941B1 (en) 2005-05-11 2009-12-29 Advanced Cardiovascular Systems, Inc. Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
AR057325A1 (en) * 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) * 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
US7622070B2 (en) 2005-06-20 2009-11-24 Advanced Cardiovascular Systems, Inc. Method of manufacturing an implantable polymeric medical device
US7823533B2 (en) * 2005-06-30 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent fixture and method for reducing coating defects
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US7785647B2 (en) * 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
US7735449B1 (en) 2005-07-28 2010-06-15 Advanced Cardiovascular Systems, Inc. Stent fixture having rounded support structures and method for use thereof
US11484312B2 (en) 2005-08-31 2022-11-01 Cilag Gmbh International Staple cartridge comprising a staple driver arrangement
US11246590B2 (en) 2005-08-31 2022-02-15 Cilag Gmbh International Staple cartridge including staple drivers having different unfired heights
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
CA2633768A1 (en) * 2005-11-10 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Reduction of restenosis
US20070128246A1 (en) * 2005-12-06 2007-06-07 Hossainy Syed F A Solventless method for forming a coating
US20070135909A1 (en) * 2005-12-08 2007-06-14 Desnoyer Jessica R Adhesion polymers to improve stent retention
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7591841B2 (en) 2005-12-16 2009-09-22 Advanced Cardiovascular Systems, Inc. Implantable devices for accelerated healing
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US7638156B1 (en) 2005-12-19 2009-12-29 Advanced Cardiovascular Systems, Inc. Apparatus and method for selectively coating a medical article
US20070156230A1 (en) 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US11793518B2 (en) 2006-01-31 2023-10-24 Cilag Gmbh International Powered surgical instruments with firing system lockout arrangements
US20110024477A1 (en) 2009-02-06 2011-02-03 Hall Steven G Driven Surgical Stapler Improvements
US11224427B2 (en) 2006-01-31 2022-01-18 Cilag Gmbh International Surgical stapling system including a console and retraction assembly
US11278279B2 (en) 2006-01-31 2022-03-22 Cilag Gmbh International Surgical instrument assembly
JP5479739B2 (en) * 2006-02-01 2014-04-23 サムヤン バイオファーマシューティカルズ コーポレイション Anti-adhesion composition
US20070185569A1 (en) * 2006-02-06 2007-08-09 Soonkap Hahn Drug eluting stent coating with extended duration of drug release
US20070196428A1 (en) * 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
US7601383B2 (en) * 2006-02-28 2009-10-13 Advanced Cardiovascular Systems, Inc. Coating construct containing poly (vinyl alcohol)
US7713637B2 (en) * 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US20070225799A1 (en) * 2006-03-24 2007-09-27 Medtronic Vascular, Inc. Stent, intraluminal stent delivery system, and method of treating a vascular condition
US20070231363A1 (en) * 2006-03-29 2007-10-04 Yung-Ming Chen Coatings formed from stimulus-sensitive material
US20080082036A1 (en) * 2006-04-25 2008-04-03 Medtronic, Inc. Cerebrospinal fluid shunt having long term anti-occlusion agent delivery
US20070259101A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Microporous coating on medical devices
US8304012B2 (en) * 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US8069814B2 (en) 2006-05-04 2011-12-06 Advanced Cardiovascular Systems, Inc. Stent support devices
US8752268B2 (en) 2006-05-26 2014-06-17 Abbott Cardiovascular Systems Inc. Method of making stents with radiopaque markers
US7775178B2 (en) * 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8568764B2 (en) 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US20080124372A1 (en) * 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
US8778376B2 (en) * 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US20070286882A1 (en) * 2006-06-09 2007-12-13 Yiwen Tang Solvent systems for coating medical devices
US20080095918A1 (en) * 2006-06-14 2008-04-24 Kleiner Lothar W Coating construct with enhanced interfacial compatibility
US8114150B2 (en) 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8535372B1 (en) 2006-06-16 2013-09-17 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with prohealing layer
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US8128688B2 (en) * 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US8956640B2 (en) * 2006-06-29 2015-02-17 Advanced Cardiovascular Systems, Inc. Block copolymers including a methoxyethyl methacrylate midblock
US20080008736A1 (en) * 2006-07-06 2008-01-10 Thierry Glauser Random copolymers of methacrylates and acrylates
US9028859B2 (en) * 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US7823263B2 (en) 2006-07-11 2010-11-02 Abbott Cardiovascular Systems Inc. Method of removing stent islands from a stent
US20080091262A1 (en) * 2006-10-17 2008-04-17 Gale David C Drug delivery after biodegradation of the stent scaffolding
US8016879B2 (en) 2006-08-01 2011-09-13 Abbott Cardiovascular Systems Inc. Drug delivery after biodegradation of the stent scaffolding
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US11980366B2 (en) 2006-10-03 2024-05-14 Cilag Gmbh International Surgical instrument
US7713541B1 (en) * 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
JP5557373B2 (en) * 2006-11-21 2014-07-23 アボット ラボラトリーズ Use of terpolymers of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug-eluting coatings
US20080118541A1 (en) * 2006-11-21 2008-05-22 Abbott Laboratories Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings on medical devices
US8597673B2 (en) * 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
US8017141B2 (en) * 2006-12-15 2011-09-13 Advanced Cardiovascular Systems, Inc. Coatings of acrylamide-based copolymers
US11291441B2 (en) 2007-01-10 2022-04-05 Cilag Gmbh International Surgical instrument with wireless communication between control unit and remote sensor
PL2565195T3 (en) * 2007-03-29 2015-10-30 Wyeth Llc Peripheral opioid receptor and antagonists and uses thereof
EP2137191B8 (en) * 2007-03-29 2016-06-08 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
MX2009010550A (en) 2007-03-29 2009-12-14 Progenics Pharm Inc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
US20080286332A1 (en) 2007-05-14 2008-11-20 Pacetti Stephen D Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties
US8147769B1 (en) 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US8084077B2 (en) * 2007-05-25 2011-12-27 Abbott Laboratories One-step phosphorylcholine-linked polymer coating and drug loading of stent
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US11857181B2 (en) 2007-06-04 2024-01-02 Cilag Gmbh International Robotically-controlled shaft based rotary drive systems for surgical instruments
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US7753245B2 (en) 2007-06-22 2010-07-13 Ethicon Endo-Surgery, Inc. Surgical stapling instruments
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
US7901452B2 (en) * 2007-06-27 2011-03-08 Abbott Cardiovascular Systems Inc. Method to fabricate a stent having selected morphology to reduce restenosis
US11849941B2 (en) 2007-06-29 2023-12-26 Cilag Gmbh International Staple cartridge having staple cavities extending at a transverse angle relative to a longitudinal cartridge axis
US7955381B1 (en) 2007-06-29 2011-06-07 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical device with different types of bioceramic particles
US20090041845A1 (en) * 2007-08-08 2009-02-12 Lothar Walter Kleiner Implantable medical devices having thin absorbable coatings
AU2008349873B2 (en) * 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US8758391B2 (en) 2008-02-14 2014-06-24 Ethicon Endo-Surgery, Inc. Interchangeable tools for surgical instruments
US11986183B2 (en) 2008-02-14 2024-05-21 Cilag Gmbh International Surgical cutting and fastening instrument comprising a plurality of sensors to measure an electrical parameter
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8202531B2 (en) * 2008-07-23 2012-06-19 Warsaw Orthopedic, Inc. Drug depots having one or more anchoring members
PL3476312T3 (en) 2008-09-19 2024-03-11 Ethicon Llc Surgical stapler with apparatus for adjusting staple height
US11648005B2 (en) 2008-09-23 2023-05-16 Cilag Gmbh International Robotically-controlled motorized surgical instrument with an end effector
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2393430A1 (en) 2009-02-06 2011-12-14 Ethicon Endo-Surgery, Inc. Driven surgical stapler improvements
SG2014010680A (en) * 2009-02-12 2014-04-28 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease
SG173634A1 (en) * 2009-02-12 2011-09-29 Stryker Corp COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
US20100249783A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Drug-eluting implant cover
US9078712B2 (en) * 2009-04-15 2015-07-14 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US9414864B2 (en) 2009-04-15 2016-08-16 Warsaw Orthopedic, Inc. Anterior spinal plate with preformed drug-eluting device affixed thereto
US8220688B2 (en) 2009-12-24 2012-07-17 Ethicon Endo-Surgery, Inc. Motor-driven surgical cutting instrument with electric actuator directional control assembly
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US9314246B2 (en) 2010-09-30 2016-04-19 Ethicon Endo-Surgery, Llc Tissue stapler having a thickness compensator incorporating an anti-inflammatory agent
US11298125B2 (en) 2010-09-30 2022-04-12 Cilag Gmbh International Tissue stapler having a thickness compensator
US10945731B2 (en) 2010-09-30 2021-03-16 Ethicon Llc Tissue thickness compensator comprising controlled release and expansion
US11812965B2 (en) 2010-09-30 2023-11-14 Cilag Gmbh International Layer of material for a surgical end effector
US12213666B2 (en) 2010-09-30 2025-02-04 Cilag Gmbh International Tissue thickness compensator comprising layers
US11925354B2 (en) 2010-09-30 2024-03-12 Cilag Gmbh International Staple cartridge comprising staples positioned within a compressible portion thereof
US9307989B2 (en) 2012-03-28 2016-04-12 Ethicon Endo-Surgery, Llc Tissue stapler having a thickness compensator incorportating a hydrophobic agent
US11207064B2 (en) 2011-05-27 2021-12-28 Cilag Gmbh International Automated end effector component reloading system for use with a robotic system
US8726483B2 (en) 2011-07-29 2014-05-20 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
EP2819741B1 (en) 2012-02-27 2018-03-28 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
MX358135B (en) 2012-03-28 2018-08-06 Ethicon Endo Surgery Inc Tissue thickness compensator comprising a plurality of layers.
US9198662B2 (en) 2012-03-28 2015-12-01 Ethicon Endo-Surgery, Inc. Tissue thickness compensator having improved visibility
WO2013181498A1 (en) 2012-06-01 2013-12-05 Surmodics, Inc. Apparatus and method for coating balloon catheters
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
RU2636861C2 (en) 2012-06-28 2017-11-28 Этикон Эндо-Серджери, Инк. Blocking of empty cassette with clips
US11278284B2 (en) 2012-06-28 2022-03-22 Cilag Gmbh International Rotary drive arrangements for surgical instruments
BR112014032776B1 (en) 2012-06-28 2021-09-08 Ethicon Endo-Surgery, Inc SURGICAL INSTRUMENT SYSTEM AND SURGICAL KIT FOR USE WITH A SURGICAL INSTRUMENT SYSTEM
CN104582782B (en) * 2012-08-20 2018-11-27 奥雷制药有限公司 The method for being used to prepare drug delivery preparation
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US10010655B2 (en) * 2013-03-15 2018-07-03 Abbott Cardiovascular Systems Inc. Drug delivery device, method, and system for administration of dual antiplatelet therapy
CA2906238A1 (en) * 2013-03-15 2014-09-18 Interface Biologics, Inc. Compounds and compositions for drug release
BR112015026109B1 (en) 2013-04-16 2022-02-22 Ethicon Endo-Surgery, Inc surgical instrument
US10391490B2 (en) * 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
MX369362B (en) 2013-08-23 2019-11-06 Ethicon Endo Surgery Llc Firing member retraction devices for powered surgical instruments.
US20150173756A1 (en) 2013-12-23 2015-06-25 Ethicon Endo-Surgery, Inc. Surgical cutting and stapling methods
BR112016021943B1 (en) 2014-03-26 2022-06-14 Ethicon Endo-Surgery, Llc SURGICAL INSTRUMENT FOR USE BY AN OPERATOR IN A SURGICAL PROCEDURE
US12232723B2 (en) 2014-03-26 2025-02-25 Cilag Gmbh International Systems and methods for controlling a segmented circuit
US20150297223A1 (en) 2014-04-16 2015-10-22 Ethicon Endo-Surgery, Inc. Fastener cartridges including extensions having different configurations
BR112016023807B1 (en) 2014-04-16 2022-07-12 Ethicon Endo-Surgery, Llc CARTRIDGE SET OF FASTENERS FOR USE WITH A SURGICAL INSTRUMENT
JP6636452B2 (en) 2014-04-16 2020-01-29 エシコン エルエルシーＥｔｈｉｃｏｎ ＬＬＣ Fastener cartridge including extension having different configurations
BR112016023825B1 (en) 2014-04-16 2022-08-02 Ethicon Endo-Surgery, Llc STAPLE CARTRIDGE FOR USE WITH A SURGICAL STAPLER AND STAPLE CARTRIDGE FOR USE WITH A SURGICAL INSTRUMENT
BR112017004361B1 (en) 2014-09-05 2023-04-11 Ethicon Llc ELECTRONIC SYSTEM FOR A SURGICAL INSTRUMENT
US11311294B2 (en) 2014-09-05 2022-04-26 Cilag Gmbh International Powered medical device including measurement of closure state of jaws
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
US11523821B2 (en) 2014-09-26 2022-12-13 Cilag Gmbh International Method for creating a flexible staple line
CN107427300B (en) 2014-09-26 2020-12-04 伊西康有限责任公司 Surgical suture buttresses and auxiliary materials
RU2703684C2 (en) 2014-12-18 2019-10-21 ЭТИКОН ЭНДО-СЕРДЖЕРИ, ЭлЭлСи Surgical instrument with anvil which is selectively movable relative to staple cartridge around discrete fixed axis
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US11154301B2 (en) 2015-02-27 2021-10-26 Cilag Gmbh International Modular stapling assembly
JP2020121162A (en) 2015-03-06 2020-08-13 エシコン エルエルシーＥｔｈｉｃｏｎ ＬＬＣ Time dependent evaluation of sensor data to determine stability element, creep element and viscoelastic element of measurement
US10441279B2 (en) 2015-03-06 2019-10-15 Ethicon Llc Multiple level thresholds to modify operation of powered surgical instruments
US10449055B2 (en) 2015-04-23 2019-10-22 Disc Fix L.L.C. Systems and methods for treatment of intervertebral disc derangements
US9700443B2 (en) 2015-06-12 2017-07-11 Abbott Cardiovascular Systems Inc. Methods for attaching a radiopaque marker to a scaffold
US10080806B2 (en) 2015-08-19 2018-09-25 International Business Machines Corporation Sulfur-containing polymers from hexahydrotriazine and dithiol precursors as a carrier for active agents
RU2725081C2 (en) 2015-08-26 2020-06-29 ЭТИКОН ЭлЭлСи Strips with surgical staples allowing the presence of staples with variable properties and providing simple loading of the cartridge
RU2725747C2 (en) 2015-08-26 2020-07-03 ЭТИКОН ЭлЭлСи Staple cartridge assembly comprising various gaps for tissue compression and gaps for forming staples
MX2022009705A (en) 2015-08-26 2022-11-07 Ethicon Llc Surgical staples comprising hardness variations for improved fastening of tissue.
MX2022006192A (en) 2015-09-02 2022-06-16 Ethicon Llc Surgical staple configurations with camming surfaces located between portions supporting surgical staples.
US11890015B2 (en) 2015-09-30 2024-02-06 Cilag Gmbh International Compressible adjunct with crossing spacer fibers
US9550863B1 (en) 2015-10-05 2017-01-24 International Business Machines Corporation Polymers from stabilized imines
US9534084B1 (en) 2015-11-02 2017-01-03 International Business Machines Corporation High molecular weight polythioaminals from a single monomer
US9862802B2 (en) 2015-11-30 2018-01-09 International Business Machines Corporation Poly(thioaminal) probe based lithography
BR112018016098B1 (en) 2016-02-09 2023-02-23 Ethicon Llc SURGICAL INSTRUMENT
US10617413B2 (en) 2016-04-01 2020-04-14 Ethicon Llc Closure system arrangements for surgical cutting and stapling devices with separate and distinct firing shafts
US11607239B2 (en) 2016-04-15 2023-03-21 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US10492783B2 (en) 2016-04-15 2019-12-03 Ethicon, Llc Surgical instrument with improved stop/start control during a firing motion
US11317917B2 (en) 2016-04-18 2022-05-03 Cilag Gmbh International Surgical stapling system comprising a lockable firing assembly
US20170296173A1 (en) 2016-04-18 2017-10-19 Ethicon Endo-Surgery, Llc Method for operating a surgical instrument
USD826405S1 (en) 2016-06-24 2018-08-21 Ethicon Llc Surgical fastener
US10500000B2 (en) 2016-08-16 2019-12-10 Ethicon Llc Surgical tool with manual control of end effector jaws
US10687810B2 (en) 2016-12-21 2020-06-23 Ethicon Llc Stepped staple cartridge with tissue retention and gap setting features
US10499914B2 (en) 2016-12-21 2019-12-10 Ethicon Llc Staple forming pocket arrangements
JP2020501779A (en) 2016-12-21 2020-01-23 エシコン エルエルシーＥｔｈｉｃｏｎ ＬＬＣ Surgical stapling system
CN110114014B (en) 2016-12-21 2022-08-09 爱惜康有限责任公司 Surgical instrument system including end effector and firing assembly lockout
US20180168609A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Firing assembly comprising a fuse
US10624635B2 (en) 2016-12-21 2020-04-21 Ethicon Llc Firing members with non-parallel jaw engagement features for surgical end effectors
CN110099619B (en) 2016-12-21 2022-07-15 爱惜康有限责任公司 Lockout device for surgical end effector and replaceable tool assembly
US10888322B2 (en) 2016-12-21 2021-01-12 Ethicon Llc Surgical instrument comprising a cutting member
US11419606B2 (en) 2016-12-21 2022-08-23 Cilag Gmbh International Shaft assembly comprising a clutch configured to adapt the output of a rotary firing member to two different systems
BR112019012227B1 (en) 2016-12-21 2023-12-19 Ethicon Llc SURGICAL INSTRUMENT
US11134942B2 (en) 2016-12-21 2021-10-05 Cilag Gmbh International Surgical stapling instruments and staple-forming anvils
JP7010957B2 (en) 2016-12-21 2022-01-26 エシコン エルエルシー Shaft assembly with lockout
US10758230B2 (en) 2016-12-21 2020-09-01 Ethicon Llc Surgical instrument with primary and safety processors
US20180168650A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Connection portions for disposable loading units for surgical stapling instruments
US11684367B2 (en) 2016-12-21 2023-06-27 Cilag Gmbh International Stepped assembly having and end-of-life indicator
US11090048B2 (en) 2016-12-21 2021-08-17 Cilag Gmbh International Method for resetting a fuse of a surgical instrument shaft
US20180168615A1 (en) 2016-12-21 2018-06-21 Ethicon Endo-Surgery, Llc Method of deforming staples from two different types of staple cartridges with the same surgical stapling instrument
US10993715B2 (en) 2016-12-21 2021-05-04 Ethicon Llc Staple cartridge comprising staples with different clamping breadths
JP7010956B2 (en) 2016-12-21 2022-01-26 エシコン エルエルシー How to staple tissue
US10881399B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Techniques for adaptive control of motor velocity of a surgical stapling and cutting instrument
US10980537B2 (en) 2017-06-20 2021-04-20 Ethicon Llc Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified number of shaft rotations
US10624633B2 (en) 2017-06-20 2020-04-21 Ethicon Llc Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument
USD879809S1 (en) 2017-06-20 2020-03-31 Ethicon Llc Display panel with changeable graphical user interface
US10779820B2 (en) 2017-06-20 2020-09-22 Ethicon Llc Systems and methods for controlling motor speed according to user input for a surgical instrument
USD890784S1 (en) 2017-06-20 2020-07-21 Ethicon Llc Display panel with changeable graphical user interface
US10646220B2 (en) 2017-06-20 2020-05-12 Ethicon Llc Systems and methods for controlling displacement member velocity for a surgical instrument
US11382638B2 (en) 2017-06-20 2022-07-12 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured time over a specified displacement distance
US10813639B2 (en) 2017-06-20 2020-10-27 Ethicon Llc Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on system conditions
US10888321B2 (en) 2017-06-20 2021-01-12 Ethicon Llc Systems and methods for controlling velocity of a displacement member of a surgical stapling and cutting instrument
US11071554B2 (en) 2017-06-20 2021-07-27 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on magnitude of velocity error measurements
USD879808S1 (en) 2017-06-20 2020-03-31 Ethicon Llc Display panel with graphical user interface
US11090046B2 (en) 2017-06-20 2021-08-17 Cilag Gmbh International Systems and methods for controlling displacement member motion of a surgical stapling and cutting instrument
US11653914B2 (en) 2017-06-20 2023-05-23 Cilag Gmbh International Systems and methods for controlling motor velocity of a surgical stapling and cutting instrument according to articulation angle of end effector
US10772629B2 (en) 2017-06-27 2020-09-15 Ethicon Llc Surgical anvil arrangements
US11266405B2 (en) 2017-06-27 2022-03-08 Cilag Gmbh International Surgical anvil manufacturing methods
US10856869B2 (en) 2017-06-27 2020-12-08 Ethicon Llc Surgical anvil arrangements
US11141154B2 (en) 2017-06-27 2021-10-12 Cilag Gmbh International Surgical end effectors and anvils
US11324503B2 (en) 2017-06-27 2022-05-10 Cilag Gmbh International Surgical firing member arrangements
US10993716B2 (en) 2017-06-27 2021-05-04 Ethicon Llc Surgical anvil arrangements
EP3420947B1 (en) 2017-06-28 2022-05-25 Cilag GmbH International Surgical instrument comprising selectively actuatable rotatable couplers
US11020114B2 (en) 2017-06-28 2021-06-01 Cilag Gmbh International Surgical instruments with articulatable end effector with axially shortened articulation joint configurations
US10765427B2 (en) 2017-06-28 2020-09-08 Ethicon Llc Method for articulating a surgical instrument
USD906355S1 (en) 2017-06-28 2020-12-29 Ethicon Llc Display screen or portion thereof with a graphical user interface for a surgical instrument
US11246592B2 (en) 2017-06-28 2022-02-15 Cilag Gmbh International Surgical instrument comprising an articulation system lockable to a frame
US11259805B2 (en) 2017-06-28 2022-03-01 Cilag Gmbh International Surgical instrument comprising firing member supports
USD869655S1 (en) 2017-06-28 2019-12-10 Ethicon Llc Surgical fastener cartridge
US10903685B2 (en) 2017-06-28 2021-01-26 Ethicon Llc Surgical shaft assemblies with slip ring assemblies forming capacitive channels
US11678880B2 (en) 2017-06-28 2023-06-20 Cilag Gmbh International Surgical instrument comprising a shaft including a housing arrangement
US10932772B2 (en) 2017-06-29 2021-03-02 Ethicon Llc Methods for closed loop velocity control for robotic surgical instrument
US11007022B2 (en) 2017-06-29 2021-05-18 Ethicon Llc Closed loop velocity control techniques based on sensed tissue parameters for robotic surgical instrument
US10898183B2 (en) 2017-06-29 2021-01-26 Ethicon Llc Robotic surgical instrument with closed loop feedback techniques for advancement of closure member during firing
EP3645004A4 (en) * 2017-06-30 2021-05-05 Otomagnetics, Inc. Magnetic nanoparticles for targeted delivery
US11304695B2 (en) 2017-08-03 2022-04-19 Cilag Gmbh International Surgical system shaft interconnection
US11974742B2 (en) 2017-08-03 2024-05-07 Cilag Gmbh International Surgical system comprising an articulation bailout
US11471155B2 (en) 2017-08-03 2022-10-18 Cilag Gmbh International Surgical system bailout
US11944300B2 (en) 2017-08-03 2024-04-02 Cilag Gmbh International Method for operating a surgical system bailout
US11399829B2 (en) 2017-09-29 2022-08-02 Cilag Gmbh International Systems and methods of initiating a power shutdown mode for a surgical instrument
US10743872B2 (en) 2017-09-29 2020-08-18 Ethicon Llc System and methods for controlling a display of a surgical instrument
USD907647S1 (en) 2017-09-29 2021-01-12 Ethicon Llc Display screen or portion thereof with animated graphical user interface
US10729501B2 (en) 2017-09-29 2020-08-04 Ethicon Llc Systems and methods for language selection of a surgical instrument
USD917500S1 (en) 2017-09-29 2021-04-27 Ethicon Llc Display screen or portion thereof with graphical user interface
USD907648S1 (en) 2017-09-29 2021-01-12 Ethicon Llc Display screen or portion thereof with animated graphical user interface
US11090075B2 (en) 2017-10-30 2021-08-17 Cilag Gmbh International Articulation features for surgical end effector
US11134944B2 (en) 2017-10-30 2021-10-05 Cilag Gmbh International Surgical stapler knife motion controls
US10842490B2 (en) 2017-10-31 2020-11-24 Ethicon Llc Cartridge body design with force reduction based on firing completion
US10779903B2 (en) 2017-10-31 2020-09-22 Ethicon Llc Positive shaft rotation lock activated by jaw closure
US10779826B2 (en) 2017-12-15 2020-09-22 Ethicon Llc Methods of operating surgical end effectors
US10869666B2 (en) 2017-12-15 2020-12-22 Ethicon Llc Adapters with control systems for controlling multiple motors of an electromechanical surgical instrument
US11071543B2 (en) 2017-12-15 2021-07-27 Cilag Gmbh International Surgical end effectors with clamping assemblies configured to increase jaw aperture ranges
US10743875B2 (en) 2017-12-15 2020-08-18 Ethicon Llc Surgical end effectors with jaw stiffener arrangements configured to permit monitoring of firing member
US10966718B2 (en) 2017-12-15 2021-04-06 Ethicon Llc Dynamic clamping assemblies with improved wear characteristics for use in connection with electromechanical surgical instruments
US11197670B2 (en) 2017-12-15 2021-12-14 Cilag Gmbh International Surgical end effectors with pivotal jaws configured to touch at their respective distal ends when fully closed
US11006955B2 (en) 2017-12-15 2021-05-18 Ethicon Llc End effectors with positive jaw opening features for use with adapters for electromechanical surgical instruments
US10828033B2 (en) 2017-12-15 2020-11-10 Ethicon Llc Handheld electromechanical surgical instruments with improved motor control arrangements for positioning components of an adapter coupled thereto
US10687813B2 (en) 2017-12-15 2020-06-23 Ethicon Llc Adapters with firing stroke sensing arrangements for use in connection with electromechanical surgical instruments
US10743874B2 (en) 2017-12-15 2020-08-18 Ethicon Llc Sealed adapters for use with electromechanical surgical instruments
US11033267B2 (en) 2017-12-15 2021-06-15 Ethicon Llc Systems and methods of controlling a clamping member firing rate of a surgical instrument
US10779825B2 (en) 2017-12-15 2020-09-22 Ethicon Llc Adapters with end effector position sensing and control arrangements for use in connection with electromechanical surgical instruments
US11045270B2 (en) 2017-12-19 2021-06-29 Cilag Gmbh International Robotic attachment comprising exterior drive actuator
US11020112B2 (en) 2017-12-19 2021-06-01 Ethicon Llc Surgical tools configured for interchangeable use with different controller interfaces
US10729509B2 (en) 2017-12-19 2020-08-04 Ethicon Llc Surgical instrument comprising closure and firing locking mechanism
US10835330B2 (en) 2017-12-19 2020-11-17 Ethicon Llc Method for determining the position of a rotatable jaw of a surgical instrument attachment assembly
USD910847S1 (en) 2017-12-19 2021-02-16 Ethicon Llc Surgical instrument assembly
US10716565B2 (en) 2017-12-19 2020-07-21 Ethicon Llc Surgical instruments with dual articulation drivers
US11576668B2 (en) 2017-12-21 2023-02-14 Cilag Gmbh International Staple instrument comprising a firing path display
US11076853B2 (en) 2017-12-21 2021-08-03 Cilag Gmbh International Systems and methods of displaying a knife position during transection for a surgical instrument
US11129680B2 (en) 2017-12-21 2021-09-28 Cilag Gmbh International Surgical instrument comprising a projector
US11311290B2 (en) 2017-12-21 2022-04-26 Cilag Gmbh International Surgical instrument comprising an end effector dampener
KR20200121816A (en) 2018-02-02 2020-10-26 리플 테라퓨틱스 코포레이션 Free formulations containing steroid dimers and uses thereof
US11207065B2 (en) 2018-08-20 2021-12-28 Cilag Gmbh International Method for fabricating surgical stapler anvils
USD914878S1 (en) 2018-08-20 2021-03-30 Ethicon Llc Surgical instrument anvil
US11083458B2 (en) 2018-08-20 2021-08-10 Cilag Gmbh International Powered surgical instruments with clutching arrangements to convert linear drive motions to rotary drive motions
US11045192B2 (en) 2018-08-20 2021-06-29 Cilag Gmbh International Fabricating techniques for surgical stapler anvils
US10842492B2 (en) 2018-08-20 2020-11-24 Ethicon Llc Powered articulatable surgical instruments with clutching and locking arrangements for linking an articulation drive system to a firing drive system
US10779821B2 (en) 2018-08-20 2020-09-22 Ethicon Llc Surgical stapler anvils with tissue stop features configured to avoid tissue pinch
US20200054321A1 (en) 2018-08-20 2020-02-20 Ethicon Llc Surgical instruments with progressive jaw closure arrangements
US10856870B2 (en) 2018-08-20 2020-12-08 Ethicon Llc Switching arrangements for motor powered articulatable surgical instruments
US11253256B2 (en) 2018-08-20 2022-02-22 Cilag Gmbh International Articulatable motor powered surgical instruments with dedicated articulation motor arrangements
US10912559B2 (en) 2018-08-20 2021-02-09 Ethicon Llc Reinforced deformable anvil tip for surgical stapler anvil
US11039834B2 (en) 2018-08-20 2021-06-22 Cilag Gmbh International Surgical stapler anvils with staple directing protrusions and tissue stability features
US11291440B2 (en) 2018-08-20 2022-04-05 Cilag Gmbh International Method for operating a powered articulatable surgical instrument
US11324501B2 (en) 2018-08-20 2022-05-10 Cilag Gmbh International Surgical stapling devices with improved closure members
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
CN111494307A (en) * 2019-01-30 2020-08-07 北京普德康利医药科技发展有限公司 Flurbiprofen injection
US11172929B2 (en) 2019-03-25 2021-11-16 Cilag Gmbh International Articulation drive arrangements for surgical systems
US11147551B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11147553B2 (en) 2019-03-25 2021-10-19 Cilag Gmbh International Firing drive arrangements for surgical systems
US11696761B2 (en) 2019-03-25 2023-07-11 Cilag Gmbh International Firing drive arrangements for surgical systems
US11471157B2 (en) 2019-04-30 2022-10-18 Cilag Gmbh International Articulation control mapping for a surgical instrument
US11452528B2 (en) 2019-04-30 2022-09-27 Cilag Gmbh International Articulation actuators for a surgical instrument
US11432816B2 (en) 2019-04-30 2022-09-06 Cilag Gmbh International Articulation pin for a surgical instrument
US11903581B2 (en) 2019-04-30 2024-02-20 Cilag Gmbh International Methods for stapling tissue using a surgical instrument
US11648009B2 (en) 2019-04-30 2023-05-16 Cilag Gmbh International Rotatable jaw tip for a surgical instrument
US11253254B2 (en) 2019-04-30 2022-02-22 Cilag Gmbh International Shaft rotation actuator on a surgical instrument
US11426251B2 (en) 2019-04-30 2022-08-30 Cilag Gmbh International Articulation directional lights on a surgical instrument
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US11684434B2 (en) 2019-06-28 2023-06-27 Cilag Gmbh International Surgical RFID assemblies for instrument operational setting control
US12004740B2 (en) 2019-06-28 2024-06-11 Cilag Gmbh International Surgical stapling system having an information decryption protocol
US11638587B2 (en) 2019-06-28 2023-05-02 Cilag Gmbh International RFID identification systems for surgical instruments
US11051807B2 (en) 2019-06-28 2021-07-06 Cilag Gmbh International Packaging assembly including a particulate trap
US11627959B2 (en) 2019-06-28 2023-04-18 Cilag Gmbh International Surgical instruments including manual and powered system lockouts
US11219455B2 (en) 2019-06-28 2022-01-11 Cilag Gmbh International Surgical instrument including a lockout key
US11376098B2 (en) 2019-06-28 2022-07-05 Cilag Gmbh International Surgical instrument system comprising an RFID system
US11224497B2 (en) 2019-06-28 2022-01-18 Cilag Gmbh International Surgical systems with multiple RFID tags
US11478241B2 (en) 2019-06-28 2022-10-25 Cilag Gmbh International Staple cartridge including projections
US11660163B2 (en) 2019-06-28 2023-05-30 Cilag Gmbh International Surgical system with RFID tags for updating motor assembly parameters
US11771419B2 (en) 2019-06-28 2023-10-03 Cilag Gmbh International Packaging for a replaceable component of a surgical stapling system
US11298132B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Inlernational Staple cartridge including a honeycomb extension
US11426167B2 (en) 2019-06-28 2022-08-30 Cilag Gmbh International Mechanisms for proper anvil attachment surgical stapling head assembly
US11464601B2 (en) 2019-06-28 2022-10-11 Cilag Gmbh International Surgical instrument comprising an RFID system for tracking a movable component
US11229437B2 (en) 2019-06-28 2022-01-25 Cilag Gmbh International Method for authenticating the compatibility of a staple cartridge with a surgical instrument
US11246678B2 (en) 2019-06-28 2022-02-15 Cilag Gmbh International Surgical stapling system having a frangible RFID tag
US11399837B2 (en) 2019-06-28 2022-08-02 Cilag Gmbh International Mechanisms for motor control adjustments of a motorized surgical instrument
US11497492B2 (en) 2019-06-28 2022-11-15 Cilag Gmbh International Surgical instrument including an articulation lock
US11553971B2 (en) 2019-06-28 2023-01-17 Cilag Gmbh International Surgical RFID assemblies for display and communication
US11259803B2 (en) 2019-06-28 2022-03-01 Cilag Gmbh International Surgical stapling system having an information encryption protocol
US11298127B2 (en) 2019-06-28 2022-04-12 Cilag GmbH Interational Surgical stapling system having a lockout mechanism for an incompatible cartridge
US11291451B2 (en) 2019-06-28 2022-04-05 Cilag Gmbh International Surgical instrument with battery compatibility verification functionality
US11523822B2 (en) 2019-06-28 2022-12-13 Cilag Gmbh International Battery pack including a circuit interrupter
US11291447B2 (en) 2019-12-19 2022-04-05 Cilag Gmbh International Stapling instrument comprising independent jaw closing and staple firing systems
US11304696B2 (en) 2019-12-19 2022-04-19 Cilag Gmbh International Surgical instrument comprising a powered articulation system
US11931033B2 (en) 2019-12-19 2024-03-19 Cilag Gmbh International Staple cartridge comprising a latch lockout
US11464512B2 (en) 2019-12-19 2022-10-11 Cilag Gmbh International Staple cartridge comprising a curved deck surface
US11576672B2 (en) 2019-12-19 2023-02-14 Cilag Gmbh International Surgical instrument comprising a closure system including a closure member and an opening member driven by a drive screw
US11504122B2 (en) 2019-12-19 2022-11-22 Cilag Gmbh International Surgical instrument comprising a nested firing member
US11446029B2 (en) 2019-12-19 2022-09-20 Cilag Gmbh International Staple cartridge comprising projections extending from a curved deck surface
US11529139B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Motor driven surgical instrument
US11234698B2 (en) 2019-12-19 2022-02-01 Cilag Gmbh International Stapling system comprising a clamp lockout and a firing lockout
US11701111B2 (en) 2019-12-19 2023-07-18 Cilag Gmbh International Method for operating a surgical stapling instrument
US11911032B2 (en) 2019-12-19 2024-02-27 Cilag Gmbh International Staple cartridge comprising a seating cam
US11529137B2 (en) 2019-12-19 2022-12-20 Cilag Gmbh International Staple cartridge comprising driver retention members
US11607219B2 (en) 2019-12-19 2023-03-21 Cilag Gmbh International Staple cartridge comprising a detachable tissue cutting knife
US11559304B2 (en) 2019-12-19 2023-01-24 Cilag Gmbh International Surgical instrument comprising a rapid closure mechanism
US12035913B2 (en) 2019-12-19 2024-07-16 Cilag Gmbh International Staple cartridge comprising a deployable knife
US11844520B2 (en) 2019-12-19 2023-12-19 Cilag Gmbh International Staple cartridge comprising driver retention members
EP4146664A4 (en) 2020-05-01 2024-11-13 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
USD975278S1 (en) 2020-06-02 2023-01-10 Cilag Gmbh International Staple cartridge
USD966512S1 (en) 2020-06-02 2022-10-11 Cilag Gmbh International Staple cartridge
USD967421S1 (en) 2020-06-02 2022-10-18 Cilag Gmbh International Staple cartridge
USD976401S1 (en) 2020-06-02 2023-01-24 Cilag Gmbh International Staple cartridge
USD975851S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
USD975850S1 (en) 2020-06-02 2023-01-17 Cilag Gmbh International Staple cartridge
USD974560S1 (en) 2020-06-02 2023-01-03 Cilag Gmbh International Staple cartridge
US11974741B2 (en) 2020-07-28 2024-05-07 Cilag Gmbh International Surgical instruments with differential articulation joint arrangements for accommodating flexible actuators
US11717289B2 (en) 2020-10-29 2023-08-08 Cilag Gmbh International Surgical instrument comprising an indicator which indicates that an articulation drive is actuatable
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly
US11617577B2 (en) 2020-10-29 2023-04-04 Cilag Gmbh International Surgical instrument comprising a sensor configured to sense whether an articulation drive of the surgical instrument is actuatable
US11844518B2 (en) 2020-10-29 2023-12-19 Cilag Gmbh International Method for operating a surgical instrument
US11931025B2 (en) 2020-10-29 2024-03-19 Cilag Gmbh International Surgical instrument comprising a releasable closure drive lock
US11452526B2 (en) 2020-10-29 2022-09-27 Cilag Gmbh International Surgical instrument comprising a staged voltage regulation start-up system
US12053175B2 (en) 2020-10-29 2024-08-06 Cilag Gmbh International Surgical instrument comprising a stowed closure actuator stop
USD980425S1 (en) 2020-10-29 2023-03-07 Cilag Gmbh International Surgical instrument assembly
US11517390B2 (en) 2020-10-29 2022-12-06 Cilag Gmbh International Surgical instrument comprising a limited travel switch
US11534259B2 (en) 2020-10-29 2022-12-27 Cilag Gmbh International Surgical instrument comprising an articulation indicator
US11779330B2 (en) 2020-10-29 2023-10-10 Cilag Gmbh International Surgical instrument comprising a jaw alignment system
US11896217B2 (en) 2020-10-29 2024-02-13 Cilag Gmbh International Surgical instrument comprising an articulation lock
US11627960B2 (en) 2020-12-02 2023-04-18 Cilag Gmbh International Powered surgical instruments with smart reload with separately attachable exteriorly mounted wiring connections
US11653920B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Powered surgical instruments with communication interfaces through sterile barrier
US11653915B2 (en) 2020-12-02 2023-05-23 Cilag Gmbh International Surgical instruments with sled location detection and adjustment features
US11678882B2 (en) 2020-12-02 2023-06-20 Cilag Gmbh International Surgical instruments with interactive features to remedy incidental sled movements
US11744581B2 (en) 2020-12-02 2023-09-05 Cilag Gmbh International Powered surgical instruments with multi-phase tissue treatment
US11944296B2 (en) 2020-12-02 2024-04-02 Cilag Gmbh International Powered surgical instruments with external connectors
US11890010B2 (en) 2020-12-02 2024-02-06 Cllag GmbH International Dual-sided reinforced reload for surgical instruments
US11849943B2 (en) 2020-12-02 2023-12-26 Cilag Gmbh International Surgical instrument with cartridge release mechanisms
US11737751B2 (en) 2020-12-02 2023-08-29 Cilag Gmbh International Devices and methods of managing energy dissipated within sterile barriers of surgical instrument housings
US11723657B2 (en) 2021-02-26 2023-08-15 Cilag Gmbh International Adjustable communication based on available bandwidth and power capacity
US11751869B2 (en) 2021-02-26 2023-09-12 Cilag Gmbh International Monitoring of multiple sensors over time to detect moving characteristics of tissue
US11696757B2 (en) 2021-02-26 2023-07-11 Cilag Gmbh International Monitoring of internal systems to detect and track cartridge motion status
US11950779B2 (en) 2021-02-26 2024-04-09 Cilag Gmbh International Method of powering and communicating with a staple cartridge
US11701113B2 (en) 2021-02-26 2023-07-18 Cilag Gmbh International Stapling instrument comprising a separate power antenna and a data transfer antenna
US11730473B2 (en) 2021-02-26 2023-08-22 Cilag Gmbh International Monitoring of manufacturing life-cycle
US11812964B2 (en) 2021-02-26 2023-11-14 Cilag Gmbh International Staple cartridge comprising a power management circuit
US12108951B2 (en) 2021-02-26 2024-10-08 Cilag Gmbh International Staple cartridge comprising a sensing array and a temperature control system
US11793514B2 (en) 2021-02-26 2023-10-24 Cilag Gmbh International Staple cartridge comprising sensor array which may be embedded in cartridge body
US11749877B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Stapling instrument comprising a signal antenna
US11744583B2 (en) 2021-02-26 2023-09-05 Cilag Gmbh International Distal communication array to tune frequency of RF systems
US11950777B2 (en) 2021-02-26 2024-04-09 Cilag Gmbh International Staple cartridge comprising an information access control system
US11925349B2 (en) 2021-02-26 2024-03-12 Cilag Gmbh International Adjustment to transfer parameters to improve available power
US11980362B2 (en) 2021-02-26 2024-05-14 Cilag Gmbh International Surgical instrument system comprising a power transfer coil
US11723658B2 (en) 2021-03-22 2023-08-15 Cilag Gmbh International Staple cartridge comprising a firing lockout
US11737749B2 (en) 2021-03-22 2023-08-29 Cilag Gmbh International Surgical stapling instrument comprising a retraction system
US11806011B2 (en) 2021-03-22 2023-11-07 Cilag Gmbh International Stapling instrument comprising tissue compression systems
US11826042B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Surgical instrument comprising a firing drive including a selectable leverage mechanism
US11717291B2 (en) 2021-03-22 2023-08-08 Cilag Gmbh International Staple cartridge comprising staples configured to apply different tissue compression
US11826012B2 (en) 2021-03-22 2023-11-28 Cilag Gmbh International Stapling instrument comprising a pulsed motor-driven firing rack
US11759202B2 (en) 2021-03-22 2023-09-19 Cilag Gmbh International Staple cartridge comprising an implantable layer
US11849945B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Rotary-driven surgical stapling assembly comprising eccentrically driven firing member
US11857183B2 (en) 2021-03-24 2024-01-02 Cilag Gmbh International Stapling assembly components having metal substrates and plastic bodies
US12102323B2 (en) 2021-03-24 2024-10-01 Cilag Gmbh International Rotary-driven surgical stapling assembly comprising a floatable component
US11786243B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Firing members having flexible portions for adapting to a load during a surgical firing stroke
US11896219B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Mating features between drivers and underside of a cartridge deck
US11744603B2 (en) 2021-03-24 2023-09-05 Cilag Gmbh International Multi-axis pivot joints for surgical instruments and methods for manufacturing same
US11944336B2 (en) 2021-03-24 2024-04-02 Cilag Gmbh International Joint arrangements for multi-planar alignment and support of operational drive shafts in articulatable surgical instruments
US11832816B2 (en) 2021-03-24 2023-12-05 Cilag Gmbh International Surgical stapling assembly comprising nonplanar staples and planar staples
US11849944B2 (en) 2021-03-24 2023-12-26 Cilag Gmbh International Drivers for fastener cartridge assemblies having rotary drive screws
US11896218B2 (en) 2021-03-24 2024-02-13 Cilag Gmbh International Method of using a powered stapling device
US11903582B2 (en) 2021-03-24 2024-02-20 Cilag Gmbh International Leveraging surfaces for cartridge installation
US11793516B2 (en) 2021-03-24 2023-10-24 Cilag Gmbh International Surgical staple cartridge comprising longitudinal support beam
US11786239B2 (en) 2021-03-24 2023-10-17 Cilag Gmbh International Surgical instrument articulation joint arrangements comprising multiple moving linkage features
US11723662B2 (en) 2021-05-28 2023-08-15 Cilag Gmbh International Stapling instrument comprising an articulation control display
US11877745B2 (en) 2021-10-18 2024-01-23 Cilag Gmbh International Surgical stapling assembly having longitudinally-repeating staple leg clusters
US11957337B2 (en) 2021-10-18 2024-04-16 Cilag Gmbh International Surgical stapling assembly with offset ramped drive surfaces
US11980363B2 (en) 2021-10-18 2024-05-14 Cilag Gmbh International Row-to-row staple array variations
US12239317B2 (en) 2021-10-18 2025-03-04 Cilag Gmbh International Anvil comprising an arrangement of forming pockets proximal to tissue stop
US12279845B2 (en) 2021-10-18 2025-04-22 Cilag Gmbh International Cable-driven actuation system for robotic surgical tool attachment
US12251105B2 (en) 2021-10-20 2025-03-18 Cilag Gmbh International Lockout arrangements for surgical instruments
US12089841B2 (en) 2021-10-28 2024-09-17 Cilag CmbH International Staple cartridge identification systems
US11937816B2 (en) 2021-10-28 2024-03-26 Cilag Gmbh International Electrical lead arrangements for surgical instruments
CN114699563B (en) * 2022-02-22 2024-02-02 中国医科大学附属盛京医院 Supported polyether polyurethane film, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US6159488A (en) * 1997-08-14 2000-12-12 Agricultural Research Org. Ministry Of Agriculture (Gov.) Intracoronary stents containing quinazolinone derivatives

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
GB1509979A (en) * 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
US4208511A (en) 1977-01-19 1980-06-17 Ethicon, Inc. Isomorphic copolyoxalates and sutures thereof
US4141087A (en) 1977-01-19 1979-02-27 Ethicon, Inc. Isomorphic copolyoxalates and sutures thereof
US4105034A (en) 1977-06-10 1978-08-08 Ethicon, Inc. Poly(alkylene oxalate) absorbable coating for sutures
US4205399A (en) 1977-06-13 1980-06-03 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4140678A (en) 1977-06-13 1979-02-20 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4130639A (en) 1977-09-28 1978-12-19 Ethicon, Inc. Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4309776A (en) * 1980-05-13 1982-01-12 Ramon Berguer Intravascular implantation device and method of using the same
CA1188988A (en) * 1981-07-02 1985-06-18 Alan G. Walton Chondroitin drug complexes
GB8403138D0 (en) * 1984-02-07 1984-03-14 Graham N B Sustained release of active ingredient
US4588525A (en) * 1984-02-27 1986-05-13 Molecular Biosystems, Inc. Prodrug compounds for dermal application
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US4923699A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Eye treatment suspension
US5194581A (en) * 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
CH679207A5 (en) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
EP0492903A1 (en) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
US5104877A (en) * 1991-02-25 1992-04-14 Abbott Laboratories Psoriasis treatment
US5176907A (en) * 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
CA2178592C (en) * 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
AU705226B2 (en) * 1994-01-28 1999-05-20 University Of Kentucky Research Foundation, The Codrugs as a method of controlled drug delivery
US5595751A (en) 1995-03-06 1997-01-21 Ethicon, Inc. Absorbable polyoxaesters containing amines and/or amido groups
US5618552A (en) 1995-03-06 1997-04-08 Ethicon, Inc. Absorbable polyoxaesters
US5607687A (en) 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5648088A (en) 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US5464929A (en) 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US5700583A (en) 1995-03-06 1997-12-23 Ethicon, Inc. Hydrogels of absorbable polyoxaesters containing amines or amido groups
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5569429A (en) * 1995-05-05 1996-10-29 Randcastle Extrusion Systems, Inc. Dynamic seal and sealing method
ATE342295T1 (en) * 1995-07-28 2006-11-15 Genzyme Corp BIODEGRADABLE MULTIBLOKHYDROGENS AND THEIR USE AS CARRIERS FOR CONTROLLED RELEASE PHARMACOLOGICALLY ACTIVE MATERIALS AND TISSUE CONTACT MATERIALS
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
WO1998056425A1 (en) * 1997-06-11 1998-12-17 The School Of Pharmacy, University Of London Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US5976169A (en) * 1997-12-16 1999-11-02 Cardiovasc, Inc. Stent with silver coating and method
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
WO2001001957A1 (en) * 1999-05-27 2001-01-11 Biocompatibles Limited Local drug delivery
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
CN1514729B (en) * 2001-06-05 2012-09-05 控制释放系统公司 Sustained-release analgesic compounds
IN2014DN10834A (en) * 2001-09-17 2015-09-04 Psivida Inc
CA2467559A1 (en) * 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US6159488A (en) * 1997-08-14 2000-12-12 Agricultural Research Org. Ministry Of Agriculture (Gov.) Intracoronary stents containing quinazolinone derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INGRAMS D R ET AL: "Slow-release 5-fluorouracil and triamcinolone reduces subglottic stenosis in a rabbit model.", THE ANNALS OF OTOLOGY, RHINOLOGY, AND LARYNGOLOGY. UNITED STATES APR 2000, vol. 109, no. 4, April 2000 (2000-04-01), pages 422 - 424, XP001096037, ISSN: 0003-4894 *

Cited By (681)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199151B2 (en) 1996-05-22 2007-04-03 Luitpold Pharmaceuticals, Inc. DHA-pharmaceutical agent conjugates of taxanes
US8314077B2 (en) 1996-05-22 2012-11-20 Luitpold Pharmaceuticals, Inc. Fatty acid-pharmaceutical agent conjugates
US7985415B2 (en) 1997-09-10 2011-07-26 Rutgers, The State University Of New Jersey Medical devices employing novel polymers
US8623068B2 (en) 1998-03-30 2014-01-07 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US8439968B2 (en) 1998-03-30 2013-05-14 Innovational Holdings, Llc Expandable medical device for delivery of beneficial agent
US8361537B2 (en) 1998-03-30 2013-01-29 Innovational Holdings, Llc Expandable medical device with beneficial agent concentration gradient
US8206435B2 (en) 1998-03-30 2012-06-26 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US8052735B2 (en) 1998-03-30 2011-11-08 Innovational Holdings, Llc Expandable medical device with ductile hinges
US7896912B2 (en) 1998-03-30 2011-03-01 Innovational Holdings, Llc Expandable medical device with S-shaped bridging elements
US7819912B2 (en) 1998-03-30 2010-10-26 Innovational Holdings Llc Expandable medical device with beneficial agent delivery mechanism
US9849085B2 (en) 2000-04-26 2017-12-26 Psivida Us Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US9192579B2 (en) 2000-04-26 2015-11-24 Psivida Us, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8187321B2 (en) 2000-10-16 2012-05-29 Innovational Holdings, Llc Expandable medical device for delivery of beneficial agent
US7850728B2 (en) 2000-10-16 2010-12-14 Innovational Holdings Llc Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
US7816398B2 (en) 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US7850727B2 (en) 2001-08-20 2010-12-14 Innovational Holdings, Llc Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7517362B2 (en) 2001-08-20 2009-04-14 Innovational Holdings Llc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7279175B2 (en) 2001-09-17 2007-10-09 Psivida Inc. Stent coated with a sustained-release drug delivery and method for use thereof
WO2003024455A3 (en) * 2001-09-17 2003-10-30 Control Delivery Sys Inc Stent coated with a sustained-release drug delivery and method for use thereof
EP1461122A4 (en) * 2001-12-10 2006-08-23 Control Delivery Sys Inc Treatment of genitourinary tract disorders
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US7264822B2 (en) 2002-04-03 2007-09-04 Poly-Med, Inc. Conjugated drug-polymer coated stent
EP1350526A1 (en) * 2002-04-03 2003-10-08 Poly-Med Inc. Conjugated drug-polymer coated stent
EP1360966A1 (en) * 2002-04-18 2003-11-12 Poly-Med Inc. Drug-polymer coated stents with segmented homochain copolyesters
US7041308B2 (en) 2002-04-18 2006-05-09 Poly-Med, Inc. Drug-polymer coated stents with segmented homochain copolyesters
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US8372420B2 (en) 2002-05-24 2013-02-12 Angiotech International Ag Compositions and methods for coating medical implants
US7135464B2 (en) 2002-06-05 2006-11-14 Supergen, Inc. Method of administering decitabine
US7144873B2 (en) 2002-06-05 2006-12-05 Supergen, Inc. Kit for delivering decitabine in vivo
US8349390B2 (en) 2002-09-20 2013-01-08 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
WO2004043511A1 (en) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Method and apparatus for treating vulnerable artherosclerotic plaque
EP2338538A1 (en) * 2002-11-08 2011-06-29 Conor Medsystems, Inc. Method and apparatus for reducing tissue damage after ischemic injury
JP2006506191A (en) * 2002-11-18 2006-02-23 ポリメリックス・コーポレーション Medical devices using new polymers
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US9060770B2 (en) 2003-05-20 2015-06-23 Ethicon Endo-Surgery, Inc. Robotically-driven surgical instrument with E-beam driver
EP2433661A1 (en) * 2003-05-28 2012-03-28 Conor Medsystems, Inc. Anti-restenotic agents to be delivered from a stent
EP1628597A4 (en) * 2003-05-28 2008-12-10 Conor Medsystems Inc METHODS OF ADMINISTERING ANTI-RESTENOSE AGENTS FROM A STENT
WO2005009480A3 (en) * 2003-06-11 2005-07-14 Control Delivery Sys Inc Implants containing codrugs
AU2004260645B2 (en) * 2003-07-10 2010-03-11 Allergan, Inc. Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
JP2007528851A (en) * 2003-07-10 2007-10-18 アラーガン、インコーポレイテッド Delivery of the active drug to the posterior portion of the eye of the prodrug via subconjunctival or periocular delivery
WO2005011741A3 (en) * 2003-07-10 2005-04-14 Allergan Inc Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
JP2007505039A (en) * 2003-09-08 2007-03-08 マイラス バイオ コーポレーション Improved delivery by hydrophobic modification of easily denatured drugs
JP2005199058A (en) * 2003-12-19 2005-07-28 Cordis Corp Local vascular delivery of trichostatin alone or in combination with sirolimus to prevent restenosis after vascular injury
JP2007530733A (en) * 2004-03-22 2007-11-01 アドヴァンスド カーディオヴァスキュラー システムズ， インコーポレイテッド Phosphorylcholine coating composition
JP2012046761A (en) * 2004-03-22 2012-03-08 Abbott Cardiovascular Systems Inc Phosphoryl choline coating composition
US9468706B2 (en) 2004-03-22 2016-10-18 Abbott Cardiovascular Systems Inc. Phosphoryl choline coating compositions
WO2005105046A1 (en) * 2004-04-30 2005-11-10 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
US9603991B2 (en) 2004-07-28 2017-03-28 Ethicon Endo-Surgery, Llc Surgical stapling instrument having a medical substance dispenser
US9844379B2 (en) 2004-07-28 2017-12-19 Ethicon Llc Surgical stapling instrument having a clearanced opening
US10314590B2 (en) 2004-07-28 2019-06-11 Ethicon Llc Articulating surgical stapling instrument incorporating a two-piece e-beam firing mechanism
US9737302B2 (en) 2004-07-28 2017-08-22 Ethicon Llc Surgical stapling instrument having a restraining member
US10383634B2 (en) 2004-07-28 2019-08-20 Ethicon Llc Stapling system incorporating a firing lockout
US10293100B2 (en) 2004-07-28 2019-05-21 Ethicon Llc Surgical stapling instrument having a medical substance dispenser
US10292707B2 (en) 2004-07-28 2019-05-21 Ethicon Llc Articulating surgical stapling instrument incorporating a firing mechanism
US9737303B2 (en) 2004-07-28 2017-08-22 Ethicon Llc Articulating surgical stapling instrument incorporating a two-piece E-beam firing mechanism
US9585663B2 (en) 2004-07-28 2017-03-07 Ethicon Endo-Surgery, Llc Surgical stapling instrument configured to apply a compressive pressure to tissue
US10278702B2 (en) 2004-07-28 2019-05-07 Ethicon Llc Stapling system comprising a firing bar and a lockout
US10485547B2 (en) 2004-07-28 2019-11-26 Ethicon Llc Surgical staple cartridges
US9282966B2 (en) 2004-07-28 2016-03-15 Ethicon Endo-Surgery, Inc. Surgical stapling instrument
US9510830B2 (en) 2004-07-28 2016-12-06 Ethicon Endo-Surgery, Llc Staple cartridge
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US10842488B2 (en) 2005-08-31 2020-11-24 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil and different staple heights
US10463369B2 (en) 2005-08-31 2019-11-05 Ethicon Llc Disposable end effector for use with a surgical instrument
US10159482B2 (en) 2005-08-31 2018-12-25 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil and different staple heights
US9561032B2 (en) 2005-08-31 2017-02-07 Ethicon Endo-Surgery, Llc Staple cartridge comprising a staple driver arrangement
US10271845B2 (en) 2005-08-31 2019-04-30 Ethicon Llc Fastener cartridge assembly comprising a cam and driver arrangement
US9592052B2 (en) 2005-08-31 2017-03-14 Ethicon Endo-Surgery, Llc Stapling assembly for forming different formed staple heights
US10278697B2 (en) 2005-08-31 2019-05-07 Ethicon Llc Staple cartridge comprising a staple driver arrangement
US9307988B2 (en) 2005-08-31 2016-04-12 Ethicon Endo-Surgery, Llc Staple cartridges for forming staples having differing formed staple heights
US10932774B2 (en) 2005-08-31 2021-03-02 Ethicon Llc Surgical end effector for forming staples to different heights
US10245032B2 (en) 2005-08-31 2019-04-02 Ethicon Llc Staple cartridges for forming staples having differing formed staple heights
US10842489B2 (en) 2005-08-31 2020-11-24 Ethicon Llc Fastener cartridge assembly comprising a cam and driver arrangement
US10245035B2 (en) 2005-08-31 2019-04-02 Ethicon Llc Stapling assembly configured to produce different formed staple heights
US10070863B2 (en) 2005-08-31 2018-09-11 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil
US10321909B2 (en) 2005-08-31 2019-06-18 Ethicon Llc Staple cartridge comprising a staple including deformable members
US9795382B2 (en) 2005-08-31 2017-10-24 Ethicon Llc Fastener cartridge assembly comprising a cam and driver arrangement
US9848873B2 (en) 2005-08-31 2017-12-26 Ethicon Llc Fastener cartridge assembly comprising a driver and staple cavity arrangement
US10729436B2 (en) 2005-08-31 2020-08-04 Ethicon Llc Robotically-controlled surgical stapling devices that produce formed staples having different lengths
US10271846B2 (en) 2005-08-31 2019-04-30 Ethicon Llc Staple cartridge for use with a surgical stapler
US10420553B2 (en) 2005-08-31 2019-09-24 Ethicon Llc Staple cartridge comprising a staple driver arrangement
US9839427B2 (en) 2005-08-31 2017-12-12 Ethicon Llc Fastener cartridge assembly comprising a fixed anvil and a staple driver arrangement
US10869664B2 (en) 2005-08-31 2020-12-22 Ethicon Llc End effector for use with a surgical stapling instrument
US9844373B2 (en) 2005-08-31 2017-12-19 Ethicon Llc Fastener cartridge assembly comprising a driver row arrangement
US9326768B2 (en) 2005-08-31 2016-05-03 Ethicon Endo-Surgery, Llc Staple cartridges for forming staples having differing formed staple heights
US9358248B2 (en) 2005-09-29 2016-06-07 Astex Pharmaceuticals, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US10456415B2 (en) 2005-09-29 2019-10-29 Astex Pharmaceuticals, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US9480698B2 (en) 2005-09-29 2016-11-01 Astex Pharmaceuticals, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US8461123B2 (en) 2005-09-29 2013-06-11 Astex Pharmaceuticals, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US10933079B2 (en) 2005-09-29 2021-03-02 Astex Pharmaceuticals, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US10028742B2 (en) 2005-11-09 2018-07-24 Ethicon Llc Staple cartridge comprising staples with different unformed heights
US9895147B2 (en) 2005-11-09 2018-02-20 Ethicon Llc End effectors for surgical staplers
US10149679B2 (en) 2005-11-09 2018-12-11 Ethicon Llc Surgical instrument comprising drive systems
US9968356B2 (en) 2005-11-09 2018-05-15 Ethicon Llc Surgical instrument drive systems
US9320520B2 (en) 2006-01-31 2016-04-26 Ethicon Endo-Surgery, Inc. Surgical instrument system
US10842491B2 (en) 2006-01-31 2020-11-24 Ethicon Llc Surgical system with an actuation console
US11051811B2 (en) 2006-01-31 2021-07-06 Ethicon Llc End effector for use with a surgical instrument
US10201363B2 (en) 2006-01-31 2019-02-12 Ethicon Llc Motor-driven surgical instrument
US10743849B2 (en) 2006-01-31 2020-08-18 Ethicon Llc Stapling system including an articulation system
US11058420B2 (en) 2006-01-31 2021-07-13 Cilag Gmbh International Surgical stapling apparatus comprising a lockout system
US9517068B2 (en) 2006-01-31 2016-12-13 Ethicon Endo-Surgery, Llc Surgical instrument with automatically-returned firing member
US10426463B2 (en) 2006-01-31 2019-10-01 Ehticon LLC Surgical instrument having a feedback system
US10499890B2 (en) 2006-01-31 2019-12-10 Ethicon Llc Endoscopic surgical instrument with a handle that can articulate with respect to the shaft
US10342533B2 (en) 2006-01-31 2019-07-09 Ethicon Llc Surgical instrument
US10098636B2 (en) 2006-01-31 2018-10-16 Ethicon Llc Surgical instrument having force feedback capabilities
US10485539B2 (en) 2006-01-31 2019-11-26 Ethicon Llc Surgical instrument with firing lockout
US10993717B2 (en) 2006-01-31 2021-05-04 Ethicon Llc Surgical stapling system comprising a control system
US10278722B2 (en) 2006-01-31 2019-05-07 Ethicon Llc Motor-driven surgical cutting and fastening instrument
US9861359B2 (en) 2006-01-31 2018-01-09 Ethicon Llc Powered surgical instruments with firing system lockout arrangements
US9451958B2 (en) 2006-01-31 2016-09-27 Ethicon Endo-Surgery, Llc Surgical instrument with firing actuator lockout
US10004498B2 (en) 2006-01-31 2018-06-26 Ethicon Llc Surgical instrument comprising a plurality of articulation joints
US10335144B2 (en) 2006-01-31 2019-07-02 Ethicon Llc Surgical instrument
US10010322B2 (en) 2006-01-31 2018-07-03 Ethicon Llc Surgical instrument
US10893853B2 (en) 2006-01-31 2021-01-19 Ethicon Llc Stapling assembly including motor drive systems
US9326770B2 (en) 2006-01-31 2016-05-03 Ethicon Endo-Surgery, Llc Surgical instrument
US10653417B2 (en) 2006-01-31 2020-05-19 Ethicon Llc Surgical instrument
US9326769B2 (en) 2006-01-31 2016-05-03 Ethicon Endo-Surgery, Llc Surgical instrument
US9743928B2 (en) 2006-01-31 2017-08-29 Ethicon Endo-Surgery, Inc. Surgical instrument having a feedback system
US10052100B2 (en) 2006-01-31 2018-08-21 Ethicon Llc Surgical instrument system configured to detect resistive forces experienced by a tissue cutting implement
US9113874B2 (en) 2006-01-31 2015-08-25 Ethicon Endo-Surgery, Inc. Surgical instrument system
US10058963B2 (en) 2006-01-31 2018-08-28 Ethicon Llc Automated end effector component reloading system for use with a robotic system
US9370358B2 (en) 2006-01-31 2016-06-21 Ethicon Endo-Surgery, Llc Motor-driven surgical cutting and fastening instrument with tactile position feedback
US10299817B2 (en) 2006-01-31 2019-05-28 Ethicon Llc Motor-driven fastening assembly
US10463383B2 (en) 2006-01-31 2019-11-05 Ethicon Llc Stapling instrument including a sensing system
US10463384B2 (en) 2006-01-31 2019-11-05 Ethicon Llc Stapling assembly
US10052099B2 (en) 2006-01-31 2018-08-21 Ethicon Llc Surgical instrument system comprising a firing system including a rotatable shaft and first and second actuation ramps
US9402626B2 (en) 2006-03-23 2016-08-02 Ethicon Endo-Surgery, Llc Rotary actuatable surgical fastener and cutter
US9492167B2 (en) 2006-03-23 2016-11-15 Ethicon Endo-Surgery, Llc Articulatable surgical device with rotary driven cutting member
US9301759B2 (en) 2006-03-23 2016-04-05 Ethicon Endo-Surgery, Llc Robotically-controlled surgical instrument with selectively articulatable end effector
US10070861B2 (en) 2006-03-23 2018-09-11 Ethicon Llc Articulatable surgical device
US10064688B2 (en) 2006-03-23 2018-09-04 Ethicon Llc Surgical system with selectively articulatable end effector
US10213262B2 (en) 2006-03-23 2019-02-26 Ethicon Llc Manipulatable surgical systems with selectively articulatable fastening device
US10420560B2 (en) 2006-06-27 2019-09-24 Ethicon Llc Manually driven surgical cutting and fastening instrument
US10314589B2 (en) 2006-06-27 2019-06-11 Ethicon Llc Surgical instrument including a shifting assembly
US9320521B2 (en) 2006-06-27 2016-04-26 Ethicon Endo-Surgery, Llc Surgical instrument
US10448952B2 (en) 2006-09-29 2019-10-22 Ethicon Llc End effector for use with a surgical fastening instrument
US9603595B2 (en) 2006-09-29 2017-03-28 Ethicon Endo-Surgery, Llc Surgical instrument comprising an adjustable system configured to accommodate different jaw heights
US10695053B2 (en) 2006-09-29 2020-06-30 Ethicon Llc Surgical end effectors with staple cartridges
US9179911B2 (en) 2006-09-29 2015-11-10 Ethicon Endo-Surgery, Inc. End effector for use with a surgical fastening instrument
US9706991B2 (en) 2006-09-29 2017-07-18 Ethicon Endo-Surgery, Inc. Staple cartridge comprising staples including a lateral base
US11406379B2 (en) 2006-09-29 2022-08-09 Cilag Gmbh International Surgical end effectors with staple cartridges
US10172616B2 (en) 2006-09-29 2019-01-08 Ethicon Llc Surgical staple cartridge
US9408604B2 (en) 2006-09-29 2016-08-09 Ethicon Endo-Surgery, Llc Surgical instrument comprising a firing system including a compliant portion
US10130359B2 (en) 2006-09-29 2018-11-20 Ethicon Llc Method for forming a staple
US10568652B2 (en) 2006-09-29 2020-02-25 Ethicon Llc Surgical staples having attached drivers of different heights and stapling instruments for deploying the same
US10595862B2 (en) 2006-09-29 2020-03-24 Ethicon Llc Staple cartridge including a compressible member
US8973804B2 (en) 2006-09-29 2015-03-10 Ethicon Endo-Surgery, Inc. Cartridge assembly having a buttressing member
US10342541B2 (en) 2006-10-03 2019-07-09 Ethicon Llc Surgical instruments with E-beam driver and rotary drive arrangements
US10206678B2 (en) 2006-10-03 2019-02-19 Ethicon Llc Surgical stapling instrument with lockout features to prevent advancement of a firing assembly unless an unfired surgical staple cartridge is operably mounted in an end effector portion of the instrument
US8883183B2 (en) 2006-12-01 2014-11-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
US8883190B2 (en) 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors
US8668703B2 (en) 2006-12-01 2014-03-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
US10517590B2 (en) 2007-01-10 2019-12-31 Ethicon Llc Powered surgical instrument having a transmission system
US10278780B2 (en) 2007-01-10 2019-05-07 Ethicon Llc Surgical instrument for use with robotic system
US11000277B2 (en) 2007-01-10 2021-05-11 Ethicon Llc Surgical instrument with wireless communication between control unit and remote sensor
US10751138B2 (en) 2007-01-10 2020-08-25 Ethicon Llc Surgical instrument for use with a robotic system
US9757123B2 (en) 2007-01-10 2017-09-12 Ethicon Llc Powered surgical instrument having a transmission system
US11064998B2 (en) 2007-01-10 2021-07-20 Cilag Gmbh International Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor
US11006951B2 (en) 2007-01-10 2021-05-18 Ethicon Llc Surgical instrument with wireless communication between control unit and sensor transponders
US12004743B2 (en) 2007-01-10 2024-06-11 Cilag Gmbh International Staple cartridge comprising a sloped wall
US10433918B2 (en) 2007-01-10 2019-10-08 Ethicon Llc Surgical instrument system configured to evaluate the load applied to a firing member at the initiation of a firing stroke
US10441369B2 (en) 2007-01-10 2019-10-15 Ethicon Llc Articulatable surgical instrument configured for detachable use with a robotic system
US10517682B2 (en) 2007-01-10 2019-12-31 Ethicon Llc Surgical instrument with wireless communication between control unit and remote sensor
US9724091B2 (en) 2007-01-11 2017-08-08 Ethicon Llc Surgical stapling device
US9730692B2 (en) 2007-01-11 2017-08-15 Ethicon Llc Surgical stapling device with a curved staple cartridge
US9700321B2 (en) 2007-01-11 2017-07-11 Ethicon Llc Surgical stapling device having supports for a flexible drive mechanism
US9675355B2 (en) 2007-01-11 2017-06-13 Ethicon Llc Surgical stapling device with a curved end effector
US9999431B2 (en) 2007-01-11 2018-06-19 Ethicon Endo-Surgery, Llc Surgical stapling device having supports for a flexible drive mechanism
US9655624B2 (en) 2007-01-11 2017-05-23 Ethicon Llc Surgical stapling device with a curved end effector
US10912575B2 (en) 2007-01-11 2021-02-09 Ethicon Llc Surgical stapling device having supports for a flexible drive mechanism
US9750501B2 (en) 2007-01-11 2017-09-05 Ethicon Endo-Surgery, Llc Surgical stapling devices having laterally movable anvils
US9603598B2 (en) 2007-01-11 2017-03-28 Ethicon Endo-Surgery, Llc Surgical stapling device with a curved end effector
US11039836B2 (en) 2007-01-11 2021-06-22 Cilag Gmbh International Staple cartridge for use with a surgical stapling instrument
US9775613B2 (en) 2007-01-11 2017-10-03 Ethicon Llc Surgical stapling device with a curved end effector
WO2008093086A1 (en) 2007-01-31 2008-08-07 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
US9757130B2 (en) 2007-02-28 2017-09-12 Ethicon Llc Stapling assembly for forming different formed staple heights
US9289206B2 (en) 2007-03-15 2016-03-22 Ethicon Endo-Surgery, Llc Lateral securement members for surgical staple cartridges
US8925788B2 (en) 2007-03-15 2015-01-06 Ethicon Endo-Surgery, Inc. End effectors for surgical stapling instruments
US9872682B2 (en) 2007-03-15 2018-01-23 Ethicon Llc Surgical stapling instrument having a releasable buttress material
US10398433B2 (en) 2007-03-28 2019-09-03 Ethicon Llc Laparoscopic clamp load measuring devices
US9585658B2 (en) 2007-06-04 2017-03-07 Ethicon Endo-Surgery, Llc Stapling systems
US10363033B2 (en) 2007-06-04 2019-07-30 Ethicon Llc Robotically-controlled surgical instruments
US9750498B2 (en) 2007-06-04 2017-09-05 Ethicon Endo Surgery, Llc Drive systems for surgical instruments
US9186143B2 (en) 2007-06-04 2015-11-17 Ethicon Endo-Surgery, Inc. Robotically-controlled shaft based rotary drive systems for surgical instruments
US9795381B2 (en) 2007-06-04 2017-10-24 Ethicon Endo-Surgery, Llc Robotically-controlled shaft based rotary drive systems for surgical instruments
US8931682B2 (en) 2007-06-04 2015-01-13 Ethicon Endo-Surgery, Inc. Robotically-controlled shaft based rotary drive systems for surgical instruments
US9987003B2 (en) 2007-06-04 2018-06-05 Ethicon Llc Robotic actuator assembly
US10327765B2 (en) 2007-06-04 2019-06-25 Ethicon Llc Drive systems for surgical instruments
US10368863B2 (en) 2007-06-04 2019-08-06 Ethicon Llc Robotically-controlled shaft based rotary drive systems for surgical instruments
US10441280B2 (en) 2007-06-04 2019-10-15 Ethicon Llc Robotically-controlled shaft based rotary drive systems for surgical instruments
US10299787B2 (en) 2007-06-04 2019-05-28 Ethicon Llc Stapling system comprising rotary inputs
US9662110B2 (en) 2007-06-22 2017-05-30 Ethicon Endo-Surgery, Llc Surgical stapling instrument with an articulatable end effector
US9138225B2 (en) 2007-06-22 2015-09-22 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with an articulatable end effector
US9687231B2 (en) 2008-02-13 2017-06-27 Ethicon Llc Surgical stapling instrument
US10765424B2 (en) 2008-02-13 2020-09-08 Ethicon Llc Surgical stapling instrument
US9962158B2 (en) 2008-02-14 2018-05-08 Ethicon Llc Surgical stapling apparatuses with lockable end effector positioning systems
US10463370B2 (en) 2008-02-14 2019-11-05 Ethicon Llc Motorized surgical instrument
US9498219B2 (en) 2008-02-14 2016-11-22 Ethicon Endo-Surgery, Llc Detachable motor powered surgical instrument
US10004505B2 (en) 2008-02-14 2018-06-26 Ethicon Llc Detachable motor powered surgical instrument
US10470763B2 (en) 2008-02-14 2019-11-12 Ethicon Llc Surgical cutting and fastening instrument including a sensing system
US9867618B2 (en) 2008-02-14 2018-01-16 Ethicon Llc Surgical stapling apparatus including firing force regulation
US9872684B2 (en) 2008-02-14 2018-01-23 Ethicon Llc Surgical stapling apparatus including firing force regulation
US9877723B2 (en) 2008-02-14 2018-01-30 Ethicon Llc Surgical stapling assembly comprising a selector arrangement
US9999426B2 (en) 2008-02-14 2018-06-19 Ethicon Llc Detachable motor powered surgical instrument
US10206676B2 (en) 2008-02-14 2019-02-19 Ethicon Llc Surgical cutting and fastening instrument
US8991677B2 (en) 2008-02-14 2015-03-31 Ethicon Endo-Surgery, Inc. Detachable motor powered surgical instrument
US9204878B2 (en) 2008-02-14 2015-12-08 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus with interlockable firing system
US10265067B2 (en) 2008-02-14 2019-04-23 Ethicon Llc Surgical instrument including a regulator and a control system
US10307163B2 (en) 2008-02-14 2019-06-04 Ethicon Llc Detachable motor powered surgical instrument
US9901345B2 (en) 2008-02-14 2018-02-27 Ethicon Llc Stapling assembly
US8998058B2 (en) 2008-02-14 2015-04-07 Ethicon Endo-Surgery, Inc. Detachable motor powered surgical instrument
US9980729B2 (en) 2008-02-14 2018-05-29 Ethicon Endo-Surgery, Llc Detachable motor powered surgical instrument
US9901346B2 (en) 2008-02-14 2018-02-27 Ethicon Llc Stapling assembly
US9901344B2 (en) 2008-02-14 2018-02-27 Ethicon Llc Stapling assembly
US9095339B2 (en) 2008-02-14 2015-08-04 Ethicon Endo-Surgery, Inc. Detachable motor powered surgical instrument
US9084601B2 (en) 2008-02-14 2015-07-21 Ethicon Endo-Surgery, Inc. Detachable motor powered surgical instrument
US10238387B2 (en) 2008-02-14 2019-03-26 Ethicon Llc Surgical instrument comprising a control system
US10238385B2 (en) 2008-02-14 2019-03-26 Ethicon Llc Surgical instrument system for evaluating tissue impedance
US10779822B2 (en) 2008-02-14 2020-09-22 Ethicon Llc System including a surgical cutting and fastening instrument
US10660640B2 (en) 2008-02-14 2020-05-26 Ethicon Llc Motorized surgical cutting and fastening instrument
US9072515B2 (en) 2008-02-14 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus
US9522029B2 (en) 2008-02-14 2016-12-20 Ethicon Endo-Surgery, Llc Motorized surgical cutting and fastening instrument having handle based power source
US9211121B2 (en) 2008-02-14 2015-12-15 Ethicon Endo-Surgery, Inc. Surgical stapling apparatus
US9839429B2 (en) 2008-02-15 2017-12-12 Ethicon Endo-Surgery, Llc Stapling system comprising a lockout
US9770245B2 (en) 2008-02-15 2017-09-26 Ethicon Llc Layer arrangements for surgical staple cartridges
US11272927B2 (en) 2008-02-15 2022-03-15 Cilag Gmbh International Layer arrangements for surgical staple cartridges
US11058418B2 (en) 2008-02-15 2021-07-13 Cilag Gmbh International Surgical end effector having buttress retention features
US10058327B2 (en) 2008-02-15 2018-08-28 Ethicon Llc End effector coupling arrangements for a surgical cutting and stapling instrument
US10390823B2 (en) 2008-02-15 2019-08-27 Ethicon Llc End effector comprising an adjunct
US10856866B2 (en) 2008-02-15 2020-12-08 Ethicon Llc Surgical end effector having buttress retention features
US9585657B2 (en) 2008-02-15 2017-03-07 Ethicon Endo-Surgery, Llc Actuator for releasing a layer of material from a surgical end effector
US9913647B2 (en) 2008-02-15 2018-03-13 Ethicon Llc Disposable loading unit for use with a surgical instrument
US9289210B2 (en) 2008-09-19 2016-03-22 Ethicon Endo-Surgery, Llc Surgical stapler with apparatus for adjusting staple height
US10258336B2 (en) 2008-09-19 2019-04-16 Ethicon Llc Stapling system configured to produce different formed staple heights
US10898184B2 (en) 2008-09-23 2021-01-26 Ethicon Llc Motor-driven surgical cutting instrument
US10130361B2 (en) 2008-09-23 2018-11-20 Ethicon Llc Robotically-controller motorized surgical tool with an end effector
US10420549B2 (en) 2008-09-23 2019-09-24 Ethicon Llc Motorized surgical instrument
US10238389B2 (en) 2008-09-23 2019-03-26 Ethicon Llc Robotically-controlled motorized surgical instrument with an end effector
US10456133B2 (en) 2008-09-23 2019-10-29 Ethicon Llc Motorized surgical instrument
US10045778B2 (en) 2008-09-23 2018-08-14 Ethicon Llc Robotically-controlled motorized surgical instrument with an end effector
US10105136B2 (en) 2008-09-23 2018-10-23 Ethicon Llc Robotically-controlled motorized surgical instrument with an end effector
US10765425B2 (en) 2008-09-23 2020-09-08 Ethicon Llc Robotically-controlled motorized surgical instrument with an end effector
US10485537B2 (en) 2008-09-23 2019-11-26 Ethicon Llc Motorized surgical instrument
US11617575B2 (en) 2008-09-23 2023-04-04 Cilag Gmbh International Motor-driven surgical cutting instrument
US9655614B2 (en) 2008-09-23 2017-05-23 Ethicon Endo-Surgery, Llc Robotically-controlled motorized surgical instrument with an end effector
US10736628B2 (en) 2008-09-23 2020-08-11 Ethicon Llc Motor-driven surgical cutting instrument
US10149683B2 (en) 2008-10-10 2018-12-11 Ethicon Llc Powered surgical cutting and stapling apparatus with manually retractable firing system
US9370364B2 (en) 2008-10-10 2016-06-21 Ethicon Endo-Surgery, Llc Powered surgical cutting and stapling apparatus with manually retractable firing system
US10758233B2 (en) 2009-02-05 2020-09-01 Ethicon Llc Articulatable surgical instrument comprising a firing drive
US11129615B2 (en) 2009-02-05 2021-09-28 Cilag Gmbh International Surgical stapling system
US10420550B2 (en) 2009-02-06 2019-09-24 Ethicon Llc Motor driven surgical fastener device with switching system configured to prevent firing initiation until activated
US9393015B2 (en) 2009-02-06 2016-07-19 Ethicon Endo-Surgery, Llc Motor driven surgical fastener device with cutting member reversing mechanism
US9486214B2 (en) 2009-02-06 2016-11-08 Ethicon Endo-Surgery, Llc Motor driven surgical fastener device with switching system configured to prevent firing initiation until activated
US9307987B2 (en) 2009-12-24 2016-04-12 Ethicon Endo-Surgery, Llc Surgical cutting instrument that analyzes tissue thickness
US9585660B2 (en) 2010-01-07 2017-03-07 Ethicon Endo-Surgery, Llc Method for testing a surgical tool
US9597075B2 (en) 2010-07-30 2017-03-21 Ethicon Endo-Surgery, Inc. Tissue acquisition arrangements and methods for surgical stapling devices
US10470770B2 (en) 2010-07-30 2019-11-12 Ethicon Llc Circular surgical fastening devices with tissue acquisition arrangements
US10675035B2 (en) 2010-09-09 2020-06-09 Ethicon Llc Surgical stapling head assembly with firing lockout for a surgical stapler
US9232945B2 (en) 2010-09-09 2016-01-12 Ethicon Endo-Surgery, Inc. Surgical stapling head assembly with firing lockout for a surgical stapler
US10492787B2 (en) 2010-09-17 2019-12-03 Ethicon Llc Orientable battery for a surgical instrument
US10039529B2 (en) 2010-09-17 2018-08-07 Ethicon Llc Power control arrangements for surgical instruments and batteries
US10188393B2 (en) 2010-09-17 2019-01-29 Ethicon Llc Surgical instrument battery comprising a plurality of cells
US9289212B2 (en) 2010-09-17 2016-03-22 Ethicon Endo-Surgery, Inc. Surgical instruments and batteries for surgical instruments
US10595835B2 (en) 2010-09-17 2020-03-24 Ethicon Llc Surgical instrument comprising a removable battery
US10130363B2 (en) 2010-09-29 2018-11-20 Ethicon Llc Staple cartridge
US10405854B2 (en) 2010-09-30 2019-09-10 Ethicon Llc Surgical stapling cartridge with layer retention features
US9282962B2 (en) 2010-09-30 2016-03-15 Ethicon Endo-Surgery, Llc Adhesive film laminate
US9332974B2 (en) 2010-09-30 2016-05-10 Ethicon Endo-Surgery, Llc Layered tissue thickness compensator
US9572574B2 (en) 2010-09-30 2017-02-21 Ethicon Endo-Surgery, Llc Tissue thickness compensators comprising therapeutic agents
US10123798B2 (en) 2010-09-30 2018-11-13 Ethicon Llc Tissue thickness compensator comprising controlled release and expansion
US9848875B2 (en) 2010-09-30 2017-12-26 Ethicon Llc Anvil layer attached to a proximal end of an end effector
US9839420B2 (en) 2010-09-30 2017-12-12 Ethicon Llc Tissue thickness compensator comprising at least one medicament
US10363031B2 (en) 2010-09-30 2019-07-30 Ethicon Llc Tissue thickness compensators for surgical staplers
US9861361B2 (en) 2010-09-30 2018-01-09 Ethicon Llc Releasable tissue thickness compensator and fastener cartridge having the same
US9301752B2 (en) 2010-09-30 2016-04-05 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising a plurality of capsules
US9833242B2 (en) 2010-09-30 2017-12-05 Ethicon Endo-Surgery, Llc Tissue thickness compensators
US9833236B2 (en) 2010-09-30 2017-12-05 Ethicon Llc Tissue thickness compensator for surgical staplers
US9833238B2 (en) 2010-09-30 2017-12-05 Ethicon Endo-Surgery, Llc Retainer assembly including a tissue thickness compensator
US9301753B2 (en) 2010-09-30 2016-04-05 Ethicon Endo-Surgery, Llc Expandable tissue thickness compensator
US9826978B2 (en) 2010-09-30 2017-11-28 Ethicon Llc End effectors with same side closure and firing motions
US10136890B2 (en) 2010-09-30 2018-11-27 Ethicon Llc Staple cartridge comprising a variable thickness compressible portion
US9883861B2 (en) 2010-09-30 2018-02-06 Ethicon Llc Retainer assembly including a tissue thickness compensator
US9358005B2 (en) 2010-09-30 2016-06-07 Ethicon Endo-Surgery, Llc End effector layer including holding features
US9592050B2 (en) 2010-09-30 2017-03-14 Ethicon Endo-Surgery, Llc End effector comprising a distal tissue abutment member
US9814462B2 (en) 2010-09-30 2017-11-14 Ethicon Llc Assembly for fastening tissue comprising a compressible layer
US10398436B2 (en) 2010-09-30 2019-09-03 Ethicon Llc Staple cartridge comprising staples positioned within a compressible portion thereof
US10258330B2 (en) 2010-09-30 2019-04-16 Ethicon Llc End effector including an implantable arrangement
US9364233B2 (en) 2010-09-30 2016-06-14 Ethicon Endo-Surgery, Llc Tissue thickness compensators for circular surgical staplers
US9808247B2 (en) 2010-09-30 2017-11-07 Ethicon Llc Stapling system comprising implantable layers
US10149682B2 (en) 2010-09-30 2018-12-11 Ethicon Llc Stapling system including an actuation system
US10463372B2 (en) 2010-09-30 2019-11-05 Ethicon Llc Staple cartridge comprising multiple regions
US9801634B2 (en) 2010-09-30 2017-10-31 Ethicon Llc Tissue thickness compensator for a surgical stapler
US9795383B2 (en) 2010-09-30 2017-10-24 Ethicon Llc Tissue thickness compensator comprising resilient members
US9386988B2 (en) 2010-09-30 2016-07-12 Ethicon End-Surgery, LLC Retainer assembly including a tissue thickness compensator
US10258332B2 (en) 2010-09-30 2019-04-16 Ethicon Llc Stapling system comprising an adjunct and a flowable adhesive
US9788834B2 (en) 2010-09-30 2017-10-17 Ethicon Llc Layer comprising deployable attachment members
US9592053B2 (en) 2010-09-30 2017-03-14 Ethicon Endo-Surgery, Llc Staple cartridge comprising multiple regions
US9566061B2 (en) 2010-09-30 2017-02-14 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a releasably attached tissue thickness compensator
US10485536B2 (en) 2010-09-30 2019-11-26 Ethicon Llc Tissue stapler having an anti-microbial agent
US9924947B2 (en) 2010-09-30 2018-03-27 Ethicon Llc Staple cartridge comprising a compressible portion
US9844372B2 (en) 2010-09-30 2017-12-19 Ethicon Llc Retainer assembly including a tissue thickness compensator
US9277919B2 (en) 2010-09-30 2016-03-08 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising fibers to produce a resilient load
US10028743B2 (en) 2010-09-30 2018-07-24 Ethicon Llc Staple cartridge assembly comprising an implantable layer
US10182819B2 (en) 2010-09-30 2019-01-22 Ethicon Llc Implantable layer assemblies
US10335148B2 (en) 2010-09-30 2019-07-02 Ethicon Llc Staple cartridge including a tissue thickness compensator for a surgical stapler
US9272406B2 (en) 2010-09-30 2016-03-01 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a cutting member for releasing a tissue thickness compensator
US9615826B2 (en) 2010-09-30 2017-04-11 Ethicon Endo-Surgery, Llc Multiple thickness implantable layers for surgical stapling devices
US10335150B2 (en) 2010-09-30 2019-07-02 Ethicon Llc Staple cartridge comprising an implantable layer
US9629814B2 (en) 2010-09-30 2017-04-25 Ethicon Endo-Surgery, Llc Tissue thickness compensator configured to redistribute compressive forces
US8864009B2 (en) 2010-09-30 2014-10-21 Ethicon Endo-Surgery, Inc. Tissue thickness compensator for a surgical stapler comprising an adjustable anvil
US10194910B2 (en) 2010-09-30 2019-02-05 Ethicon Llc Stapling assemblies comprising a layer
US10213198B2 (en) 2010-09-30 2019-02-26 Ethicon Llc Actuator for releasing a tissue thickness compensator from a fastener cartridge
US9433419B2 (en) 2010-09-30 2016-09-06 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising a plurality of layers
US9232941B2 (en) 2010-09-30 2016-01-12 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising a reservoir
US10265072B2 (en) 2010-09-30 2019-04-23 Ethicon Llc Surgical stapling system comprising an end effector including an implantable layer
US10064624B2 (en) 2010-09-30 2018-09-04 Ethicon Llc End effector with implantable layer
US9220500B2 (en) 2010-09-30 2015-12-29 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising structure to produce a resilient load
US8978954B2 (en) 2010-09-30 2015-03-17 Ethicon Endo-Surgery, Inc. Staple cartridge comprising an adjustable distal portion
US9480476B2 (en) 2010-09-30 2016-11-01 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising resilient members
US9700317B2 (en) 2010-09-30 2017-07-11 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a releasable tissue thickness compensator
US9220501B2 (en) 2010-09-30 2015-12-29 Ethicon Endo-Surgery, Inc. Tissue thickness compensators
US10588623B2 (en) 2010-09-30 2020-03-17 Ethicon Llc Adhesive film laminate
US10265074B2 (en) 2010-09-30 2019-04-23 Ethicon Llc Implantable layers for surgical stapling devices
US9687236B2 (en) 2010-10-01 2017-06-27 Ethicon Endo-Surgery, Inc. Surgical instrument having a power control circuit
US10045769B2 (en) 2011-03-14 2018-08-14 Ethicon Llc Circular surgical staplers with foldable anvil assemblies
US10130352B2 (en) 2011-03-14 2018-11-20 Ethicon Llc Surgical bowel retractor devices
US9980713B2 (en) 2011-03-14 2018-05-29 Ethicon Llc Anvil assemblies with collapsible frames for circular staplers
US9974529B2 (en) 2011-03-14 2018-05-22 Ethicon Llc Surgical instrument
US9113884B2 (en) 2011-03-14 2015-08-25 Ethicon Endo-Surgery, Inc. Modular surgical tool systems
US10588612B2 (en) 2011-03-14 2020-03-17 Ethicon Llc Collapsible anvil plate assemblies for circular surgical stapling devices
US9033204B2 (en) 2011-03-14 2015-05-19 Ethicon Endo-Surgery, Inc. Circular stapling devices with tissue-puncturing anvil features
US9918704B2 (en) 2011-03-14 2018-03-20 Ethicon Llc Surgical instrument
US9211122B2 (en) 2011-03-14 2015-12-15 Ethicon Endo-Surgery, Inc. Surgical access devices with anvil introduction and specimen retrieval structures
US9241714B2 (en) 2011-04-29 2016-01-26 Ethicon Endo-Surgery, Inc. Tissue thickness compensator and method for making the same
US10117652B2 (en) 2011-04-29 2018-11-06 Ethicon Llc End effector comprising a tissue thickness compensator and progressively released attachment members
US9351730B2 (en) 2011-04-29 2016-05-31 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising channels
US9211120B2 (en) 2011-04-29 2015-12-15 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising a plurality of medicaments
US9775614B2 (en) 2011-05-27 2017-10-03 Ethicon Endo-Surgery, Llc Surgical stapling instruments with rotatable staple deployment arrangements
US9271799B2 (en) 2011-05-27 2016-03-01 Ethicon Endo-Surgery, Llc Robotic surgical system with removable motor housing
US10524790B2 (en) 2011-05-27 2020-01-07 Ethicon Llc Robotically-controlled surgical stapling devices that produce formed staples having different lengths
US10420561B2 (en) 2011-05-27 2019-09-24 Ethicon Llc Robotically-driven surgical instrument
US10231794B2 (en) 2011-05-27 2019-03-19 Ethicon Llc Surgical stapling instruments with rotatable staple deployment arrangements
US10426478B2 (en) 2011-05-27 2019-10-01 Ethicon Llc Surgical stapling systems
US10335151B2 (en) 2011-05-27 2019-07-02 Ethicon Llc Robotically-driven surgical instrument
US10004506B2 (en) 2011-05-27 2018-06-26 Ethicon Llc Surgical system
US10383633B2 (en) 2011-05-27 2019-08-20 Ethicon Llc Robotically-driven surgical assembly
US10130366B2 (en) 2011-05-27 2018-11-20 Ethicon Llc Automated reloading devices for replacing used end effectors on robotic surgical systems
US9072535B2 (en) 2011-05-27 2015-07-07 Ethicon Endo-Surgery, Inc. Surgical stapling instruments with rotatable staple deployment arrangements
US10485546B2 (en) 2011-05-27 2019-11-26 Ethicon Llc Robotically-driven surgical assembly
US10071452B2 (en) 2011-05-27 2018-09-11 Ethicon Llc Automated end effector component reloading system for use with a robotic system
US9913648B2 (en) 2011-05-27 2018-03-13 Ethicon Endo-Surgery, Llc Surgical system
US10517886B2 (en) 2011-08-30 2019-12-31 Astex Pharmaceuticals, Inc. Drug formulations
US9913856B2 (en) 2011-08-30 2018-03-13 Astex Pharmaceuticals, Inc. Drug formulations
US9381207B2 (en) 2011-08-30 2016-07-05 Astex Pharmaceuticals, Inc. Drug formulations
US9055941B2 (en) 2011-09-23 2015-06-16 Ethicon Endo-Surgery, Inc. Staple cartridge including collapsible deck
US9050084B2 (en) 2011-09-23 2015-06-09 Ethicon Endo-Surgery, Inc. Staple cartridge including collapsible deck arrangement
US9592054B2 (en) 2011-09-23 2017-03-14 Ethicon Endo-Surgery, Llc Surgical stapler with stationary staple drivers
US9687237B2 (en) 2011-09-23 2017-06-27 Ethicon Endo-Surgery, Llc Staple cartridge including collapsible deck arrangement
US9216019B2 (en) 2011-09-23 2015-12-22 Ethicon Endo-Surgery, Inc. Surgical stapler with stationary staple drivers
US9730697B2 (en) 2012-02-13 2017-08-15 Ethicon Endo-Surgery, Llc Surgical cutting and fastening instrument with apparatus for determining cartridge and firing motion status
US9044230B2 (en) 2012-02-13 2015-06-02 Ethicon Endo-Surgery, Inc. Surgical cutting and fastening instrument with apparatus for determining cartridge and firing motion status
US10166025B2 (en) 2012-03-26 2019-01-01 Ethicon Llc Surgical stapling device with lockout system for preventing actuation in the absence of an installed staple cartridge
US9078653B2 (en) 2012-03-26 2015-07-14 Ethicon Endo-Surgery, Inc. Surgical stapling device with lockout system for preventing actuation in the absence of an installed staple cartridge
US9974538B2 (en) 2012-03-28 2018-05-22 Ethicon Llc Staple cartridge comprising a compressible layer
US9204880B2 (en) 2012-03-28 2015-12-08 Ethicon Endo-Surgery, Inc. Tissue thickness compensator comprising capsules defining a low pressure environment
US9724098B2 (en) 2012-03-28 2017-08-08 Ethicon Endo-Surgery, Llc Staple cartridge comprising an implantable layer
US9320523B2 (en) 2012-03-28 2016-04-26 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprising tissue ingrowth features
US9414838B2 (en) 2012-03-28 2016-08-16 Ethicon Endo-Surgery, Llc Tissue thickness compensator comprised of a plurality of materials
US10441285B2 (en) 2012-03-28 2019-10-15 Ethicon Llc Tissue thickness compensator comprising tissue ingrowth features
US9517063B2 (en) 2012-03-28 2016-12-13 Ethicon Endo-Surgery, Llc Movable member for use with a tissue thickness compensator
US9918716B2 (en) 2012-03-28 2018-03-20 Ethicon Llc Staple cartridge comprising implantable layers
WO2014004199A1 (en) * 2012-03-28 2014-01-03 Ethicon Endo-Surgery, Inc. Tissue stapler having a thickness compensator incorporating an anti-inflammatory agent
US10064621B2 (en) 2012-06-15 2018-09-04 Ethicon Llc Articulatable surgical instrument comprising a firing drive
US9101358B2 (en) 2012-06-15 2015-08-11 Ethicon Endo-Surgery, Inc. Articulatable surgical instrument comprising a firing drive
US9125662B2 (en) 2012-06-28 2015-09-08 Ethicon Endo-Surgery, Inc. Multi-axis articulating and rotating surgical tools
US9649111B2 (en) 2012-06-28 2017-05-16 Ethicon Endo-Surgery, Llc Replaceable clip cartridge for a clip applier
US9561038B2 (en) 2012-06-28 2017-02-07 Ethicon Endo-Surgery, Llc Interchangeable clip applier
US10874391B2 (en) 2012-06-28 2020-12-29 Ethicon Llc Surgical instrument system including replaceable end effectors
US9364230B2 (en) 2012-06-28 2016-06-14 Ethicon Endo-Surgery, Llc Surgical stapling instruments with rotary joint assemblies
US11058423B2 (en) 2012-06-28 2021-07-13 Cilag Gmbh International Stapling system including first and second closure systems for use with a surgical robot
US10485541B2 (en) 2012-06-28 2019-11-26 Ethicon Llc Robotically powered surgical device with manually-actuatable reversing system
US10383630B2 (en) 2012-06-28 2019-08-20 Ethicon Llc Surgical stapling device with rotary driven firing member
US9226751B2 (en) 2012-06-28 2016-01-05 Ethicon Endo-Surgery, Inc. Surgical instrument system including replaceable end effectors
US10687812B2 (en) 2012-06-28 2020-06-23 Ethicon Llc Surgical instrument system including replaceable end effectors
US11622766B2 (en) 2012-06-28 2023-04-11 Cilag Gmbh International Empty clip cartridge lockout
US9101385B2 (en) 2012-06-28 2015-08-11 Ethicon Endo-Surgery, Inc. Electrode connections for rotary driven surgical tools
US9204879B2 (en) 2012-06-28 2015-12-08 Ethicon Endo-Surgery, Inc. Flexible drive member
US9028494B2 (en) 2012-06-28 2015-05-12 Ethicon Endo-Surgery, Inc. Interchangeable end effector coupling arrangement
US10639115B2 (en) 2012-06-28 2020-05-05 Ethicon Llc Surgical end effectors having angled tissue-contacting surfaces
US9907620B2 (en) 2012-06-28 2018-03-06 Ethicon Endo-Surgery, Llc Surgical end effectors having angled tissue-contacting surfaces
US9408606B2 (en) 2012-06-28 2016-08-09 Ethicon Endo-Surgery, Llc Robotically powered surgical device with manually-actuatable reversing system
US9072536B2 (en) 2012-06-28 2015-07-07 Ethicon Endo-Surgery, Inc. Differential locking arrangements for rotary powered surgical instruments
US10258333B2 (en) 2012-06-28 2019-04-16 Ethicon Llc Surgical fastening apparatus with a rotary end effector drive shaft for selective engagement with a motorized drive system
US10420555B2 (en) 2012-06-28 2019-09-24 Ethicon Llc Hand held rotary powered surgical instruments with end effectors that are articulatable about multiple axes
US9282974B2 (en) 2012-06-28 2016-03-15 Ethicon Endo-Surgery, Llc Empty clip cartridge lockout
US9119657B2 (en) 2012-06-28 2015-09-01 Ethicon Endo-Surgery, Inc. Rotary actuatable closure arrangement for surgical end effector
US10413294B2 (en) 2012-06-28 2019-09-17 Ethicon Llc Shaft assembly arrangements for surgical instruments
US9289256B2 (en) 2012-06-28 2016-03-22 Ethicon Endo-Surgery, Llc Surgical end effectors having angled tissue-contacting surfaces
US9386985B2 (en) 2012-10-15 2016-07-12 Ethicon Endo-Surgery, Llc Surgical cutting instrument
US9386984B2 (en) 2013-02-08 2016-07-12 Ethicon Endo-Surgery, Llc Staple cartridge comprising a releasable cover
US9398911B2 (en) 2013-03-01 2016-07-26 Ethicon Endo-Surgery, Llc Rotary powered surgical instruments with multiple degrees of freedom
US9700309B2 (en) 2013-03-01 2017-07-11 Ethicon Llc Articulatable surgical instruments with conductive pathways for signal communication
US9468438B2 (en) 2013-03-01 2016-10-18 Eticon Endo-Surgery, LLC Sensor straightened end effector during removal through trocar
US10226249B2 (en) 2013-03-01 2019-03-12 Ethicon Llc Articulatable surgical instruments with conductive pathways for signal communication
US10575868B2 (en) 2013-03-01 2020-03-03 Ethicon Llc Surgical instrument with coupler assembly
US9326767B2 (en) 2013-03-01 2016-05-03 Ethicon Endo-Surgery, Llc Joystick switch assemblies for surgical instruments
US9782169B2 (en) 2013-03-01 2017-10-10 Ethicon Llc Rotary powered articulation joints for surgical instruments
US9307986B2 (en) 2013-03-01 2016-04-12 Ethicon Endo-Surgery, Llc Surgical instrument soft stop
US9554794B2 (en) 2013-03-01 2017-01-31 Ethicon Endo-Surgery, Llc Multiple processor motor control for modular surgical instruments
US9358003B2 (en) 2013-03-01 2016-06-07 Ethicon Endo-Surgery, Llc Electromechanical surgical device with signal relay arrangement
US10285695B2 (en) 2013-03-01 2019-05-14 Ethicon Llc Articulatable surgical instruments with conductive pathways
US20140256651A1 (en) * 2013-03-08 2014-09-11 Allergan, Inc. Cyclosporine A steroid conjugates
US9402912B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
US9402913B2 (en) 2013-03-08 2016-08-02 Allergan, Inc. Cyclosporine A steroid conjugates
US9345481B2 (en) 2013-03-13 2016-05-24 Ethicon Endo-Surgery, Llc Staple cartridge tissue thickness sensor system
US9629629B2 (en) 2013-03-14 2017-04-25 Ethicon Endo-Surgey, LLC Control systems for surgical instruments
US9883860B2 (en) 2013-03-14 2018-02-06 Ethicon Llc Interchangeable shaft assemblies for use with a surgical instrument
US9808244B2 (en) 2013-03-14 2017-11-07 Ethicon Llc Sensor arrangements for absolute positioning system for surgical instruments
US9687230B2 (en) 2013-03-14 2017-06-27 Ethicon Llc Articulatable surgical instrument comprising a firing drive
US9332987B2 (en) 2013-03-14 2016-05-10 Ethicon Endo-Surgery, Llc Control arrangements for a drive member of a surgical instrument
US9629623B2 (en) 2013-03-14 2017-04-25 Ethicon Endo-Surgery, Llc Drive system lockout arrangements for modular surgical instruments
US9351727B2 (en) 2013-03-14 2016-05-31 Ethicon Endo-Surgery, Llc Drive train control arrangements for modular surgical instruments
US10238391B2 (en) 2013-03-14 2019-03-26 Ethicon Llc Drive train control arrangements for modular surgical instruments
US10470762B2 (en) 2013-03-14 2019-11-12 Ethicon Llc Multi-function motor for a surgical instrument
US9888919B2 (en) 2013-03-14 2018-02-13 Ethicon Llc Method and system for operating a surgical instrument
US9351726B2 (en) 2013-03-14 2016-05-31 Ethicon Endo-Surgery, Llc Articulation control system for articulatable surgical instruments
US9572577B2 (en) 2013-03-27 2017-02-21 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a tissue thickness compensator including openings therein
US9795384B2 (en) 2013-03-27 2017-10-24 Ethicon Llc Fastener cartridge comprising a tissue thickness compensator and a gap setting element
US9332984B2 (en) 2013-03-27 2016-05-10 Ethicon Endo-Surgery, Llc Fastener cartridge assemblies
US9649110B2 (en) 2013-04-16 2017-05-16 Ethicon Llc Surgical instrument comprising a closing drive and a firing drive operated from the same rotatable output
US9867612B2 (en) 2013-04-16 2018-01-16 Ethicon Llc Powered surgical stapler
US9801626B2 (en) 2013-04-16 2017-10-31 Ethicon Llc Modular motor driven surgical instruments with alignment features for aligning rotary drive shafts with surgical end effector shafts
US9814460B2 (en) 2013-04-16 2017-11-14 Ethicon Llc Modular motor driven surgical instruments with status indication arrangements
US9826976B2 (en) 2013-04-16 2017-11-28 Ethicon Llc Motor driven surgical instruments with lockable dual drive shafts
US10149680B2 (en) 2013-04-16 2018-12-11 Ethicon Llc Surgical instrument comprising a gap setting system
US10136887B2 (en) 2013-04-16 2018-11-27 Ethicon Llc Drive system decoupling arrangement for a surgical instrument
US9844368B2 (en) 2013-04-16 2017-12-19 Ethicon Llc Surgical system comprising first and second drive systems
US10405857B2 (en) 2013-04-16 2019-09-10 Ethicon Llc Powered linear surgical stapler
US9574644B2 (en) 2013-05-30 2017-02-21 Ethicon Endo-Surgery, Llc Power module for use with a surgical instrument
US9445813B2 (en) 2013-08-23 2016-09-20 Ethicon Endo-Surgery, Llc Closure indicator systems for surgical instruments
US9924942B2 (en) 2013-08-23 2018-03-27 Ethicon Llc Motor-powered articulatable surgical instruments
US9775609B2 (en) 2013-08-23 2017-10-03 Ethicon Llc Tamper proof circuit for surgical instrument battery pack
US10828032B2 (en) 2013-08-23 2020-11-10 Ethicon Llc End effector detection systems for surgical instruments
US9510828B2 (en) 2013-08-23 2016-12-06 Ethicon Endo-Surgery, Llc Conductor arrangements for electrically powered surgical instruments with rotatable end effectors
US9283054B2 (en) 2013-08-23 2016-03-15 Ethicon Endo-Surgery, Llc Interactive displays
US9987006B2 (en) 2013-08-23 2018-06-05 Ethicon Llc Shroud retention arrangement for sterilizable surgical instruments
US11918209B2 (en) 2013-08-23 2024-03-05 Cilag Gmbh International Torque optimization for surgical instruments
US10624634B2 (en) 2013-08-23 2020-04-21 Ethicon Llc Firing trigger lockout arrangements for surgical instruments
US10441281B2 (en) 2013-08-23 2019-10-15 Ethicon Llc surgical instrument including securing and aligning features
US9808249B2 (en) 2013-08-23 2017-11-07 Ethicon Llc Attachment portions for surgical instrument assemblies
US9700310B2 (en) 2013-08-23 2017-07-11 Ethicon Llc Firing member retraction devices for powered surgical instruments
US10201349B2 (en) 2013-08-23 2019-02-12 Ethicon Llc End effector detection and firing rate modulation systems for surgical instruments
US10265065B2 (en) 2013-12-23 2019-04-23 Ethicon Llc Surgical staples and staple cartridges
US9681870B2 (en) 2013-12-23 2017-06-20 Ethicon Llc Articulatable surgical instruments with separate and distinct closing and firing systems
US9642620B2 (en) 2013-12-23 2017-05-09 Ethicon Endo-Surgery, Llc Surgical cutting and stapling instruments with articulatable end effectors
US9724092B2 (en) 2013-12-23 2017-08-08 Ethicon Llc Modular surgical instruments
US9968354B2 (en) 2013-12-23 2018-05-15 Ethicon Llc Surgical staples and methods for making the same
US9549735B2 (en) 2013-12-23 2017-01-24 Ethicon Endo-Surgery, Llc Fastener cartridge comprising a firing member including fastener transfer surfaces
US9763662B2 (en) 2013-12-23 2017-09-19 Ethicon Llc Fastener cartridge comprising a firing member configured to directly engage and eject fasteners from the fastener cartridge
US9839428B2 (en) 2013-12-23 2017-12-12 Ethicon Llc Surgical cutting and stapling instruments with independent jaw control features
US9585662B2 (en) 2013-12-23 2017-03-07 Ethicon Endo-Surgery, Llc Fastener cartridge comprising an extendable firing member
US9962161B2 (en) 2014-02-12 2018-05-08 Ethicon Llc Deliverable surgical instrument
US9884456B2 (en) 2014-02-24 2018-02-06 Ethicon Llc Implantable layers and methods for altering one or more properties of implantable layers for use with fastening instruments
US9775608B2 (en) 2014-02-24 2017-10-03 Ethicon Llc Fastening system comprising a firing member lockout
US9839423B2 (en) 2014-02-24 2017-12-12 Ethicon Llc Implantable layers and methods for modifying the shape of the implantable layers for use with a surgical fastening instrument
US9757124B2 (en) 2014-02-24 2017-09-12 Ethicon Llc Implantable layer assemblies
US9839422B2 (en) 2014-02-24 2017-12-12 Ethicon Llc Implantable layers and methods for altering implantable layers for use with surgical fastening instruments
US9693777B2 (en) 2014-02-24 2017-07-04 Ethicon Llc Implantable layers comprising a pressed region
US10426481B2 (en) 2014-02-24 2019-10-01 Ethicon Llc Implantable layer assemblies
US9730695B2 (en) 2014-03-26 2017-08-15 Ethicon Endo-Surgery, Llc Power management through segmented circuit
US9826977B2 (en) 2014-03-26 2017-11-28 Ethicon Llc Sterilization verification circuit
US10201364B2 (en) 2014-03-26 2019-02-12 Ethicon Llc Surgical instrument comprising a rotatable shaft
US11497488B2 (en) 2014-03-26 2022-11-15 Cilag Gmbh International Systems and methods for controlling a segmented circuit
US9820738B2 (en) 2014-03-26 2017-11-21 Ethicon Llc Surgical instrument comprising interactive systems
US9743929B2 (en) 2014-03-26 2017-08-29 Ethicon Llc Modular powered surgical instrument with detachable shaft assemblies
US9750499B2 (en) 2014-03-26 2017-09-05 Ethicon Llc Surgical stapling instrument system
US9913642B2 (en) 2014-03-26 2018-03-13 Ethicon Llc Surgical instrument comprising a sensor system
US9690362B2 (en) 2014-03-26 2017-06-27 Ethicon Llc Surgical instrument control circuit having a safety processor
US10136889B2 (en) 2014-03-26 2018-11-27 Ethicon Llc Systems and methods for controlling a segmented circuit
US10117653B2 (en) 2014-03-26 2018-11-06 Ethicon Llc Systems and methods for controlling a segmented circuit
US10028761B2 (en) 2014-03-26 2018-07-24 Ethicon Llc Feedback algorithms for manual bailout systems for surgical instruments
US9804618B2 (en) 2014-03-26 2017-10-31 Ethicon Llc Systems and methods for controlling a segmented circuit
US9733663B2 (en) 2014-03-26 2017-08-15 Ethicon Llc Power management through segmented circuit and variable voltage protection
US10013049B2 (en) 2014-03-26 2018-07-03 Ethicon Llc Power management through sleep options of segmented circuit and wake up control
US10004497B2 (en) 2014-03-26 2018-06-26 Ethicon Llc Interface systems for use with surgical instruments
US10470768B2 (en) 2014-04-16 2019-11-12 Ethicon Llc Fastener cartridge including a layer attached thereto
US9877721B2 (en) 2014-04-16 2018-01-30 Ethicon Llc Fastener cartridge comprising tissue control features
US9844369B2 (en) 2014-04-16 2017-12-19 Ethicon Llc Surgical end effectors with firing element monitoring arrangements
US10010324B2 (en) 2014-04-16 2018-07-03 Ethicon Llc Fastener cartridge compromising fastener cavities including fastener control features
US11185330B2 (en) 2014-04-16 2021-11-30 Cilag Gmbh International Fastener cartridge assemblies and staple retainer cover arrangements
US10299792B2 (en) 2014-04-16 2019-05-28 Ethicon Llc Fastener cartridge comprising non-uniform fasteners
US10327776B2 (en) 2014-04-16 2019-06-25 Ethicon Llc Surgical stapling buttresses and adjunct materials
US9833241B2 (en) 2014-04-16 2017-12-05 Ethicon Llc Surgical fastener cartridges with driver stabilizing arrangements
US11517315B2 (en) 2014-04-16 2022-12-06 Cilag Gmbh International Fastener cartridges including extensions having different configurations
US10542988B2 (en) 2014-04-16 2020-01-28 Ethicon Llc End effector comprising an anvil including projections extending therefrom
US10045781B2 (en) 2014-06-13 2018-08-14 Ethicon Llc Closure lockout systems for surgical instruments
US10016199B2 (en) 2014-09-05 2018-07-10 Ethicon Llc Polarity of hall magnet to identify cartridge type
US9724094B2 (en) 2014-09-05 2017-08-08 Ethicon Llc Adjunct with integrated sensors to quantify tissue compression
US9737301B2 (en) 2014-09-05 2017-08-22 Ethicon Llc Monitoring device degradation based on component evaluation
US10135242B2 (en) 2014-09-05 2018-11-20 Ethicon Llc Smart cartridge wake up operation and data retention
US10111679B2 (en) 2014-09-05 2018-10-30 Ethicon Llc Circuitry and sensors for powered medical device
US9757128B2 (en) 2014-09-05 2017-09-12 Ethicon Llc Multiple sensors with one sensor affecting a second sensor's output or interpretation
US9788836B2 (en) 2014-09-05 2017-10-17 Ethicon Llc Multiple motor control for powered medical device
US10426477B2 (en) 2014-09-26 2019-10-01 Ethicon Llc Staple cartridge assembly including a ramp
US9801628B2 (en) 2014-09-26 2017-10-31 Ethicon Llc Surgical staple and driver arrangements for staple cartridges
US10426476B2 (en) 2014-09-26 2019-10-01 Ethicon Llc Circular fastener cartridges for applying radially expandable fastener lines
US10206677B2 (en) 2014-09-26 2019-02-19 Ethicon Llc Surgical staple and driver arrangements for staple cartridges
US10327764B2 (en) 2014-09-26 2019-06-25 Ethicon Llc Method for creating a flexible staple line
US9801627B2 (en) 2014-09-26 2017-10-31 Ethicon Llc Fastener cartridge for creating a flexible staple line
US10076325B2 (en) 2014-10-13 2018-09-18 Ethicon Llc Surgical stapling apparatus comprising a tissue stop
US10052104B2 (en) 2014-10-16 2018-08-21 Ethicon Llc Staple cartridge comprising a tissue thickness compensator
US9924944B2 (en) 2014-10-16 2018-03-27 Ethicon Llc Staple cartridge comprising an adjunct material
US11141153B2 (en) 2014-10-29 2021-10-12 Cilag Gmbh International Staple cartridges comprising driver arrangements
US10517594B2 (en) 2014-10-29 2019-12-31 Ethicon Llc Cartridge assemblies for surgical staplers
US11633366B2 (en) 2014-10-30 2023-04-25 Textile-Based Delivery, Inc. Delivery systems
US10799464B2 (en) 2014-10-30 2020-10-13 Textile-Based Delivery, Inc. Delivery systems
US11690808B2 (en) 2014-10-30 2023-07-04 Textile-Based Delivery, Inc. Delivery systems
US9844376B2 (en) 2014-11-06 2017-12-19 Ethicon Llc Staple cartridge comprising a releasable adjunct material
US10736636B2 (en) 2014-12-10 2020-08-11 Ethicon Llc Articulatable surgical instrument system
US10188385B2 (en) 2014-12-18 2019-01-29 Ethicon Llc Surgical instrument system comprising lockable systems
US9844375B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Drive arrangements for articulatable surgical instruments
US10004501B2 (en) 2014-12-18 2018-06-26 Ethicon Llc Surgical instruments with improved closure arrangements
US10085748B2 (en) 2014-12-18 2018-10-02 Ethicon Llc Locking arrangements for detachable shaft assemblies with articulatable surgical end effectors
US10245027B2 (en) 2014-12-18 2019-04-02 Ethicon Llc Surgical instrument with an anvil that is selectively movable about a discrete non-movable axis relative to a staple cartridge
US9987000B2 (en) 2014-12-18 2018-06-05 Ethicon Llc Surgical instrument assembly comprising a flexible articulation system
US10117649B2 (en) 2014-12-18 2018-11-06 Ethicon Llc Surgical instrument assembly comprising a lockable articulation system
US9968355B2 (en) 2014-12-18 2018-05-15 Ethicon Llc Surgical instruments with articulatable end effectors and improved firing beam support arrangements
US9844374B2 (en) 2014-12-18 2017-12-19 Ethicon Llc Surgical instrument systems comprising an articulatable end effector and means for adjusting the firing stroke of a firing member
US9943309B2 (en) 2014-12-18 2018-04-17 Ethicon Llc Surgical instruments with articulatable end effectors and movable firing beam support arrangements
US9993258B2 (en) 2015-02-27 2018-06-12 Ethicon Llc Adaptable surgical instrument handle
US10182816B2 (en) 2015-02-27 2019-01-22 Ethicon Llc Charging system that enables emergency resolutions for charging a battery
US10180463B2 (en) 2015-02-27 2019-01-15 Ethicon Llc Surgical apparatus configured to assess whether a performance parameter of the surgical apparatus is within an acceptable performance band
US9931118B2 (en) 2015-02-27 2018-04-03 Ethicon Endo-Surgery, Llc Reinforced battery for a surgical instrument
US10159483B2 (en) 2015-02-27 2018-12-25 Ethicon Llc Surgical apparatus configured to track an end-of-life parameter
US10226250B2 (en) 2015-02-27 2019-03-12 Ethicon Llc Modular stapling assembly
US10045779B2 (en) 2015-02-27 2018-08-14 Ethicon Llc Surgical instrument system comprising an inspection station
US10321907B2 (en) 2015-02-27 2019-06-18 Ethicon Llc System for monitoring whether a surgical instrument needs to be serviced
US10245028B2 (en) 2015-02-27 2019-04-02 Ethicon Llc Power adapter for a surgical instrument
US10617412B2 (en) 2015-03-06 2020-04-14 Ethicon Llc System for detecting the mis-insertion of a staple cartridge into a surgical stapler
US9901342B2 (en) 2015-03-06 2018-02-27 Ethicon Endo-Surgery, Llc Signal and power communication system positioned on a rotatable shaft
US10687806B2 (en) 2015-03-06 2020-06-23 Ethicon Llc Adaptive tissue compression techniques to adjust closure rates for multiple tissue types
US10206605B2 (en) 2015-03-06 2019-02-19 Ethicon Llc Time dependent evaluation of sensor data to determine stability, creep, and viscoelastic elements of measures
US9895148B2 (en) 2015-03-06 2018-02-20 Ethicon Endo-Surgery, Llc Monitoring speed control and precision incrementing of motor for powered surgical instruments
US10548504B2 (en) 2015-03-06 2020-02-04 Ethicon Llc Overlaid multi sensor radio frequency (RF) electrode system to measure tissue compression
US10729432B2 (en) 2015-03-06 2020-08-04 Ethicon Llc Methods for operating a powered surgical instrument
US10045776B2 (en) 2015-03-06 2018-08-14 Ethicon Llc Control techniques and sub-processor contained within modular shaft with select control processing from handle
US9993248B2 (en) 2015-03-06 2018-06-12 Ethicon Endo-Surgery, Llc Smart sensors with local signal processing
US9924961B2 (en) 2015-03-06 2018-03-27 Ethicon Endo-Surgery, Llc Interactive feedback system for powered surgical instruments
US10052044B2 (en) 2015-03-06 2018-08-21 Ethicon Llc Time dependent evaluation of sensor data to determine stability, creep, and viscoelastic elements of measures
US9808246B2 (en) 2015-03-06 2017-11-07 Ethicon Endo-Surgery, Llc Method of operating a powered surgical instrument
US10245033B2 (en) 2015-03-06 2019-04-02 Ethicon Llc Surgical instrument comprising a lockable battery housing
US10390825B2 (en) 2015-03-31 2019-08-27 Ethicon Llc Surgical instrument with progressive rotary drive systems
US10213201B2 (en) 2015-03-31 2019-02-26 Ethicon Llc Stapling end effector configured to compensate for an uneven gap between a first jaw and a second jaw
US10433844B2 (en) 2015-03-31 2019-10-08 Ethicon Llc Surgical instrument with selectively disengageable threaded drive systems
US10052102B2 (en) 2015-06-18 2018-08-21 Ethicon Llc Surgical end effectors with dual cam actuated jaw closing features
US10485764B2 (en) 2015-07-02 2019-11-26 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
US11058425B2 (en) 2015-08-17 2021-07-13 Ethicon Llc Implantable layers for a surgical instrument
US10835249B2 (en) 2015-08-17 2020-11-17 Ethicon Llc Implantable layers for a surgical instrument
US10980538B2 (en) 2015-08-26 2021-04-20 Ethicon Llc Surgical stapling configurations for curved and circular stapling instruments
US10166026B2 (en) 2015-08-26 2019-01-01 Ethicon Llc Staple cartridge assembly including features for controlling the rotation of staples when being ejected therefrom
US11103248B2 (en) 2015-08-26 2021-08-31 Cilag Gmbh International Surgical staples for minimizing staple roll
US10028744B2 (en) 2015-08-26 2018-07-24 Ethicon Llc Staple cartridge assembly including staple guides
US10433845B2 (en) 2015-08-26 2019-10-08 Ethicon Llc Surgical staple strips for permitting varying staple properties and enabling easy cartridge loading
US10188394B2 (en) 2015-08-26 2019-01-29 Ethicon Llc Staples configured to support an implantable adjunct
US10470769B2 (en) 2015-08-26 2019-11-12 Ethicon Llc Staple cartridge assembly comprising staple alignment features on a firing member
US10098642B2 (en) 2015-08-26 2018-10-16 Ethicon Llc Surgical staples comprising features for improved fastening of tissue
US10390829B2 (en) 2015-08-26 2019-08-27 Ethicon Llc Staples comprising a cover
US11058426B2 (en) 2015-08-26 2021-07-13 Cilag Gmbh International Staple cartridge assembly comprising various tissue compression gaps and staple forming gaps
US10517599B2 (en) 2015-08-26 2019-12-31 Ethicon Llc Staple cartridge assembly comprising staple cavities for providing better staple guidance
US10357251B2 (en) 2015-08-26 2019-07-23 Ethicon Llc Surgical staples comprising hardness variations for improved fastening of tissue
US10213203B2 (en) 2015-08-26 2019-02-26 Ethicon Llc Staple cartridge assembly without a bottom cover
US10238390B2 (en) 2015-09-02 2019-03-26 Ethicon Llc Surgical staple cartridges with driver arrangements for establishing herringbone staple patterns
US10251648B2 (en) 2015-09-02 2019-04-09 Ethicon Llc Surgical staple cartridge staple drivers with central support features
US10357252B2 (en) 2015-09-02 2019-07-23 Ethicon Llc Surgical staple configurations with camming surfaces located between portions supporting surgical staples
US10172619B2 (en) 2015-09-02 2019-01-08 Ethicon Llc Surgical staple driver arrays
US10314587B2 (en) 2015-09-02 2019-06-11 Ethicon Llc Surgical staple cartridge with improved staple driver configurations
US10105139B2 (en) 2015-09-23 2018-10-23 Ethicon Llc Surgical stapler having downstream current-based motor control
US10327769B2 (en) 2015-09-23 2019-06-25 Ethicon Llc Surgical stapler having motor control based on a drive system component
US10085751B2 (en) 2015-09-23 2018-10-02 Ethicon Llc Surgical stapler having temperature-based motor control
US10076326B2 (en) 2015-09-23 2018-09-18 Ethicon Llc Surgical stapler having current mirror-based motor control
US10363036B2 (en) 2015-09-23 2019-07-30 Ethicon Llc Surgical stapler having force-based motor control
US10238386B2 (en) 2015-09-23 2019-03-26 Ethicon Llc Surgical stapler having motor control based on an electrical parameter related to a motor current
US10299878B2 (en) 2015-09-25 2019-05-28 Ethicon Llc Implantable adjunct systems for determining adjunct skew
US10980539B2 (en) 2015-09-30 2021-04-20 Ethicon Llc Implantable adjunct comprising bonded layers
US10172620B2 (en) 2015-09-30 2019-01-08 Ethicon Llc Compressible adjuncts with bonding nodes
US10561420B2 (en) 2015-09-30 2020-02-18 Ethicon Llc Tubular absorbable constructs
US10433846B2 (en) 2015-09-30 2019-10-08 Ethicon Llc Compressible adjunct with crossing spacer fibers
US10524788B2 (en) 2015-09-30 2020-01-07 Ethicon Llc Compressible adjunct with attachment regions
US10307160B2 (en) 2015-09-30 2019-06-04 Ethicon Llc Compressible adjunct assemblies with attachment layers
US11690623B2 (en) 2015-09-30 2023-07-04 Cilag Gmbh International Method for applying an implantable layer to a fastener cartridge
US10285699B2 (en) 2015-09-30 2019-05-14 Ethicon Llc Compressible adjunct
US10478188B2 (en) 2015-09-30 2019-11-19 Ethicon Llc Implantable layer comprising a constricted configuration
US10327777B2 (en) 2015-09-30 2019-06-25 Ethicon Llc Implantable layer comprising plastically deformed fibers
US10271849B2 (en) 2015-09-30 2019-04-30 Ethicon Llc Woven constructs with interlocked standing fibers
US10265068B2 (en) 2015-12-30 2019-04-23 Ethicon Llc Surgical instruments with separable motors and motor control circuits
US10368865B2 (en) 2015-12-30 2019-08-06 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10292704B2 (en) 2015-12-30 2019-05-21 Ethicon Llc Mechanisms for compensating for battery pack failure in powered surgical instruments
US10245030B2 (en) 2016-02-09 2019-04-02 Ethicon Llc Surgical instruments with tensioning arrangements for cable driven articulation systems
US11213293B2 (en) 2016-02-09 2022-01-04 Cilag Gmbh International Articulatable surgical instruments with single articulation link arrangements
US10653413B2 (en) 2016-02-09 2020-05-19 Ethicon Llc Surgical instruments with an end effector that is highly articulatable relative to an elongate shaft assembly
US10245029B2 (en) 2016-02-09 2019-04-02 Ethicon Llc Surgical instrument with articulating and axially translatable end effector
US10433837B2 (en) 2016-02-09 2019-10-08 Ethicon Llc Surgical instruments with multiple link articulation arrangements
US10470764B2 (en) 2016-02-09 2019-11-12 Ethicon Llc Surgical instruments with closure stroke reduction arrangements
US10413291B2 (en) 2016-02-09 2019-09-17 Ethicon Llc Surgical instrument articulation mechanism with slotted secondary constraint
US11224426B2 (en) 2016-02-12 2022-01-18 Cilag Gmbh International Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10258331B2 (en) 2016-02-12 2019-04-16 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10448948B2 (en) 2016-02-12 2019-10-22 Ethicon Llc Mechanisms for compensating for drivetrain failure in powered surgical instruments
US10433849B2 (en) 2016-04-01 2019-10-08 Ethicon Llc Surgical stapling system comprising a display including a re-orientable display field
US11284890B2 (en) 2016-04-01 2022-03-29 Cilag Gmbh International Circular stapling system comprising an incisable tissue support
US10314582B2 (en) 2016-04-01 2019-06-11 Ethicon Llc Surgical instrument comprising a shifting mechanism
US10307159B2 (en) 2016-04-01 2019-06-04 Ethicon Llc Surgical instrument handle assembly with reconfigurable grip portion
US10531874B2 (en) 2016-04-01 2020-01-14 Ethicon Llc Surgical cutting and stapling end effector with anvil concentric drive member
US10709446B2 (en) 2016-04-01 2020-07-14 Ethicon Llc Staple cartridges with atraumatic features
US10376263B2 (en) 2016-04-01 2019-08-13 Ethicon Llc Anvil modification members for surgical staplers
US11045191B2 (en) 2016-04-01 2021-06-29 Cilag Gmbh International Method for operating a surgical stapling system
US10682136B2 (en) 2016-04-01 2020-06-16 Ethicon Llc Circular stapling system comprising load control
US10420552B2 (en) 2016-04-01 2019-09-24 Ethicon Llc Surgical stapling system configured to provide selective cutting of tissue
US10456140B2 (en) 2016-04-01 2019-10-29 Ethicon Llc Surgical stapling system comprising an unclamping lockout
US10675021B2 (en) 2016-04-01 2020-06-09 Ethicon Llc Circular stapling system comprising rotary firing system
US10413297B2 (en) 2016-04-01 2019-09-17 Ethicon Llc Surgical stapling system configured to apply annular rows of staples having different heights
US10342543B2 (en) 2016-04-01 2019-07-09 Ethicon Llc Surgical stapling system comprising a shiftable transmission
US10285705B2 (en) 2016-04-01 2019-05-14 Ethicon Llc Surgical stapling system comprising a grooved forming pocket
US10357246B2 (en) 2016-04-01 2019-07-23 Ethicon Llc Rotary powered surgical instrument with manually actuatable bailout system
US10271851B2 (en) 2016-04-01 2019-04-30 Ethicon Llc Modular surgical stapling system comprising a display
US10485542B2 (en) 2016-04-01 2019-11-26 Ethicon Llc Surgical stapling instrument comprising multiple lockouts
US10413293B2 (en) 2016-04-01 2019-09-17 Ethicon Llc Interchangeable surgical tool assembly with a surgical end effector that is selectively rotatable about a shaft axis
US10335145B2 (en) 2016-04-15 2019-07-02 Ethicon Llc Modular surgical instrument with configurable operating mode
US11179150B2 (en) 2016-04-15 2021-11-23 Cilag Gmbh International Systems and methods for controlling a surgical stapling and cutting instrument
US10426467B2 (en) 2016-04-15 2019-10-01 Ethicon Llc Surgical instrument with detection sensors
US10828028B2 (en) 2016-04-15 2020-11-10 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10456137B2 (en) 2016-04-15 2019-10-29 Ethicon Llc Staple formation detection mechanisms
US10357247B2 (en) 2016-04-15 2019-07-23 Ethicon Llc Surgical instrument with multiple program responses during a firing motion
US10405859B2 (en) 2016-04-15 2019-09-10 Ethicon Llc Surgical instrument with adjustable stop/start control during a firing motion
US10478181B2 (en) 2016-04-18 2019-11-19 Ethicon Llc Cartridge lockout arrangements for rotary powered surgical cutting and stapling instruments
US10426469B2 (en) 2016-04-18 2019-10-01 Ethicon Llc Surgical instrument comprising a primary firing lockout and a secondary firing lockout
US10433840B2 (en) 2016-04-18 2019-10-08 Ethicon Llc Surgical instrument comprising a replaceable cartridge jaw
US10363037B2 (en) 2016-04-18 2019-07-30 Ethicon Llc Surgical instrument system comprising a magnetic lockout
US10368867B2 (en) 2016-04-18 2019-08-06 Ethicon Llc Surgical instrument comprising a lockout
USD847989S1 (en) 2016-06-24 2019-05-07 Ethicon Llc Surgical fastener cartridge
US10675024B2 (en) 2016-06-24 2020-06-09 Ethicon Llc Staple cartridge comprising overdriven staples
US11000278B2 (en) 2016-06-24 2021-05-11 Ethicon Llc Staple cartridge comprising wire staples and stamped staples
US10542979B2 (en) 2016-06-24 2020-01-28 Ethicon Llc Stamped staples and staple cartridges using the same
US12161328B2 (en) 2016-06-24 2024-12-10 Cilag Gmbh International Staple cartridge comprising wire staples and stamped staples
USD850617S1 (en) 2016-06-24 2019-06-04 Ethicon Llc Surgical fastener cartridge
US10702270B2 (en) 2016-06-24 2020-07-07 Ethicon Llc Stapling system for use with wire staples and stamped staples
US11191539B2 (en) 2016-12-21 2021-12-07 Cilag Gmbh International Shaft assembly comprising a manually-operable retraction system for use with a motorized surgical instrument system
US11571210B2 (en) 2016-12-21 2023-02-07 Cilag Gmbh International Firing assembly comprising a multiple failed-state fuse
US10973516B2 (en) 2016-12-21 2021-04-13 Ethicon Llc Surgical end effectors and adaptable firing members therefor
US10517596B2 (en) 2016-12-21 2019-12-31 Ethicon Llc Articulatable surgical instruments with articulation stroke amplification features
US10918385B2 (en) 2016-12-21 2021-02-16 Ethicon Llc Surgical system comprising a firing member rotatable into an articulation state to articulate an end effector of the surgical system
US10492785B2 (en) 2016-12-21 2019-12-03 Ethicon Llc Shaft assembly comprising a lockout
US10945727B2 (en) 2016-12-21 2021-03-16 Ethicon Llc Staple cartridge with deformable driver retention features
US10517595B2 (en) 2016-12-21 2019-12-31 Ethicon Llc Jaw actuated lock arrangements for preventing advancement of a firing member in a surgical end effector unless an unfired cartridge is installed in the end effector
US10893864B2 (en) 2016-12-21 2021-01-19 Ethicon Staple cartridges and arrangements of staples and staple cavities therein
US11160551B2 (en) 2016-12-21 2021-11-02 Cilag Gmbh International Articulatable surgical stapling instruments
US10603036B2 (en) 2016-12-21 2020-03-31 Ethicon Llc Articulatable surgical instrument with independent pivotable linkage distal of an articulation lock
US10568625B2 (en) 2016-12-21 2020-02-25 Ethicon Llc Staple cartridges and arrangements of staples and staple cavities therein
US10448950B2 (en) 2016-12-21 2019-10-22 Ethicon Llc Surgical staplers with independently actuatable closing and firing systems
US10426471B2 (en) 2016-12-21 2019-10-01 Ethicon Llc Surgical instrument with multiple failure response modes
US10856868B2 (en) 2016-12-21 2020-12-08 Ethicon Llc Firing member pin configurations
US10390841B2 (en) 2017-06-20 2019-08-27 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10368864B2 (en) 2017-06-20 2019-08-06 Ethicon Llc Systems and methods for controlling displaying motor velocity for a surgical instrument
US10327767B2 (en) 2017-06-20 2019-06-25 Ethicon Llc Control of motor velocity of a surgical stapling and cutting instrument based on angle of articulation
US10307170B2 (en) 2017-06-20 2019-06-04 Ethicon Llc Method for closed loop control of motor velocity of a surgical stapling and cutting instrument
US10881396B2 (en) 2017-06-20 2021-01-05 Ethicon Llc Surgical instrument with variable duration trigger arrangement
US11517325B2 (en) 2017-06-20 2022-12-06 Cilag Gmbh International Closed loop feedback control of motor velocity of a surgical stapling and cutting instrument based on measured displacement distance traveled over a specified time interval
USD854151S1 (en) 2017-06-28 2019-07-16 Ethicon Llc Surgical instrument shaft
USD851762S1 (en) 2017-06-28 2019-06-18 Ethicon Llc Anvil
US10716614B2 (en) 2017-06-28 2020-07-21 Ethicon Llc Surgical shaft assemblies with slip ring assemblies with increased contact pressure
US11564686B2 (en) 2017-06-28 2023-01-31 Cilag Gmbh International Surgical shaft assemblies with flexible interfaces
US10211586B2 (en) 2017-06-28 2019-02-19 Ethicon Llc Surgical shaft assemblies with watertight housings
US10258418B2 (en) 2017-06-29 2019-04-16 Ethicon Llc System for controlling articulation forces
US10398434B2 (en) 2017-06-29 2019-09-03 Ethicon Llc Closed loop velocity control of closure member for robotic surgical instrument
US10519190B2 (en) 2017-08-03 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US10796471B2 (en) 2017-09-29 2020-10-06 Ethicon Llc Systems and methods of displaying a knife position for a surgical instrument
US10765429B2 (en) 2017-09-29 2020-09-08 Ethicon Llc Systems and methods for providing alerts according to the operational state of a surgical instrument

Also Published As

Publication number Publication date
MXPA03009727A (en) 2004-01-29
EP1383504A1 (en) 2004-01-28
CN1520297A (en) 2004-08-11
BR0209198A (en) 2004-06-08
IL158527A0 (en) 2004-05-12
CA2444894C (en) 2013-06-25
EP2033648A3 (en) 2009-06-03
KR20040005936A (en) 2004-01-16
EP2033648A2 (en) 2009-03-11
AU2002259045B2 (en) 2008-05-22
JP2004536799A (en) 2004-12-09
EP2283845A1 (en) 2011-02-16
CA2444894A1 (en) 2002-11-07
NZ528994A (en) 2006-02-24
JP2011052015A (en) 2011-03-17
US20030039689A1 (en) 2003-02-27
US20120016467A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
CA2444894C (en) Sustained release drug delivery system containing codrugs
US20040022853A1 (en) Polymer-based, sustained release drug delivery system
AU2002259045A1 (en) Sustained release drug delivery system containing codrugs
US7279175B2 (en) Stent coated with a sustained-release drug delivery and method for use thereof
US20030229390A1 (en) On-stent delivery of pyrimidines and purine analogs
US20030158598A1 (en) System for sustained-release delivery of anti-inflammatory agents from a coated medical device
AU2002339938A1 (en) Stent coated with a sustained-release drug delivery
EP1180013B1 (en) Local drug delivery
EP2392364B1 (en) Rapamycin coated expandable devices
JP5153340B2 (en) Drug release control composition and drug release medical device
US8257729B2 (en) Implants with membrane diffusion-controlled release of active ingredient
JP2003521354A (en) Medical equipment
CA2455832A1 (en) Method for dip coating medical devices with an aqueous latex polymeric emulsion
US20150190556A1 (en) Drugs with improved hydrophobicity for incorporation in medical devices
US20080172124A1 (en) Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention
US9592322B2 (en) Coating composition and medical device
WO2013102842A2 (en) Device and composition for drug release
AU2017201712A1 (en) Drugs with improved hydrophobicity for incorporation in medical devices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1707/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 528994

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 158527

Country of ref document: IL

Ref document number: 2444894

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009727

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002259045

Country of ref document: AU

Ref document number: 2002584931

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037014032

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002729028

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 028129563

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002729028

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 528994

Country of ref document: NZ